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Abstracts
The objective of this thesis was to use health administrative data to investigate two important
adverse drug reactions (ADRs) related to renal function. The first study examined the risk of
hyperkalemia associated with the antibiotic trimethoprim-sulfamethoxazole (TMP-SMX) and
its interaction with beta-adrenergic receptor blockers (“beta blockers”). The second study
evaluated the effect of impaired kidney function on the risk of hypoglycemia conferred by
the anti-diabetic drug glyburide.

The simultaneous use of beta adrenergic receptor blockers (β-blockers) and trimethoprimsulfamethoxazole (TMP-SMX) may confer a high risk of hyperkalemia. We conducted two
nested case-control studies to examine the association between hospitalization for
hyperkalemia and the use of TMP-SMX in older patients receiving β-blockers. We used
linked health administrative records from Ontario, Canada to assemble a cohort of 299,749 βblockers users, aged 66 years or older and capture data regarding medication use and hospital
admissions for hyperkalemia. Over the study period from 1994 to 2008, 189 patients in this
cohort were hospitalized for hyperkalemia within 14 days of receiving a study antibiotic.
Compared to amoxicillin, the use of TMP-SMX was associated with a substantially greater
risk of hyperkalemia requiring hospital admission (adjusted odds ratio 5.1 [95% CI, 2.8 to
9.4]). No such risk was identified with ciprofloxacin, norfloxacin, or nitrofurantoin. When
dosing was considered, the association was greater at higher doses of TMP-SMX. When we
repeated the primary analysis in a cohort of non-β-blocker users, the risk of hyperkalemia
comparing TMP-SMX to amoxicillin was not significantly different from that found among
β-blocker users. Although TMP-SMX is associated with an increased risk of hyperkalemia in
older adults, our findings show no added risk when used in combination with β-blockers.

Little evidence justifies the avoidance of glyburide in patients with impaired renal function.
We aimed to determine if renal function modifies the risk of hypoglycemia among patients
using glyburide. We conducted a nested case-control study using administrative records and
ii

laboratory data from Ontario, Canada. We included outpatients 66 years of age and older
with diabetes mellitus and prescriptions for glyburide, insulin or metformin. We ascertained
hypoglycemic events using administrative records and we estimated glomerular filtration
rates (eGFR) using serum creatinine concentrations. From a cohort of 19,620 patients, we
identified 204 cases whose eGFR was ≥ 60 ml/min/1.73m2 (normal renal function) and 354
cases whose eGFR was < 60 ml/min/1.73m2 (impaired renal function). Compared to
metformin, glyburide associated with a greater risk of hypoglycemia in patients with both
normal (adjusted OR 9.0, 95% CI 4.9 to 16.4) and impaired renal function (adjusted OR 6.0,
95% CI 3.8 to 9.5). We observed a similar relationship when comparing insulin to
metformin; the risk was greater in patients with normal renal function (adjusted OR 18.7,
95% CI 10.5 to 33.5) compared to those with impaired renal function (adjusted OR 7.9, 95%
CI 5.0 to 12.4). Tests of interaction showed that among glyburide users renal function did not
significantly modify the risk of hypoglycemia, but among insulin users, impaired renal
function associated with a lower risk. In this population-based study, impaired renal function
did not augment the risk of hypoglycemia associated with glyburide use.

In summary, these studies described important ADRs associated with commonly used
prescription drugs and highlighted the kidney’s role, both as a target of the drug effect, as in
the case of TMP-SMX, and as the cause of the drug accumulation, as in the case of
glyburide. Both studies identified significant risks associated with the study drugs and
reinforce the need for vigilance when monitoring patients prescribed these medications.

Keywords
Kidney, renal, pharmacoepidemiology, adverse drug events
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Chapter 1

1

Introduction

1.1 Definitions
The field of pharmacoepidemiology uses a variety of terms to describe the intentional and
unintentional outcomes of medication use. Although the terms “side-effect”, “adverse
drug event” and “adverse drug reaction” are often used interchangeably, their definitions
differ in important ways. 1 “Side-effect” refers to an unintended outcome associated with
medication use that may be beneficial, neutral, or harmful. “Adverse drug event” refers to
any unintended, noxious outcome occurring during the course of medication use.
“Adverse drug reaction” refers to an unintended, noxious outcome caused directly by
medication use. Adverse drug reactions have multiple sub-categories based on the
suspected underlying mechanisms.
Because the studies conducted for this thesis were observational, a direct, causal link
cannot be drawn between the study drugs and the outcomes of interest. Therefore, the
most appropriate term to describe the outcomes of these studies is “adverse drug event”
(ADE).

1.2 The burden of adverse drug events
ADEs pose a significant challenge to patients, health care providers and the healthcare
system as a whole. A Dutch study found that ADEs caused 41,000 hospitalizations per
year, 2 and a longitudinal German study found that 2.4% of all hospitalizations were
caused by ADEs. 3 Once admitted to hospital, ADEs remain a significant concern.
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Among British inpatients, 850,000 ADEs occur per year, 4 in the United States ADEs
rank as the eighth leading cause of in-hospital death. 5 In addition, the increased duration
of admission caused by ADEs has been estimated to cost the United Kingdom’s National
Health Service over $900 million dollars annually. 6 In a Canadian study that examined
medical errors occurring in hospitals, nearly one quarter were found to involve ADEs. 7
Although these findings are troubling in their own right, the problem of ADEs is even
more significant among elderly patients.

1.3 ADEs and the elderly
Of the 2.4% of hospital admissions attributed to ADEs in the study by Schneeweis,
almost half (46.3%) of the patients were 70 years of age or older. 3 A study conducted by
the Hospital Admissions Related to Medications (HARM) group found that compared to
all unplanned hospitalizations, those related to ADEs were more likely to involve elderly
patients. 8 In addition to being at higher risk for ADE-related hospitalization, elderly
patients are also more likely to experience ADEs once admitted to hospital. Among 346
elderly Dutch patients admitted for a mean of 6 days, 32% experienced an ADE. 9 A
nearly identical finding was reported in a study of 377 patients admitted to a Veterans
Affairs Medical Center. 10 Finally, elderly patients who experience an ADE are more
likely to die or be left with significant disability. 11,12 Many factors predispose elderly
patients to ADEs, including polypharmacy, malnutrition, cognitive impairment, agerelated changes in pharmacodynamics and pharmacokinetics, and co-existing chronic
diseases. 13 In many studies, including a recently published tool for predicting ADEs in
elderly patients, impaired renal function has been identified as a significant ADE risk
factor. 8,14,15
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1.4 The kidney’s role in ADEs
Although the kidney can be a target of ADEs, as in the case of gentamycin-induced acute
tubular necrosis, its primary role is that of a mediator. This mediation occurs via two
mechanisms. First, in all patients, some drugs may disrupt specific renal functions.
Examples include sodium retention induced by non-steroidal anti-inflammatory drugs, 16
potassium wasting induced thaizide diuretics, 17 and the potassium retention caused by
trimethoprim-sulfamethoxazole (TMP-SMX). 18 Second, in patients with impaired renal
function, the therapeutic effects of some drugs can be augmented. This occurs because
many drugs and their active metabolites are cleared from the bloodstream by the kidneys;
such drugs will be cleared at a slower rate in patients with reduced kidney function,
leading to their accumulation. Examples include the anti-metabolite drug methotrexate, 19
the anti-inflammatory agent colchicine, 20 and the hypoglycemic drug glyburide. 21 In
each case, toxicity occurs due to accumulation of the drug (or its active metabolites),
which enhances its therapeutic effect.

1.5 Clinically important kidney-mediated ADEs
There are many consequences of kidney-mediated ADEs; however, some of the most
dangerous are those that affect potassium and glucose homeostasis. Unfortunately,
kidney-mediated derangements in serum concentrations of potassium and glucose can
result from the use of commonly prescribed medications.
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1.5.1

Potassium
The concentration of potassium in the blood is normally maintained between 3.5
and 5.5 millimoles per litre (mmol/L). “Hyperkalemia” refers to a state in which
the potassium concentration exceeds 5.5 mmol/L. Mild hyperkalemia (5.6 to 6.9
mmol/L) is often asymptomatic, but in severe cases (≥ 7.0 mmol/L), hyperkalemia
can cause paralysis and fatal cardiac arrhythmias. The kidney is primarily
responsible for maintaining potassium levels in a safe range, which it does by
excreting excess dietary potassium in the urine. This process involves a number of
hormones, cellular receptors and transmembrane channels. Of particular
importance is the epithelial sodium channel (abbreviated as ENaC). By allowing
the absorption of sodium from the distal tubules of the kidney, the ENaC
establishes an electrochemical gradient that facilitates potassium excretion. 22
Blockade of this channel causes impaired potassium excretion that may lead to
hyperkalemia. In the treatment of high blood pressure, the ENaC can blocked by
two anti-hypertensive medications designed specifically for that purpose
(amiloride and triamterene); however, the ENaC can also be blocked
inadvertently by medications prescribed for reasons unrelated to the channel’s
function. Case reports, 23,24,25,26 and small cohort studies (summarized in Table 11) have suggested that the fixed-dose combination antibiotic trimethoprimsulfamethoxazole (Septra®) is associated with hyperkalemia. 27,28 The
trimethoprim component of this antibiotic is structurally similar to amiloride and
is thought to be responsible for antagonism of the ENaC. 29

5

Although the kidney is responsible for the long-term management of serum
potassium concentrations, short-acting mechanisms are also in place to deal with
sudden increases in serum potassium. In particular, the sympathetic nervous
system is responsible for approximately 40% of the initial compensatory response
to increases in serum potassium. 30 Hyperkalemia stimulates the sympathetic
nervous system to release epinephrine, which binds to beta-2 adrenergic receptors.
This binding increases the activity of the Na-K-ATPase pump resulting in the
movement of potassium from the extracellular fluid (including the blood stream)
into the intracellular fluid. 31 This mechanism has important clinical implications
because the beta-2 adrenergic receptor is blocked by a commonly prescribed class
of drugs called “beta blockers”.

1.5.2

Glucose
Through a complex balance of hyper- and hypoglycemic hormones, serum
glucose concentrations are maintained between approximately 3.9 mmol/L and
7.0 mmol/L. In patients with type II diabetes mellitus (“diabetes”), the effects of
the hypoglycemic hormone insulin are less potent; this results in elevated serum
glucose concentrations. 32 To lower their glucose concentrations, patients with
diabetes may use a number of ‘hypoglycemic’ medications that work through a
variety of mechanisms. Medications such as metformin work by increasing
insulin sensitivity and limiting hepatic glucose production. 33,34 Drugs such as
glyburide work by increasing pancreatic insulin production. 35 Injectable forms of
insulin supplement the body’s own supply of this hormone. These medications are
all effective therapies for patients with diabetes, and all carry a risk of ADEs. One
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of the most important ADEs associated with their use is severe hypoglycemia. If
serum glucose concentrations fall below 3.1 mmol/L patients can experience heart
palpitations, sweating, anxiety, and tremors. 36 Levels that fall below 2.8 mmol/L
are associated with cognitive impairment, seizures, coma and the possibility of
death. 36 Glyburide lies at the nexus of drug-induced hypoglycemia and kidney
function.
Glyburide is a potent member of the sulfonylurea family of hypoglycemic drugs.
It is known to cause hypoglycemia, but its pharmacokinetic characteristics have
implicated it in severe, prolonged cases of hypoglycemia in patients with impaired
kidney function. 21 Glyburide is broken down by the liver into two metabolites,
each of which retains some of the parent compound’s hypoglycemic activity. 37
Because these active metabolites are cleared from the circulation by the kidney,
there exists a potential for them to accumulate and cause severe hypoglycemia in
patients whose kidney function is impaired (see table 1-2). 38

1.6 The need for research
ADEs among elderly patients is a significant cause of morbidity and mortality, and the
kidney’s role in mediating these ADEs is under-recognized. To draw attention to two of
the most important renally mediated ADEs we conducted two studies among elderly
residents of Ontario. First, we examined the risk of hospital admission for hyperkalemia
among elderly patients using both trimethoprim-sulfamethoxazole and beta blockers.
Second, we examined the interaction between impaired renal function and glyburide use
in the risk of severe hypoglycemia.
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1.7 Tables
Table 1-1 Trimethoprim-sulphamethoxazole and hyperkalemia: Literature
summary.
Author

Title

Date

Study
Type

Description

Finding

Low transtubular
Case of

76 year old

potassium gradient and

trimethoprim-

man with

normal plasma renin

hyperkalemia

activity and aldosterone

during

concentrations

prophylaxis

suggested TMP-SMX

against

produced hyperkalemia

associated

Pneumocysti

in a fashion similar to a

vasculitis

s jiroveci.

potassium-sparring

induced
Shishido, T

hyperkalemia

39

complicating

Case
2012

Report
(Japan)

ANCA-

diuretic.
Trimethoprimsulfamethoxazol

Administ

e induced

rative

hyperkalaemia

data

Antoniou, T

in elderly

(ON,

40

patients

2011

Canada)

receiving

Nested

spironolactone:

case-

nested case-

control

17,859

Compared to amoxicillin,

patients co-

those prescribed TMP-

prescribed

SMX had a adjusted

spironolacton

odds ratio of admission

e and short-

to hospital with

course

hyperkalemia of 12.4

antibiotics.

(95% CI 7.1 to 21.6).

control study.

Lam, N

41

Hospital

Administ

admissions for

rative

hyperkalemia
with

2011

data
(ON,

trimethoprim-

Canada)

sulfamethoxazol

Retrosp

393,039
women
prescribed
an antibiotic
for cystitis.

The adjusted odds ratio
for the risk of admission
with hyperkalemia was
3.33 (95% CI 1.32 to
8.42) comparing TMPSMX to amoxicillin.
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e: a cohort study

ective

using health

cohort

care database
codes for
393,039 older
women with
urinary tract
infections

CalderónOrtiz, R

42

Life threatening

3 patients

hyperkalemia

treated with

chronic kidney

standard-

Case

diseases
patients treated

2011

with

series
(Puerto
Rico)

trimethoprim-

dose TMPSMX. All had
pre-existing
chronic

sulfamethoxazol

kidney

e: a case series.

disease.

Refractory hyperkalemia
developed after 4 days
to therapy and in each
case, hemodialysis was
required to normalize
the serum potassium.

Trimethoprimsulfamethoxazol
e-induced

Administ

4148

hyperkalemia in

rative

admissions

patients

data

for

Antoniou, T

receiving

(ON,

hyperkalemia

43

inhibitors of the

Canada)

among users

renin-

Nested

of ACE

angiotensin

case-

inhibitors or

system: a

control

ARBs.

2010

population-

The adjusted odds ratio
of hyperkalemia
admission with the coadministration of ACE or
ARB and TMP-SMX was
6.7 (95% CI 4.5 to 10.0)
compared to coadministration of ACE or
ARB and amoxicillin.

based study.
Influence of
concomitant
Mohan, S

prednisolone on

44

trimethoprimassociated
hyperkalaemia.

Non2009

randomi
zed trial

30 patients

Seven patients

assigned to

developed hyperkalemia

receive either

and all were in the

TMP-SMX

combined therapy

alone (n=12)

group. This is an unclear

or TMP-SMX

relationship between

9

and

prednisone use and the

prednisone

hyperkalemic potential

(n=18) for

of TMP-SMX.

the treatment
of
Pneumocysti
s jiroveci
pneumonia.
Refractory
hyperkalaemia
Sanjay, S
45

due to
trimethoprim,

Case
2007

successfully

report
(India)

treated with

Elderly man
treated with
high-dose
TMP-SMX.

Severe and refractory
hyperkalemia developed
and was treated
successfully with
mineralocorticoid.

fludrocortisone.
The effect of

Effect of

TMP-SMX on

trimethoprimsulfamethoxazol
e on Na and K+
Muto, S

46

transport

2006

properties in the
rabbit cortical
collecting duct

In vitro

the

TMP inhibited the

study of

conductance

amiloride-sensitive

rabbit

of tubule cell

sodium channel on the

renal

apical and

apical membrane of

tubule

basolateral

rabbit cortical collecting

cells

membranes

duct cells.

was studied

perfused in vitro.

in vitro.

Hyponatremia
and/or
hyperkalemia in
patients treated
Mori, H

47

with the
standard dose
of trimethoprimsulfamethoxazol
e.

2003

53 patients

The risk of hyperkalemia

Retrosp

prescribed

was higher among

ective

TMP-SMX

patients on higher doses

cohort

for a variety

of TMP and with more

of infections.

impaired renal function.

10

77 year old

Life threatening

man with

hyperkalemia
Margasser
y

48

,S

and acidosis
secondary to

Case
2001

trimethoprim-

report
(USA)

sulfamethoxazol

occurred with the use of
TMP-SMX and resolved
with its discontinuation.

with

two renal
transplant
treated with

SMX for a

and metabolic acidosis

Two patients

hyperkalemia in

Koç, M

with TMP-

Severe hyperkalemia

infection.

Severe

recipients

CKD, treated

urinary tract

e treatment.

49

moderate

2000

Case
series

standard dose
of trimethoprim-

functioning

Both patients developed

renal

severe hyperkalemia

transplants

that resolved with

treated with

suspension of TMP-

treatment

SMX.

doses of

sulfamethoxazol

TMP-SMX.

e.

Most patients were on a
Nine case

TrimethoprimMarinella,
M

50

induced
hyperkalemia:

Review
1999

An analysis of

of case
reports

reported cases.

reports of
TMP-SMX
associated
hyperkalemia
.

standard dose of TMPSMX. Mean age of
patients was 78 years,
mean duration of
therapy with TMP-SMX
was 10 days. Mean level
of hyperkalemia was 7
mml/L.

Alappan, R
51

Trimethoprim-

97 patients

Mean potassium

sulfamethoxazol

with various

concentrations in the

minor

TMP-SMX group

infections

increased significantly

were

from baseline to day 5.

significant

randomized

Mean potassium levels

problem?

to TMP-SMX

fell over the same time

e therapy in
outpatients: is
hyperkalemia a

1999

Random
ized trial

11

(n=51) or

period in the control

other

group. In the TMP-SMX,

antibiotics

none of the serum

(n=46).

potassium levels
increased to clinically
significant levels. Older
patients taking TMPSMX had larger
increases in potassium
than did younger
patients.

A patient with

Sheehan,
M

52

HIV/AIDS

The patient underwent

contracted

two treatment courses

Hyperkalemic

through

with TMP-SMX and

renal tubular

blood

clinically significant

Case

transfusion

hyperkalemia occurred

report

(sickle cell

both times. The first

(USA)

anemia)

episode resolved when

amethoxazole in

being treated

Amphotericin B was

an AIDS patient.

for

added and the second

Pneumocysti

resolved when TMP-

s jiroveci

SMX was discontinued.

acidosis induced
by

1998

trimethoprim/sulf

pneumonia.
Severe
hyponatraemia

A patient with

and severe

HIV/AIDS

Severe hyperkalemia

Case

being treated

developed after 5 days

report

with TMP for

of treatment and

(USA)

Pneumocysti

resolved upon

who received

s jiroveci

discontinuation of TMP.

high dose co-

pneumonia.

hyperkalaemia
David, L

53

in an HIV

1998

positive patient

trimoxazole.
Marinella,
M

26

Trimethoprimsulfamethoxazol

1997

Case

81 year-old

Hyperkalemia of 6.3

report

man on an

mmol/L developed 4

12

e associated

(USA)

ACE inhibitor

days into treatment with

with

with an

TMP-SMX. It resolved

hyperkalemia

urinary tract

with discontinuation of

infection

the drug.

treated with
TMP-SMX.
71 year-old
man with
Severe

mild CKD

hyperkalaemia

and mild

after

hyporeninae

cotrimoxazole
Elisaf, M

54

administration in

1997

a patient with

Case

mic

report

hypoaldoster

(Greece)

onism who

hyporeninaemic

received

hypoaldosteroni

TMP-SMX

sm.

for a urinary

Hyperkalemia of 7.8
mmol/L developed 5
days into treatment with
TMP-SMX. This
resolved with withdrawal
of the drug.

tract
infection.
Reversible
voltage-

61 year-old

dependent distal

man

Hyperkalemia and

receiving

metabolic acidosis arose

TMP-SMX

after 5 days of treatment

for treatment

with TMP-SMX and

of a urinary

resolved within 2 weeks

of trimethoprim-

tract

of its discontinuation.

sulphamethoxaz

infection.

renal tubular
Lin, S

55

acidosis in a
patient receiving

Case
1997

report
(Taiwan)

standard doses

ole.
Comparison of
oral agents for
Perazella.
M

56

the treatment of
Pneumocystis
carinii
pneumonia.

Prospec
1997

tive
cohort

Patients with

Hyperkalemia > 5.6

HIV/AIDS

mmol/L occurred in

and

20.3% of TMP-SMX,

Pneumocysti

10.3% of dapsone-

s jiroveci

trimethoprim, and 3.5%

pneumonia.

of clindamycin-

13

Treatment

primaquine treated

was with

patients.

TMP-SMX,
dapsonetrimethoprim,
or
clindamycinprimaquine.
Cell lines and
the urine of

Schreiber,
M

57

animals was

Higher concentrations of

alkalinized in

TMP were required to

Antikaliuretic

In vitro

order to see

induce potassium

action of

and

if high pH

retention as the culture

Animal

had the

medium or urine pH

minimized by

study

same

increased. This helped

raising urine pH.

(rats)

inhibitory

confirm that TMP acts in

effect on

a similar way to

TMP as it

amiloride.

trimethoprim is

1996

does on
amiloride.
Intrarenal TMP infusion
caused potassium

Reversal of
Reiser, I

58

trimethopriminduced
antikalluresis.

1996

Intrarenal

retention in the

infusion of

ipsilateral kidney. There

vehicle,

was no effect on the

amiloride, or

contralateral kidney.

Animal

TMP

Concomitant treatment

study

(0.2mg/kg/mi

with furosemide of

(dog)

n). Then

saline infusion reversed

infusion of

the potassium retention.

furosemide

Administration of

or normal

amiloride competed with

saline.

the actions of TMP. This
implicates blockade of
the ENaC as the

14

mechanism by which
TMP causes
hyperkalemia.
Severe

Bugge, J

24

hyperkalaemia

40 year old

induced by

woman with

trimethoprim in

lung

combination

transplant

with an
angiotensin-

Case
1996

report
(Norway)

converting

and TMPSMX
treatment for

enzyme inhibitor

Pneumocysti

in a patient with

s jiroveci

transplanted

pneumonia.

Hyperkalemia of 6.8
mmol/L occurred during
use of TMP-SMX and
ACE inhibitor together.
This resolved with
discontinuation of TMPSMX.

lungs.

80 patients
on standard
dose TMP-

Hyperkalemia in

SMX and 25

hospitalized
Alappan, R
28

patients treated
with

Retrosp
1996

trimethoprim-

ective
cohort

sulfamethoxazol

on other
antibiotics
were
followed for
development

e.

of
hyperkalemia
.

Witt, J

associated with a
significant increase in
serum potassium
concentrations. 62.5%
of patients had a
potassium concentration
over 5.0 mmol/L. 21.2%
had a potassium over
5.5 mmol/L. Those with
pre-existing CKD were
at higher risk for
significant hyperkalemia.

Effect of

33 inpatients

There was a small

standard-dose

on TMP-SMX

increase (0.31 mmol/L)

Retrosp

and 20

in the mean serum

ective

patients on

potassium concentration

cohort

cephradine

of the TMP-SMX group,

potassium

or amoxicillin

but none in the control

concentration in

were

group.

trimethoprim/sulf
59

TMP-SMX was

amethoxazole
on the serum

1996

15

elderly men.

followed for
changes in
serum
potassium.

Case report:

Perlmutter,
E

25

severe

96 year-old

hyperkalemia in

woman with

a geriatric
patient receiving

1996

standard doses

Case

treated with

report

TMP-SMX

(USA)

for a bladder

of trimethoprim-

infection and

sulfamethoxazol

pneumonia.

Hyperkalemia of 9.3
mmol/L developed 1
week into therapy. This
normalized after
withdrawal of TMPSMX.

e.
Acute infusion of TMP
into rats produced no
significant effect on
serum potassium,
creatinine or sodium
concentrations. Chronic
oral intake of TMP over
14 days resulted in
significantly higher
Studies on the
Eiam-Ong,
S

60

mechanism of
trimethopriminduced
hyperkalemia.

Animal
1996

study
(rats)

Rats given
TMP either
acutely or
chronically.

serum potassium levels
compared to control
animals. In dissected
segments of tubules,
Na-K-ATPase activity
was significantly
reduced by TMP in the
cortical and medullary
collecting ducts. There
was no significant
decrease in the function
of the H-ATPase or H-KATPase. This pattern is
consistent with the

16

effects of amiloride.
Hyperkalemia

25 year-old

Hyperkalemia of 6.9

associated with

man with HIV

mmol/L occurred after 8

high-dose

and

days of treatment and

Pneumocysti

after concomitant oral

s jiroveci

potassium

pneumonia

supplementation for an

was treated

initially low level of 3.0

acquired

with high

mmol/L. Hyperkalemia

immunodeficien

dose TMP-

resolved with withdrawal

cy syndrome.

SMX.

of TMP-SMX.

trimethoprimMihm, L

61

sulfamethoxazol
e in a patient

Case
1995

report
(USA)

with the

78 year-old
man treated
with high
Reversible
hyperkalemia
Marinella,
M

62

associated with
trimethoprim-

Case
1995

report
(USA)

sulfamethoxazol
e.

dose IV

Hyperkalemia of 6.2

TMP-SMX

mmol/L occurred after 5

for a severe

days of therapy and

soft-tissue

resolved with

infection. The

discontinuation of TMP-

patient had

SMX.

normal
kidney
function.

Noto, H

63

Severe

Two adult

Hyponatremia

men with

and

hematologic

Hyperkalemia

malignancy

Induced by

who

TrimethoprimSulfamethoxazol
e in Patients

Case
1995

series
(Japan)

developed
Pneumocysti
s jiroveci

with

pneumonia

Pneumocystis

after

carinii

receiving

Pneumonia.

chemotherap

Hyperkalemia
developed in both
patients during
treatment with high dose
TMP-SMX, but not
during subsequent lowdose prophylactic use.
During the treatment
phases, hyperkalemia
resolved with withdrawal
of TMP-SMX.

17

y. TMP-SMX
was used to
treat the
pneumonia in
both cases.

A6 cells

Schlanger,
L

64

K(+)-sparing

In vitro

diuretic actions

(A6

of trimethoprim:

mammal

inhibition of Na+

1994

ian

channels in A6

cortical

distal nephron

tubule

cells.

cell line)

grown on
permeable
supports
were
exposed to
TMP and the
activity of the
ENaC was
assessed.

72 year-old

Hyperkalemia in

woman with

Elderly Patients
Modest, G
23

Receiving
Standard Doses

Case
1994

of Trimethoprim-

report
(USA)

Sulfamethoxazol

sarcoidosis
treated for
pneumonia
with standard
dose TMP-

e

SMX.

Adding TMP to the
basolateral side of the
cells had no effect
ENaC activity, but
adding TMP to the
apical side reduced
ENaC activity 10-fold.
Progressive dilution of
the TMP concentration
produced lower degrees
of ENaC inhibition.

Hyperkalemia of 6.0
mmol/L developed
during the 4 day course
of treatment. The
potassium returned to
normal 24 hours after
stopping TMP-SMX.

A patient with
Hyperkalemia
Greenberg,
S

27

with high-dose
trimethoprim-

1993

sulfamethoxazol

HIV and

Hyperkalemia

Case

Pneumocysti

developed 5 days into

report

s jiroveci

therapy and resolved

(USA)

pneumonia

upon withdrawal of

treated with

TMP-SMX.

e therapy.

TMP-SMX

Greenberg,
S

65

Trimethoprimsulfamethoxazol
e induces

1993

Retrosp

51 patients

For the 26 patients not

ective

admitted with

treated with TMP-SMX,

cohort

symptomatic

the mean serum

18

reversible

HIV infection

potassium remained

hyperkalemia.

between

unchanged over the

1989 and

course of their

1991.

hospitalization. For the

Twenty-five

25 patients treated with

of them

TMP-SMX, the serum

required

potassium underwent a

treatment for

mean increase of 1.1

at least 6

mmol/L (p < 0.0001).

days with

Seven patients had

high dose

potassiums > 5.5

TMP-SMX

mmol/L. Potassium

for

levels returned to

Pneumocysti

baseline after

s jiroveci

withdrawal of TMP-

pneumonia.

SMX.

2 patients

Hyperkalaemia

with

with renal

lymphoid

tubular

malignancy

dysfunction by

who

sulfamethoxazol
e-trimethoprim
Funai, N

66

for

Case
1993

Pneumocystis

series
(Japan)

carinii

mechanism of

hyperkalemia.

treatment with high dose
TMP-SMX and also
subsequently with
standard dose TMPSMX. Hyperkalemia
resolved with the drug’s
withdrawal.

SMX.

Renal

induced

developed during

dose TMP-

malignancy.

H

pneumonia

with high-

lymphoid

trimethoprim-

s jiroveci

treatment

patients with

29

Pneumocysti

and required

pneumonia in

Velázquez,

developed

Hyperkalemia

1993

Human

Human: 30

Despite normal adrenal

and

consecutive

and renal function, TMP-

Animal

patients

SMX increased the

study

being treated

mean serum potassium

(Spragu

with TMP-

levels in the human

e-

SMX.

subjects (0.6 mmol/L,

19

Dawley

Animal: 39

95%CI 0.29 – 0.95).

rats)

male rats

50% of subjects had

with TMP

levels > 5.0 mmol/L. In

infused into

the animals, TMP

the renal

infusion reduced

tubules.

potassium excretion by
40% and depolarized
the lumen-negative
transepithelial voltage
by 66%. These findings
are similar to those
observed with amiloride.
Hyperkalemia of 7.9
mmol/L developed after
9 days of treatment and

A patient with
HIV/AIDS

Brief report:

receiving

trimethoprimChoi, M

67

induced
hyperkalemia in

1993

Case
report

a patient with

high-dose
TMP-SMX
for
Pneumocysti

AIDS.

s jiroveci
pneumonia

a concurrently low
urinary potassium
concentration of 5
mmol/L was noted. The
adrenal function was
normal and
fludrocortisone failed to
increase the urinary
potassium. Both the
hyperkalemia and
hypokaluria resolved
with withdrawal of TMPSMX.

Oral therapy for

60 patients

Mild hyperkalemia

Pneumocystis

with AIDS

occurred in 20% of the

Random

and

patients taking TMP-

ized

Pneumocysti

SMX and 53% of the

controlle

s jiroveci

patients taking TMP-

d trial

pneumonia

dapsone. The peak

cy syndrome. A

randomized

potassium was 6.1

controlled trial of

to TMP-SMX

mmol/L and occurred in

carinii
Medina, I

68

pneumonia in
the acquired
immunodeficien

1990

20

trimethoprim-

or TMP-

the TMP-dapsone

sulfamethoxazol

dapsone

group.

e versus
trimethoprimdapsone.
An HIVinfected 41

Mineralocorticoi
Guy, R

69

d deficiency in

Case
1989

HIV infection.

report
(UK)

year-old man

Unrecognized role of

admitted for

TMP-SMX and the

treatment of

electrolyte abnormalities

Pneumocysti

were attributed to

s jiroveci

mineralocorticoid

pneumonia

deficiency.

with TMPSMX.
Hyperkalemia of 7.7
mmol/L and
A 60 year-old
HIV-infected
man with

Re:
Murphy, C

Mineralocorticoi

70

d deficiency in

1989

HIV infection.

Case

Pneumocysti

report

s jiroveci

(UK)

pneumonia
treated with
high dose
TMP-SMX.

hyponatremia developed
9 days into treatment
and resolved after
cessation of TMP-SMX.
Plasma renin activity
and aldosterone
concentrations were
within expected limits
and therefore ruled out
as a cause of
hyperkalemia in this
patient.

Kalin, M

71

Hyporeninemic

4 patients

The hyperkalemia was

hypo-

with

attributed to

Case

HIV/AIDS

hyporeninemic hypo-

series

and

aldosteronism, but all

acquired

hyperkalemia

four patients were taking

immune

.

TMP-SMX at the times

aldosteronism
associated with

1987

21

deficiency

of their electrolyte

syndrome.

disturbances.

A patient

Renal salt
wasting and
Kaufman,
A

72

metabolic
acidosis with
trimethoprimsulfamethoxazol
e therapy.

Case
1983

report
(USA)

undergoing

Hyperkalemia (7.0

chemotherap

mmol/L) developed 6

y for

days into therapy,

leukemia

resolved with withdrawal

with

of TMP-SMX and then

developed

recurred again after

Pneumocysti

TMP-SMX was re-

s jiroveci

introduced. The authors

pneumonia

speculated that TMP-

and required

SMX was involved, but

treatment

the mechanism was no

with TMP-

known.

SMX.
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Table 1-2 Glyburide and hypoglycemia and patients with CKD: Literature
summary.
Author

Title

Date

Study
Type

Description

Finding

Severe
sulfonylureainduced
hypoglycemia: a
Holstein, A
73

problem of
uncritical

2010

prescription and
deficiencies of
diabetes care in
geriatric

Prospec

All cases of

tive

sulfonylurea-

populati

associated

on-

hypoglycemi

based

a were

observat

registered

ional

from 2000 to

study

2009.

Glyburide accounted for
a number of cases of
hypoglycemia
disproportionate to its
use in the studied
population. Renal
dysfunction was found in
73% of the cases of
hypoglycemia.

patients.
400 German
physicians
were

Characteristics
and time course
of severe
Holstein, A

glimepiride-

74

versus

2003

Survey

glibenclamideinduced
hypoglycaemia.

surveyed and

11 of the 13 patients

asked about

with severe, prolonged

the

hypoglycemia

characteristic

associated with

s of their

glibenclamide

patients who

(glyburide) had impaired

had had

renal function.

severe
hypoglycemi
c episodes.

Lower incidence
Holstein, A

of severe

75

hypoglycaemia
in patients with

2001

Prospec

44 cases of

Despite equivalent

tive

hypoglycemi

exposure, glibenclamide

populati

a requiring

(glyburide) was

on-

hospitalizatio

associated with 38

23

type 2 diabetes

based

n

treated with

observat

cases for glimepiride.

glimepiride

ional

62% of the

versus

study

hypoglycemic patients

glibenclamide

cases, compared to 6

had renal insufficiency.
All case patients were
38 patients
receiving

Krepinsky,
J

21

Prolonged

hemodialysis

sulfonylurea-

: 7 case

induced

patients and

hypoglycemia in

2000

diabetic patients

Casecontrol

31 controls.
Cases had

with end-stage

prolonged

renal disease.

episodes of
hypoglycemi
a.

taking glyburide at the
time of hypoglycemia.
28 out of the 31 control
patients were taking
glyburide. Risk factors
for hypoglycemia in
dialysis patients taking
glyburide included (1)
poor oral intake, (2)
previous hypoglycemia,
(3) longer duration of
diabetes, (4) history of
stroke.
All cases were

Drug-induced
Ben-Ami, H
76

hypoglycemic
coma in 102

Case
1999

diabetic

series
(Israel)

patients.

102 patients
with
hypoglycemi
c coma.

associated with either
insulin or glyburide use.
Renal impairment was a
significant risk factor for
drug-induced
hypoglycemia.

Glibenclamide-

Ben-Ami, H
77

induced

51 patients

hypoglycemic

with

coma in 51 older
patients with
type 2 diabetes
mellitus

1999

Retrosp

glibenclamid

ective

e (glyburide)

cohort

induced
hypoglycemi
a.

Risk factors for
glibenclamide-induced
hypoglycemia included
age > 60 years, renal
dysfunction,
malnutrition, infection,
overdose, cirrhosis,
other liver disease.

24

Hypolgycemia was
Prolonged
Sills, M

78

hypoglycemic
crisis associated

Case
1997

report
(USA)

with glyburide.

79 year old

refractory to medical

patient with

management and

renal

persisted for 3 days.

impairment

Renal dysfunction was

and using

thought to have played a

glyburide.

role in the delayed
clearance of glyburide.

79 year old
Hypoglycemic

woman with

coma induced
Sketris, I

79

by inadvertent
administration of
glyburide.

1984

Case

mild renal

report

insufficiency

(USA)

given 5 mg of
glyburide
mistakenly.

Hypoglycemic lasting 3
days resolved with
continuous IV dextrose
infusion.
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2.1 Introduction
Adverse drug reactions among the elderly are common. It is estimated that 50 serious
adverse drug reactions occur for every 1000 patient-years.1 Drug-induced hyperkalemia
is of particular concern because of its association with commonly used medications and
its significant potential for harm, including sudden death.2-5 Common cardiovascular
agents such as angiotensin converting enzyme inhibitors, angiotensin receptor blockers,
and potassium sparing diuretics all impart a risk of hyperkalemia.2;6-10 Many studies have
suggested an augmented risk of hyperkalemia associated with simultaneous use of two or
more of these agents.11-15 However, there may also be significant risks associated with
other combinations of common, hyperkalemia-inducing medications such as beta
adrenergic receptor blockers (β-blockers) and trimethoprim-sulfamethoxazole antibiotics
(TMP-SMX).
β-blocker prescriptions have steadily increased over the last ten years.16 Their role in
hyperkalemia through inhibition of cellular adrenergic receptor dependent potassium
translocation has been extensively studied.17-19 TMP-SMX is also in common use,
representing 30% of all antibiotics prescribed for urinary tract infections.20;21
Trimethoprim is structurally related to the potassium-sparing diuretic amiloride and has
been shown to block sodium channels in the distal nephron thereby limiting the
electrochemical gradient driving potassium elimination.22-27
Given their popularity, β-blockers and TMP-SMX antibiotics are frequently coadministered. We conducted a nested case-control study using health administrative data
to explore the risk of hyperkalemia conferred by this combination of drugs. We
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hypothesized that concurrent use of β-blockers and TMP-SMX would pose a
substantially greater risk of hyperkalemia requiring hospital admission than would the
use of TMP-SMX alone.

2.2 Materials and Methods
2.2.1

Design

Using health administrative data from July 1, 1994 to March 31, 2008, we established
two cohorts of outpatient residents of Ontario, age 66 years and older. One cohort
included only those with evidence of continuous β-blocker use, and the other included
only those without evidence of any β-blocker use. Within these cohorts, we conducted
separate nested case-control studies comparing the risk of hyperkalemia posed by TMPSMX to that of amoxicillin. To assess interaction between β-blockers and TMP-SMX, we
compared the estimates of risk from the two cohorts. We acquired and analyzed
exposure, outcome and covariate data according to a predefined protocol. The study was
approved by the institutional review board at Sunnybrook Health Sciences Centre,
Toronto, Canada. The reporting of this study follows the STROBE statement
guidelines.28

2.2.2

Setting

Ontario is the most populous Canadian province, with approximately 12 million residents
in the year 2008, of whom 1.6 million were older than 65 years.29 All residents received
universal access to hospital and physician services, and elderly residents received
coverage for prescription medications. Coverage for medical services and medications
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from a single provincial payer provided a comprehensive set of health administrative
data.

2.2.3

Sources of Data

We identified prescription drug use using the Ontario Drug Benefits (ODB) database.
The ODB program provides residents of Ontario 65 years of age or older with coverage
for most prescription medications. We identified all hospitalizations attributed to
hyperkalemia based on ninth and tenth editions of the International Classification of
Disease (ICD-9 and ICD-10) codes recorded in the Canadian Institute for Health
Information Discharge Abstract Database (CIHI-DAD).We obtained covariate
information from multiple databases including the ODB database, CIHI-DAD and the
Ontario Health Insurance Plan (OHIP) database. The OHIP database contains claims
information on inpatient, outpatient and laboratory services rendered to residents of
Ontario. We obtained demographic data from the Registered Persons Database (RPD)
which contains demographic information on all Ontarians ever issued a health card.
Census data from Statistics Canada was linked to postal codes and used to determine
neighborhood income quintile. These databases have been validated in previous
epidemiologic studies.30-34 Data were complete except for 5% of income estimates which
we imputed as the mean.

2.2.4

Participants

Cohorts: Drug coverage for each individual prescription in ODB is maximally 100 days’
duration; therefore, we established the cohort of continuous β-blocker users by including
only those with repeated β-blocker prescriptions that were no more than 100 days apart.
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We established a cohort of non-users by including only those without a β-blocker
prescription in the ODB database.
Cases: Within the cohorts we identified hospitalizations for hyperkalemia within 14 days
after filling a prescription for one of the five study antibiotics: TMP-SMX, ciprofloxacin,
norfloxacin, nitrofurantoin, or amoxicillin. These antibiotics are typically prescribed for
urinary tract infections, which is one of the most common reasons for outpatient
antibiotic therapy.35 We chose these antibiotics to help mitigate indication bias by
restricting the range of possible infections underlying the prescriptions. We chose
amoxicillin as the reference drug because it is one of the most commonly prescribed
antibiotics and its use is not associated with hyperkalemia. We defined cases as
hospitalizations attributed to hyperkalemia at the time of admission (ICD-9 or ICD-10
diagnosis codes 276.7 and E87.5, respectively). The date of hospital admission served as
the index date for all analyses. Among individuals with multiple episodes of
hyperkalemia, we considered only the first hospitalization.
Controls: For each case, we randomly selected up to four patients who had filled a
prescription for a study antibiotic but who had not been hospitalized for hyperkalemia.
Potential controls had the same index date as their corresponding case patient and were
included only if a study antibiotic prescription was detected in the preceding 14 days.
Controls were also matched to cases on age at the index date (± 1 year), sex, history of
chronic kidney disease, and history of diabetes mellitus.
In both cases and controls, we excluded patients with prescriptions for multiple study
antibiotics or a single non-study antibiotic within the 14 days prior to the index date. We
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also excluded those with evidence of end-stage renal disease or renal transplantation in
the three years preceding the index date. All patients were at least 66 years of age at the
time of analysis to ensure the availability of at least one year of drug use records
preceding the index date.

2.2.5

Statistical Methods

We assessed differences between the baseline characteristics of case and control groups
and those who received various types of antibiotics using standardized differences.36;37
We examined odds ratios for hyperkalemia comparing five groups of patients prescribed
different study antibiotics. We used conditional logistic regression to estimate the odds
ratios and their 95% confidence intervals. We adjusted for characteristics that may have
predisposed to hyperkalemia in the multivariable model using all available data in the
three years preceding the index date, including the Charlson comorbidity score (0, 1,
≥2),38;39 the number of distinct prescriptions in the preceding year (≤5, 6-10, 11-15, 1620, 21-25, ≥ 26),40 socioeconomic status (quintiles 1-2, quintiles 3-5), congestive heart
failure, coronary artery disease, and previous episodes of hyperkalemia. We adjusted for
medications used within the 120 day interval prior to the index date that may have
influenced serum potassium concentrations: non-potassium sparing diuretics, potassiumsparing diuretics,7;8 potassium supplements, non-steroidal anti-inflammatory drugs,
angiotensin converting enzyme inhibitors,9 and angiotensin receptor blockers.6 We
assessed for a statistical interaction by comparing the odds ratios from the two cohorts
using the technique of Altman and Bland; the odds ratio from the first cohort reflected the
risk of hyperkalemia among users of both β-blockers and TMP-SMX, and the odds ratio
from the second cohort reflected the same risk among users of TMP-SMX alone.41 Two-
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tailed p values of less than 0.05 were interpreted as statistically significant. We conducted
all analyses using SAS 9.1.3 software (SAS Institute, Carey, NC).

2.2.6

Additional Analyses

Severity of hospital admissions: For case patients, we determined the median duration of
the hospital admission, whether there was an intensive care unit admission, and whether
the patient died during the hospital admission.
Dose response: To identify a dose-response relationship, we repeated the primary
analysis with the TMP-SMX exposure stratified into single strength (400mg/80mg) and
double strength (800mg/160mg) dose categories. We expected a higher risk of
hyperkalemia with a larger dose of TMP-SMX.
Time from antibiotic prescription: We altered the time from antibiotic prescription and
index date first to 7 days and then 21 days rather than 14 days as used in the primary
analysis.
β-1 receptor selectivity: We repeated the primary analysis and test for interaction
differentiating between β-1-selective and non-selective β-blockers. Given the role of the
β-2 adrenergic receptor in translocation of potassium, we expected to find a stronger
relationship with hyperkalemia when TMP-SMX was used in the setting of non-selective
β-blockers.17;42;43
Serum potassium testing: For the purposes of billing, the performing of serum potassium
tests but not the test results are recorded in Ontario administrative databases. We
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examined the number of outpatient serum potassium tests performed between the dates of
antibiotic prescription and the index date.
Absolute risk of hyperkalemia: To obtain a crude estimate of the absolute risk of hospital
admission for hyperkalemia we ascertained the number of cohort patients who received at
least one TMP-SMX prescription and the number of those who required admission for
hyperkalemia within the following 21 days.
Absolute risk of death: To obtain a crude estimate of the absolute risk of death we
ascertained the number of cohort patients who received at least one TMP-SMX
prescription and the number of those who died within the following 21 days.

2.3 Results
2.3.1

Primary Analysis

During the 14 year accrual period we identified a cohort of 299,749 β-blocker users. Of
these, 31,186 filled at least one prescription for TMP-SMX and 195 were admitted to
hospital for hyperkalemia. We excluded six cases who could not be matched to a control.
The final sample comprised 189 cases of hyperkalemia and 641 controls.
Characteristics according to hyperkalemia and antibiotic use are shown in table 2-1 and
table 2-2, respectively. Cases had slightly lower incomes and greater comorbidity (table
2-1). The distribution of baseline characteristics was relatively consistent across the five
types of antibiotics (table 2-2). As shown in table 2-3, among patients receiving βblockers, those receiving concomitant TMP-SMX were five times more likely to be
hospitalized for hyperkalemia than patients using amoxicillin (adjusted odds ratio [OR]
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5.1, 95% CI 2.8 to 9.4). No significant associations were observed between the other
study antibiotics and admissions for hyperkalemia.
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Table 2-1 Characteristics of beta blocker users admitted to hospital with
hyperkalemia and matched controls.*
Cases
N = 189

Controls
N = 641

80 (73-84)

80 (74-84)

65-74

56 (29.6)

189 (29.5)

75-84

88 (46.6)

305 (47.6)

≥ 85

45 (23.8)

147 (22.9)

Male sex

66 (34.9)

219 (34.2)

1 to 2 (lower)

100 (52.9)

286 (44.6) †

3 to 5 (higher)

89 (47.1)

355 (55.4) †

Demographic and medical characteristics
Age, years
Age groups

Income quintile

Charlson Score
0

30 (15.9)

224 (34.9)

1

26 (13.8)

115 (17.9) †

≥2

133 (70.4)

302 (47.1) †

<6

17 (2.7)

6 to 10

13 (6.9)

156 (24.3) †

11 to 15

58 (30.7)

191 (29.8)

16 to 20

59 (31.2)

171 (26.7) †

21 to 25

31 (16.4)

59 (9.2) †

≥ 26

25 (13.2)

47 (7.3) †

Congestive heart failure

113 (59.8)

273 (42.6) †

Coronary artery disease

138 (73.0)

393 (61.3) †

Diabetes

81 (42.9)

245 (38.2)

Chronic kidney disease

99 (52.4)

316 (49.3)

Prior hospitalisation for hyperkalemia

16 (8.5)

13 (2.0) †

Non-potassium sparing diuretics

124 (65.6)

319 (49.8) †

Potassium sparing diuretics

52 (27.5)

72 (11.2) †

<6

8 (1.2) †

69 (36.5)

231 (36.0)

No. of prescription drugs in previous year
≤5

Medication use in preceding 120 days

Potassium supplements
NSAIDs

ACE / ARB
133 (70.4)
343 (53.5) †
* Data presented as number (percent) with the exception of age, which is presented as median (interquartile range). In
accordance with Ontario privacy law, patient values less than 6 are not reported. NSAID, non-steroidal antiinflammatory drug; ACE, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker.
†
Indicates a standardised difference between case patients and controls greater than 10%. Standardised differences are
less sensitive to sample size than tradition hypothesis tests. They provide a measure of the difference between groups
divided by the pooled standard deviation.36;37
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TMP-SMX

Ciprofloxacin

Norfloxacin

Nitrofurantoin

Amoxicillin

Table 2-2 Characteristics of beta blocker users by antibiotic use.*

N = 223

N = 210

N = 109

N = 108

N = 180

80 (74-86)

80 (73-84)

81 (76-85)

81 (75-86)

78 (71-82)

65-74

63 (28.3)

68 (32.4)

25 (22.9)

24 (22.2)

65 (36.1)

75-84

98 (43.9)

99 (47.1)

52 (47.7)

52 (48.1)

92 (51.1)

≥ 85

62 (27.8)

43 (20.5)

32 (29.4)

32 (29.6)

23 (12.8)

77 (34.5)

83 (39.5)

35 (32.1)

20 (18.5)

70 (38.9)

1 to 2

109 (48.9)

106 (50.5)

47 (43.1)

45 (41.7)

79 (43.9)

3 to 5

114 (51.1)

104 (49.5)

62 (56.9)

63 (58.3)

101 (56.1)

0

59 (26.5)

52 (24.8)

41 (37.6)

35 (32.4)

67 (37.2)

1

40 (17.9)

35 (16.7)

19 (17.4)

13 (12.0)

34 (18.9)

≥2

Demographics and medical characteristics
Age
Age group

Male
Income Quintile

Charlson Score

124 (55.6)

123 (58.6)

49 (45.0)

60 (55.6)

79 (43.9)

Congestive heart failure

112 (50.2)

102 (48.6)

53 (48.6)

45 (41.7)

74 (41.1)

Coronary artery disease

146 (65.5)

145 (69.0)

67 (61.5)

61 (56.5)

112 (62.2)

Diabetes in past 3 years

93 (41.7)

78 (37.1)

41 (37.6)

43 (39.8)

71 (39.4)

Prior hospitalisation for hyperkalemia

11 (4.9)

<6

<6

<6

<6

122 (54.7)

101 (48.1)

49 (45.0)

64 (59.3)

79 (43.9)

Chronic kidney disease
No. of prescription drugs in previous year
≤5

<6

<6

7 (6.4)

<6

<6

6 to 10

32 (14.3)

36 (17.1)

26 (23.9)

17 (15.7)

58 (32.2)

11 to 15

80 (35.9)

61 (29.0)

33 (30.3)

29 (26.9)

46 (25.6)

16 to 20

65 (29.1)

65 (31.0)

24 (22.0)

32 (29.6)

44 (24.4)

21 to 25

24 (10.8)

25 (11.9)

11 (10.1)

13 (12.0)

17 (9.4)

≥ 26

20 (9.0)

18 (8.6)

8 (7.3)

14 (13.0)

12 (6.7)

Non-potassium sparing diuretics

127 (57.0)

122 (58.1)

51 (46.8)

58 (53.7)

85 (47.2)

Potassium sparing diuretics

32 (14.3)

41 (19.5)

18 (16.5)

15 (13.9)

18 (10.0)

<6

<6

0

<6

<6

83 (37.2)

83 (39.5)

38 (34.9)

21 (19.4)

75 (41.7)

Medication use in preceding 120 days

Potassium supplements
NSAIDs

ACE / ARB
146 (65.5)
128 (61.0)
46 (42.2)
58 (53.7)
98 (54.4)
* Data presented as number (percent) with the exception of age, which is presented as median (interquartile range). In
accordance with Ontario privacy law, patient values less than 6 are not reported. NSAID, non-steroidal antiinflammatory drug; ACE, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker.
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The cohort of non-β-blocker users had a distribution of baseline characteristics similar to
that of the β-blocker cohort (tables available upon request). Among non-β-blocker users
we identified 1349 cases patients and 5378 controls (table 2-4). The OR for hyperkalemia
requiring hospital admission comparing TMP-SMX to amoxicillin was 5.8 (95% CI 4.7
to 7.3). This was not significantly different from the risk associated with TMP-SMX use
among β-blocker users (p value for interaction 0.65). This indicated the risk of
hyperkalemia was attributable to TMP-SMX alone, rather than its combination with βblockers.
Table 2-3 Association between hospitalization for hyperkalemia and antibiotic use
among beta blocker users.*
Cases

Controls

N = 189

N = 641

Unadjusted

TMP-SMX

98 (51.9)

125 (19.5)

5.9 (3.4 – 10.2)

5.1 (2.8 – 9.4)

Ciprofloxacin

51 (27.0)

159 (24.8)

2.3 (1.3 – 4.1)

1.8 (0.9 – 3.3)

8 (4.2)

101 (15.8)

0.7 (0.3 – 1.5)

0.5 (0.1 – 1.2)

Variable

Norfloxacin

Odds Ratio (95% CI)
Adjusted

Nitrofurantoin

12 (6.3)

96 (15.0)

0.9 (0.4 – 2.0)

0.7 (0.3 – 1.7)

Amoxicillin †

20 (10.6)

160 (25.0)

1.0

1.0

* CI, confidence interval, TMP-SMX, trimethoprim-sulfamethoxazole
† Amoxicillin users served as the reference group

Table 2-4 Association between hospitalization for hyperkalemia and antibiotic use
among non-beta blocker users.*
Variable
TMP-SMX
Amoxicillin

†

Cases

Controls

N = 1349

N = 5378

670 (49.7)

1064 (19.8)

6.3 (5.2 – 7.7)

5.8 (4.7 – 7.3)

163 (12.1)

1603 (29.8)

1.0

1.0

* CI, confidence interval, TMP-SMX, trimethoprim-sulfamethoxazole
† Amoxicillin users served as the reference group

Odds Ratio (95% CI)
Unadjusted

Adjusted
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2.3.2

Additional Analyses

Severity of hospital admissions: For the 189 hospitalizations for hyperkalemia within the
β-blocker cohort, the median length of stay was 7 days (interquartile range 4 to 13 days);
17 patients (9%) were admitted to intensive care units, and 26 died during their hospital
stay (14%).
Dose-response: There was graded association with hospital admissions for hyperkalemia
when TMP-SMX use was stratified by dose. For single-strength tablets the adjusted OR
was 3.4 (95% CI 1.6 to 7.4) compared to 6.6 (95% CI 3.5 to 12.6) for double-strength
tablets.
Time from antibiotic prescription: When we altered the time from antibiotic prescription
to index date, the risk of hospital admission for hyperkalemia with TMP-SMX compared
to amoxicillin was unchanged (7 days OR 5.5, 95% CI 2.3 to 13.0; 21 days OR 5.9, 95%
CI 3.3 to 10.4).
β-blocker selectivity: The prevalence of non-selective β-blocker usage (7.3%) was
insufficient for meaningful analysis.
Serum potassium testing: Between the date of antibiotic prescription and index date, 26
(14%) of case patients and 33 (5%) of controls had an outpatient serum potassium
measurement. There was no difference in the proportion of patients tested across the five
types of antibiotic users (between 6 to 7% for all five types).
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Absolute risk of hyperkalemia: Within the β-blocker cohort, for every 1000 TMP-SMX
prescriptions there were 6.9 (95% CI, 6.0 to 7.9) hospital admissions attributed to
hyperkalemia within the subsequent 21 days. In comparison, there were 2.9 (95% CI, 2.4
to 3.4) admissions for every 1000 amoxicillin prescriptions.
Absolute risk of death: Within the β-blocker cohort, for every 1000 TMP-SMX
prescriptions there were 26.2 (95% CI, 24.5 to 28.0) deaths within the subsequent 21
days. In comparison, there were 15.7 (95% CI, 14.6 to 16.9) deaths for every 1000
amoxicillin prescriptions.

2.4 Discussion
2.4.1

Main Finding

Based on their pharmacodynamic interaction, we hypothesized that concomitant βblocker and TMP-SMX use would be associated with an excess risk of hyperkalemia.
While we did observe a significant risk of hyperkalemia among elderly users of TMPSMX, concomitant β-blocker use did not augment this risk.

2.4.2

Interpretation

The role of β-blockers in hyperkalemia among elderly ambulatory patients may not be as
great as originally anticipated. Historic evidence for this role comes largely from
experimental studies, where β-blocker administration has been associated with transient
rises in serum potassium concentrations in the local circulation of heavily exercising
limbs, in anuric dialysis patients, or subsequent to potassium-chloride infusion.18;42-47 In
some clinical studies of hyperkalemic events, the causal role of β-blockers has been
assumed without the presence of a referent group,2;48 and in other studies their role has
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been examined only in high-risk patient populations.49-51 Conversely, in more rigorously
conducted clinical studies, β-blockers were not associated with hyperkalemia.6;52;53 Our
study does not refute the physiologic effects of β-blockers, but does suggest their
contribution to hyperkalemia in ambulatory patients may be relatively minor. An
important caveat is the high prevalence of β-1-selective agent use in our cohort. This
distribution of β-blocker selectivity reflects the usage of these drugs in Ontario and does
not threaten the external validity of our study; however, extension of our findings to a
specific population of non-selective β-blocker users would not be appropriate.
Furthermore, in detecting modest effects, tests of statistical interaction are of limited
power and failure to show significant effect measure modification does not rule out a
biological interaction.
Although the absolute rate of hospital admissions with a primary diagnosis of
hyperkalemia was small, this finding must be interpreted judiciously. Our definition of
hyperkalemia was very strict. We did not count events that did not prompt hospital
admission, emergency room visits without hospital admission, hospital admissions
attributed to another primary reason, or more severe events resulting in prehospital death.
It is of concern that in absolute terms, the risk of death within 21 days of antibiotic use
appeared higher in TMP-SMX users compared to those who took amoxicillin.
Nonetheless, with all antibiotics there is a potential for adverse events that must be
balanced against their benefits. We recognize the importance of TMP-SMX in the
modern antibiotic armamentarium and do not suggest curtailing its use. Rather, it is likely
that some cases of severe morbidity associated with TMP-SMX may be prevented

49

through simple measures such as serum potassium testing. In this analysis, only a small
proportion of patients had such testing in the days following TMP-SMX prescription.

2.4.3

Strengths and Limitations

Our study has a number of strengths. The interaction between β-blockers and TMP-SMX
has not been previously examined in a population-based study. Although the results can
be generalized only to the elderly, our study was free of the screening biases that arise in
the setting of clinical trials and restrictive cohorts. Ontario’s universal health care system
allowed us to draw upon the records of approximately 1.4 million people over the age of
66 years. The large sample afforded a unique opportunity to examine a relatively rare yet
serious adverse drug event. Furthermore, emigration out of the Ontario Health Insurance
plan is less than one percent per year, making it a very stable dataset (2001 Canadian
Census).
The most important limitation of our study is the non-random allocation of the study
antibiotics. Therefore, residual confounding is certainly a possibility in driving the
findings. Information on risk factors such as dietary potassium intake, non-prescription
medication use, and medication compliance is not recorded within the administrative
databases. Confounding by indication could also have occurred because severe infections
can predispose to hyperkalemia through sepsis and resultant kidney injury. TMP-SMX is
active against common and virulent organisms such as Staphylococcus aureus and
methicillin-resistant Staphylococcus aureus, so it is possible that patients treated with
TMP-SMX had particularly severe infections compared to patients using other types of
antibiotics.54-56 We attempted to avoid this problem by restricting our case definition to
patients admitted with a primary diagnosis of hyperkalemia, rather than hyperkalemia
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occurring secondary to sepsis or acute kidney injury. Furthermore, while we cannot know
the impact of potential confounders, the magnitude of the risk estimate observed in the
primary analysis provides reassurance of a true biological effect. It is difficult to conceive
of an unmeasured confounder that is predictive of hyperkalemia and differentially present
among the various antibiotic types to the extent that it accounts for all of the excess risk
we observed.
We relied upon administrative databases and diagnostic codes to define the study
outcome. Although our definition of hyperkalemia has not been validated, we believe it
to be reliable for two of reasons. A similar definition of hyponatremia was shown to have
a specificity greater than 99%.57 Also, electrolyte disturbances as a whole are accurately
recorded in the CIHI-DAD with a sensitivity of 80% and a specificity greater than 95%.32
Misclassification of exposure and outcome variables can occur when using health
administrative data. However, the occurrence of coding errors between cases, controls
and the β-blocker and non β-blocker cohorts was unlikely to have occurred at differential
rates.
Finally, knowledge of the hyperkalemic effects of β-blockers and TMP-SMX may have
caused some physicians to more frequently measure serum potassium levels in patients
who were using these drugs. However, there was no difference in rates of outpatient
potassium measurement between antibiotic types. As well, serum electrolyte
measurement is a routine component of emergency department assessment, making
differential case ascertainment between exposure groups less likely.

51

2.5 Conclusions
Our study shows a significant, biologically plausible, dose-dependent risk of
hyperkalemia among elderly users of TMP-SMX. Physicians should be cognizant of this
risk and consider measurement of serum potassium in older patients treated with this
antibiotic.
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3.1 Introduction
Strict glycemic control is a tenet of diabetes mellitus management because it is associated
with improved micro- and macrovascular outcomes.1-8 Diabetes is the primary etiology in
one quarter of patients with chronic kidney disease (CKD) and about half of those with
end-stage renal disease (ESRD).9;10 Among patients with established diabetic
nephropathy, disease progression can be slowed by controlling blood glucose to nearnormal levels.1;4;7;11 However, this rigorous control is achieved at the expense of an
increased rate of hypoglycemic events.1;7
The risk of hypoglycemia is a particular concern among patients with impaired renal
function.12 In these patients, the counter-regulatory response to hypoglycemia may be
limited by impaired renal gluconeogenesis or poor glycogen reserves caused by uremiainduced anorexia.13-15 In addition, the clearance of some commonly prescribed diabetes
therapies depends on renal function. This is the case for glyburide, the active metabolites
of which are slowly eliminated in the setting of impaired renal function.16-20 Based
largely on glyburide’s pharmacokinetic data, national treatment guidelines have
recommended avoiding its use once the estimated glomerular filtration rate (eGFR) falls
below 60 ml/min/1.73m2.21 However, the body of evidence supporting this
recommendation is weak and contradictory,22;23 and the limited clinical data on
glyburide’s hypoglycemic potential has arisen from descriptive studies and small
observational studies.24-26 Glyburide remains an effective diabetes therapy that has been
used in a trial demonstrating the benefits of strict glycemic control.1 Unfortunately, this
trial is of little use in understanding glyburide’s side-effect profile because, like many
trials, it did not include patients with CKD.27 Without a clear understanding of the risk
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glyburide poses to patients with impaired renal function we cannot adequately assess the
appropriateness of its use in this population.
To quantify this risk in a large population-based analysis, we conducted two nested casecontrol studies using outpatient laboratory data that we linked to Ontario’s health
administrative data. We designed each study to assess drug-specific hypoglycemia risks
in patients with impaired and normal kidney function. We hypothesized that the risk of
severe hypoglycemic events in patients using glyburide would be greater in those with
impaired kidney function compared to those with normal kidney function.

3.2 Materials and Methods
3.2.1

Design

We used health administrative databases in Ontario, Canada to establish a nest cohort of
patients older than 65 years with diabetes. Within this cohort we conducted two casecontrol studies to assess the risk of hypoglycemia associated with the use of glyburide or
insulin as compared to the reference drug, metformin. Two studies were done to explore
the interaction between renal function and these diabetes therapies in terms of their
hypoglycemic risks; patients with eGFR values above 60 mL/min/1.73m2 were included
in the first study, and patients with an eGFR value below this level were included in the
second study. To assess interaction we compared adjusted odds ratios derived from the
two studies. We collected and analyzed all exposure, outcome and covariate data
according to a predefined protocol. The study was approved by the institutional review
board at Sunnybrook Health Sciences Centre, Toronto, Canada and its design and
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reporting follow the Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) statement guidelines.28

3.2.2

Setting

We acquired data from January 1, 1997 to March 31, 2008 using the linked health
administrative data of Ontario, Canada. Ontario has approximately 12 million residents,
1.6 million of whom are 65 years of age or older.29 All Ontario residents receive
universal access to physician and hospital services through the Ontario Health Insurance
Plan (OHIP). Ontario residents older than 65 years also receive universal formulary
coverage for prescription medications through the Ontario Drug Benefits (ODB)
program. Ontario’s single health insurance payer and the yearly emigration rate of less
than one percent provide a set of health administrative data that is both comprehensive
and stable.30

3.2.3

Sources of Data

We ascertained dispensed prescription medications using the ODB database, which has a
basic error rate less than one percent.31 We collected data regarding inpatient and
outpatient hospital visits from the Canadian Institute for Health Information Discharge
Abstract Database (CIHI-DAD) and the National Ambulatory Care Reporting System
(NACRS) database. These databases contain detailed diagnostic information coded using
the ninth and tenth revisions of the International Classification of Disease (ICD-9 and
ICD-10). The coding accuracy of these databases has been assessed for many
diagnoses.32;33 We determined kidney function using serum creatinine values obtained
from the Gamma-Dynacare laboratory database. Gamma-Dynacare laboratories provide
ambulatory blood work in South-Western Ontario and have maintained a database of test
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results since 2002. We collected demographic information and vital statistics from the
Registered Persons Database (RPD) and we estimated neighborhood income levels using
Statistics Canada census data.34 We also collected diagnostic information and physician
service claims data from the Ontario Health Insurance Plan (OHIP) database.

3.2.4

Participants

Cohorts: In order to estimate GFR for all participants, we restricted cohort entry to those
with at least one serum creatinine measurement. These measurements were available
beginning January 1, 2002. Outcome ascertainment began on this date and continued to
March 31, 2008, the last date for which complete data were available. To ensure all
cohort members had at least one full year of medication use data, we restricted entry to
those aged 66 years and older as of March 31, 2008. Finally, to exclude diet-controlled
diabetes, we included only patients with at least one prescription for a diabetes therapy.
Cases and Controls: We studied patients separately in groups determined by renal
function (“normal” or “impaired”, defined by their most recent eGFR). In each of the two
studies we defined cases as cohort members who presented to an emergency room or
hospital with an admission diagnosis of hypoglycemia. We identified these events by
detecting hypoglycemia diagnosis codes in either the CIHI-DAD or NACRS databases
(ICD-9 codes 250.8, 251.0, 251.1, 251.2, or 962.3; ICD-10 codes E10.63, E11.63,
E13.63, E14.63, E15, E16.0, E16.1, or E16.2). For patients with multiple hypoglycemic
events during the study period, only the first event was counted. The date of the
hypoglycemic event served as the index date. For each case, we randomly selected up to
four cohort patients who at the time of the index date had no evidence of a hypoglycemic
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event during the study period. These controls were matched to cases on age at the index
date (±1 year) and sex.
Exposure Status: For all patients, we searched the ODB database in the 120 day interval
immediately preceding the index date to identify prescriptions for diabetes therapies. The
ODB formulary provided coverage for the following diabetes therapies: acarbose,
gliclazide, glyburide, glimepiride, chlorpropamide, tolbutamide, metformin, pioglitazone,
rosiglitazone, nateglinide, repaglinide, and multiple formulations of insulin. To simplify
interpretation, we excluded patients with prescriptions for more than one type of diabetes
therapy in the 120 days prior to the index date. Patients with a prescription for metformin
served as the reference group for comparison with each of the other drugs. Patients with
prescriptions for different insulin formulations were all deemed to be taking insulin.
Renal Function: Using the abbreviated Modification of Diet in Renal Disease (MDRD)
formula,35 we used the most recent serum creatinine value prior to the index date to
calculate each patient’s eGFR. For the primary analysis, patients with an eGFR less than
60 mL/min/1.73m2 were considered to have impaired kidney function while those with an
eGFR greater than or equal to 60 mL/min/1.73m2 were considered to have normal renal
function. All serum creatinine measurements during the study period were calibrated for
use in the MDRD formula.
Potential Confounders: Point estimates of risk were adjusted for multiple baseline
characteristics, confounding diagnoses and medication exposures.
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3.2.5

Statistical methods

We used standardized differences to compare baseline characteristics between case and
control groups, and groups receiving different diabetes therapies. This metric describes
differences between group means relative to the pooled standard deviation, and is deemed
significant if greater than 10%.36;37 We conducted the primary analysis separately for
each of the two studies. Using conditional logistic regression, we estimated odds ratios
and 95% confidence intervals describing the risk of hypoglycemia for glyburide and
insulin compared to metformin. We forced four variables well-associated with
hypoglycemia into the regression models (Charlson score, hospital discharge within 30
days prior to index date, infection within 21 days prior to index date, and liver disease).
We included other variables based on their performance in bivariate testing. Those
having an association with hypoglycemia with a two-sided p value less than or equal to
0.2 were included in the regression model. We used a two-tailed Type I error rate of less
than 0.05 as the threshold for statistical significance. We conducted all analyses with
SAS 9.1.3 software (SAS Institute, Carey, NC).
To assess interaction between specific diabetes therapies and renal function, we
compared the drug-specific adjusted odds ratios that were determined separately for the
impaired and normal kidney function groups using the technique of Altman and Bland.38
Altered definition of impaired renal function: To explore the effect of altering the
definition of impaired renal function, we repeated the primary analysis using eGFR cutoff
values of 45 and 30 mL/min/1.73m2.
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3.3 Results
3.3.1

Participants

Over the accrual period we identified 19,620 patients aged 66 years and older with one or
more serum creatinine levels who had at least one prescription for a diabetes therapy.
Within this cohort, 364 patients with impaired kidney function experienced a
hypoglycemic event after use of a single drug. We identified 207 such cases among those
with normal kidney function. Matching was relatively complete with only 13 cases
excluded for lack of a matched control (ten from the impaired kidney function group and
three from the normal kidney function group). Although we recorded exposure data on all
diabetes therapies in the province-wide drug formulary, only metformin, glyburide and
insulin provided enough data for meaningful analysis.
Patient characteristics according to hypoglycemic events and diabetes therapy are shown
in table 3-1 and table 3-2. Cases and controls within both renal function groups were
similar with respect to age and socioeconomic status; however case patients were more
likely than controls to have significant comorbidities, and were more likely to have
higher stage CKD. Table 3-2 shows a similar pattern, with patients prescribed glyburide
or insulin more likely to have markers of poor health than those receiving metformin.
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Table 3-1 Baseline characteristics for cases and matched controls
NORMAL
RENAL FUNCTION

Demographics
Age at Index Date
66-74
75-84
≥ 85
Female
Income Quintile
≤2
≥3
Co-morbidity†
No. of distinct prescriptions in last year
Charlson Score
≤1
2
≥3
Missing§
Hospital discharge within 30 days
Infection within 30 days
Liver disease
Alcoholism
Coronary artery disease
Congestive heart failure
Cerebrovascular disease
Number of primary care visits
Number of internist visits
Previous hypoglycemic event
Kidney Function
Serum creatinine, mg/dL
eGFR mL/min/1.73 m2
Most recent eGFR category
Normal: ≥ 90 mL/min/1.73m2
Normal: 60 to 89 mL/min/1.73m

2

IMPAIRED
RENAL FUNCTION

Control

Case

Control

Case

N=802

N=204

N=1,290

N=354

326 (40.6)
371 (46.3)
105 (13.1)
397 (49.5)

84 (41.2)
93 (45.6)
27 (13.2)
102 (50.0)

417 (32.3)
616 (47.8)
257 (19.9)
660 (51.2)

112 (31.6)
174 (49.2)
68 (19.2)
183 (51.7)

368 (45.9)
432 (53.9)

89 (43.6)
115 (56.4)

555 (43.0)
729 (56.5)

167 (47.2)
187 (52.8)

10 (7-14)

13 (10-19) ‡

13 (9-17)

15 (11-21)‡

349 (43.5)
103 (12.8)
157 (19.6)
193 (24.1)
21 (2.6)
63 (7.9)
35 (4.4)
9 (1.1)
253 (31.5)
148 (18.5)
163 (20.3)
1 (0-3)
1 (0-4)
10 (1.2)

56 (27.5) ‡
48 (23.5) ‡
76 (37.3) ‡
24 (11.8) ‡
33 (16.2) ‡
30 (14.7) ‡
16 (7.8) ‡
6 (2.9) ‡
94 (46.1) ‡
65 (31.9) ‡
66 (32.4) ‡
2 (0-3) ‡
4 (1-8) ‡
20 (9.8) ‡

452 (35.0)
192 (14.9)
430 (33.3)
216 (16.7)
62 (4.8)
113 (8.8)
56 (4.3)
13 (1.0)
637 (49.4)
478 (37.1)
320 (24.8)
1 (0-3)
2 (0-7)
58 (4.5)

79 (22.3) ‡
53 (15.0)
188 (53.1) ‡
34 (9.6) ‡
43 (12.1) ‡
62 (17.5) ‡
23 (6.5) ‡
6 (1.7)
211 (59.6) ‡
177 (50.0) ‡
101 (28.5)
1 (0-3)
6 (2-10) ‡
38 (10.7) ‡

0.9 (0.7-1.0)

0.9 (0.7-1.0)

1.4 (1.2-1.7)

1.6 (1.3-2.0) ‡

76 (68-87)

74 (67-87)

46 (35-53)

40 (28-50) ‡

171 (21.3)

39 (19.1)

--

--

631 (78.7)

165 (80.9)

--

--

CKD III: 30 to 59 mL/min/1.73m2

--

--

1,081 (83.8)

247 (69.8) ‡

CKD IV: 15 to 29 mL/min/1.73m2

--

--

168 (13.0)

83 (23.4) ‡

--

--

41 (3.2)

24 (6.8) ‡

249 (31.0)
433 (54.0)

69 (33.8)
118 (57.8)

564 (43.7)
740 (57.4)

168 (47.5)
209 (59.0)

34 (4.2)
194 (24.2)
39 (4.9)

15 (7.4) ‡
38 (18.6) ‡
14 (6.9)

72 (5.6)
346 (26.8)
56 (4.3)

37 (10.5) ‡
78 (22.0) ‡
23 (6.5) ‡

140 (17.5)

53 (26.0)

335 (26.0)

109 (30.8)

CKD V: < 15 mL/min/1.73m
Hypoglycemic Medications
β – Blockers
ACE Inhibitors
Hyperglycemic Medications
Corticosteroids
Thiazide diuretics
Atypical antipsychotics
Diabetes Therapy Use
Glyburide

2
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Metformin

545 (68.0)

27 (13.2)

551 (42.7)

29 (8.2)

Insulin

117 (14.6)

124 (60.8)

404 (31.3)

216 (61.0)

Note: Data presented as number (percent) or as median (interquartile range). In accordance with Ontario privacy law,
patient values less than 6 are not reported. In accordance with Ontario privacy law, patient values less than 6 are not
reported. Conversion factors for units: serum creatinine in mg/dL to mol/L, ×88.4
† Comorbidity data was obtained for the 5 years prior to the index date unless otherwise specified.
‡ Indicates a standardized difference between cases and controls greater than 10%. Standardized differences are less
sensitive to sample size than tradition hypothesis testing. They express the difference between the means of two
populations as a proportion of the pooled standard deviation.36;37
§ Charlson scores were based on previous hospitalizations, and are only missing where patients did not have a
previous hospitalization.
Abbreviations: eGFR, estimated glomerular filtration rate; CKD, chronic kidney disease; ACE, angiotensin
converting enzyme.
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Table 3-2 Baseline characteristics according to diabetes therapy used
NORMAL
RENAL FUNCTION

IMPAIRED
RENAL FUNCTION

Metformin
N=572

Glyburide
N=193

Insulin
N=241

Metformin
N=580

Glyburide
N=444

Insulin
N=620

244 (42.7)
259 (45.3)
69 (12.1)
278 (48.6)

57 (29.5)‡
95 (49.2)
41 (21.2) ‡
95 (49.2)

109 (45.2)
110 (45.6)
22 (9.1)
126 (52.3)

179 (30.9)
282 (48.6)
119 (20.5)
309 (53.3)

111 (25.0)‡
220 (49.5)
113 (25.5) ‡
216 (48.6)

239 (38.5)§
288 (46.5)
93 (15.0) §
318 (51.3)

253 (44.2)
319 (55.8)

102 (52.8) ‡

89 (46.1) ‡

102 (42.3)
139 (57.7)

246 (42.4)
330 (56.9)

203 (45.7)
240 (54.1)

273 (44.0)
346 (55.8)

10 (7-14)

10 (8-14)

13 (9-17)§

11 (8-15)

13 (9-17) ‡

16 (12-20) §

270 (47.2)
61 (10.7)
96 (16.8)
145 (25.3)

69 (35.8) ‡
35 (18.1) ‡
47 (24.4) ‡
42 (21.8)

66 (27.4) §
55 (22.8) §
90 (37.3) §
30 (12.4) §

259 (44.7)
83 (14.3)
125 (21.6)
113 (19.5)

127 (28.6) ‡
65 (14.6)
172 (38.7) ‡
80 (18.0)

145 (23.4) §
97 (15.6)
321 (51.8) §
57 (9.2) §

17 (3.0)

15 (7.8) ‡

22 (9.1) §

25 (4.3)

23 (5.2)

57 (9.2) §

45 (7.9)
26 (4.5)
6 (1.0)
162 (28.3)
99 (17.3)
116 (20.3)
1 (0-3)
1 (0-4)
<6

17 (8.8)
7 (3.6)
<6
74 (38.3) ‡
39 (20.2)
49 (25.4) ‡
1 (0-3)
1 (0-2) ‡
<6

31 (12.9) §
18 (7.5) §
7 (2.9) §
111 (46.1) §
75 (31.1) §
64 (26.6) §
2 (0-3) §
4 (1-8) §
24 (10.0) §

51 (8.8)
25 (4.3)
6 (1.0)
217 (37.4)
155 (26.7)
128 (22.1)
1 (0-3)
1 (0-4)
11 (1.9)

47 (10.6)
13 (2.9)
7 (1.6)
245 (55.2) ‡
196 (44.1) ‡
109 (24.5)
1 (0-3)
3 (0-6) ‡
19 (4.3) ‡

77 (12.4) §
41 (6.6) §
6 (1.0)
386 (62.3)§
304 (49.0) §
184 (29.7) §
1 (0-3)
7 (2-12) §
66 (10.6) §

0.9 (0.8-1.0)

0.8 (0.7-1.0)

0.8 (0.7-0.9)

1.3 (1.1-1.5)

1.4 (1.2-1.9)

76 (68-88)

77 (69-87)

75 (66-87)

49 (41-55)

44 (32-53) ‡

--

--

Demographics
Age at Index Date
66-74
75-84
85+
Female
Income Quintile
≤2
≥3
Co-morbidity†
No. of distinct drugs in last year
Charlson Score
≤1
2
≥3
Missing§§
Hospital discharge within 30
days
Infection within 30 days
Liver disease
Alcoholism
Coronary artery disease
Congestive heart failure
Cerebrovascular disease
Number of primary care visits
Number of internist visits
Previous hypoglycemic event
Kidney Function
Serum creatinine, mg/dL
eGFR mL/min/1.73 m2
Most recent eGFR category
Normal: ≥ 90 mL/min/1.73m2

‡

1.6 (1.3-2.0)

§

39 (29-49) §

124 (21.7)

35 (18.1)

51 (21.2)

2

448 (78.3)

158 (81.9)

190 (78.8)

--

--

--

2

---

---

---

532 (91.7)

349 (78.6) ‡

447 (72.1) §

44 (7.6)

74 (16.7) ‡

133 (21.5) §

--

--

--

<6

21 (4.7)

β – Blockers
ACE Inhibitors
Hyperglycemic Medications

179 (31.3)
303 (53.0)

56 (29.0)
101 (52.3)

83 (34.4)
147 (61.0) §

232 (40.0)
337 (58.1)

205 (46.2) ‡
256 (57.7)

295 (47.6) §
356 (57.4)

Corticosteroids
Thiazide diuretics

27 (4.7)
140 (24.5)
29 (5.1)

12 (6.2)
44 (22.8)
8 (4.1)

10 (4.1)
48 (19.9) §
16 (6.6)

31 (5.3)
190 (32.8)
23 (4.0)

20 (4.5)
98 (22.1) ‡
21 (4.7)

58 (9.4) §
136 (21.9) §
35 (5.6)

Normal: 60 - 89 mL/min/1.73m

CKD III: 30 - 59 mL/min/1.73m

CKD IV: 15 - 29 mL/min/1.73m2
CKD V: < 15 mL/min/1.73m
Hypoglycemic Medications

Atypical antipsychotics

2

--

‡

40 (6.5) §

Note: Data presented as number (percent) or as median (interquartile range). In accordance with Ontario privacy law, patient
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values less than 6 are not reported. In accordance with Ontario privacy law, patient values less than 6 are not reported.
Conversion factors for units: serum creatinine in mg/dL to mol/L, ×88.4
† Comorbidity data was obtained for the 5 years prior to the index date unless otherwise specified.
‡ Indicates a standardized difference between glyburide and metformin users greater than 10%.
§ Indicates a standardized difference between insulin and metformin users greater than 10%. Standardized differences are less
sensitive to sample size than tradition hypothesis testing. They express the difference between the means of two populations as a
proportion of the pooled standard deviation.36;37
§§ Charlson scores were based on previous hospitalizations, and are only missing where patients did not have a previous
hospitalization.
Abbreviations: eGFR, estimated glomerular filtration rate; CKD, chronic kidney disease; ACE, angiotensin converting enzyme.

3.3.2

Primary Analysis

Table 3-3 displays the results of the primary analysis. In patients with normal kidney
function, we found the risk of a severe hypoglycemic event to be 18 fold higher
comparing insulin to metformin (adjusted odds ratio [OR] 18.7, 95% CI 10.5 to 33.5),
and nine fold higher comparing glyburide to metformin (adjusted OR 9.0, 95% CI 4.9 to
16.4). Unexpectedly, we found that the analogous risks among patients with impaired
kidney function were lower for both insulin (adjusted OR 7.9, 95% CI 5.0 to 12.4) and
glyburide (adjusted OR 6.0, 95% CI 3.8 to 9.5).
We found that renal function did not significantly modify glyburide’s hypoglycemic risk
(p for interaction 0.15). However, we did find that insulin’s hypoglycemic risk was
significantly attenuated in the setting of impaired renal function (p for interaction <
0.001).

3.3.3

Additional analysis: Altered definition of impaired renal
function

Table 3-4 displays the risks of hypoglycemia that associate with glyburide and insulin
when the primary analysis was repeated with stricter definitions of impaired kidney
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function. For both glyburide and insulin users, we found that the risk of hypoglycemia
attenuates as kidney function decreases.
Table 3-3 Association between diabetes therapy and hypoglycemia
Normal Kidney Function

Insulin
Glyburide
Metformin†

Cases
N = 204
124 (60.8)
53 (26.0)
27 (13.2)

Controls
N = 802
117 (14.6)
140 (17.5)
545 (68.0)

Odds Ratio (95% CI)
Unadjusted
22.5 (13.4 - 37.8)
8.1 (4.7 - 13.9)
1.0

Adjusted*
18.7 (10.5 - 33.5)
9.0 (4.9 - 16.4)
1.0

Impaired Kidney Function

Insulin
Glyburide
Metformin†

Cases
N = 354

Controls
N = 1290

216 (61.0)
109 (30.8)
29 (8.2)

404 (31.3)
335 (26.0)
551 (42.7)

Odds Ratio (95% CI)
Unadjusted
Adjusted*
10.5 (6.9 - 16.1)
7.9 (5.0 - 12.4)
6.4 (4.1 - 10.0)
6.0 (3.8 - 9.5)
1.0
1.0

* Adjusted for previous hypoglycemic events, Charlson comorbidity index (1, 2, or ≥ 3), recent
hospitalization, chronic liver disease, alcoholism, coronary artery disease, congestive heart failure,
number of distinct medications used in the previous year (≤ 5, 6-10, 11-15, 16-20, 21-26, or ≥ 26),
number of internist visits in the previous five years (≤ 5, 6-14, or ≥ 15), concurrent use of
corticosteroids, thiazide diuretics, or atypical antipsychotics.
† Metformin users served as the reference group.
Abbreviations: CI, confidence interval.

Table 3-4 Association between diabetes therapy and hypoglycemia using two
different definitions of impaired renal function
Odds Ratio (95% CI)
Adjusted*

eGFR
(ml/min/1.73m2)

Unadjusted

Insulin

< 45
< 30

11.6 (6.0 - 22.5)
3.4 (1.3 - 9.1)

8.9 (4.3 - 17.8)
3.2 (1.1 - 9.5)

Glyburide

< 45
< 30

7.7 (3.8 - 15.3)
3.8 (1.4 - 10.5)

7.5 (3.7 - 15.3)
4.7 (1.5 - 14.1)

* Adjusted for previous hypoglycemic events, Charlson comorbidity index (1, 2, or ≥ 3), recent
hospitalization, chronic liver disease, alcoholism, coronary artery disease, congestive heart
failure, number of distinct medications used in the previous year (≤ 5, 6-10, 11-15, 16-20, 21-26,
or ≥ 26), number of internist visits in the previous five years (≤ 5, 6-14, or ≥ 15), concurrent use
of corticosteroids, thiazide diuretics, or atypical antipsychotics.
Note: In all comparisons, metformin users served as the reference groups. Abbreviations: CI,
confidence interval; eGFR, estimated glomerular filtration rate.
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3.4 Discussion
3.4.1

Main Findings

The risk of hypoglycemia among elderly patients with diabetes is significantly greater for
those using insulin or glyburide as compared to metformin. We expected to find an
augmented risk among glyburide users with impaired renal function, but no such
relationship was observed. Instead, for both glyburide users and insulin users, our data
showed less risk when the eGFR was below 60 ml/min/1.73m2.

3.4.2

Interpretation

It is not surprising that glyburide and insulin conferred higher risks of hypoglycemia than
metformin. These findings are congruent with those of previous studies.24;39-43 Less
expected was the lack of interaction found between impaired renal function and glyburide
use. This contradicts the predictions of existing pharmacokinetic data; however, relying
on the delayed clearance of glyburide’s weakly active metabolites to explain
hypoglycemic events in these patients discounts the nuanced relationship between renal
function and serum glucose concentration.
The impaired kidney plays a complex and dynamic role in serum glucose control.
Reductions in drug clearance, gluconeogenesis, and insulin metabolism can predispose
patients with CKD to hypoglycemia,12 but a number of mitigating factors must also be
considered. Clinically significant reductions in renal insulin metabolism are uncommon
until the GFR falls below 20 ml/min/1.73m2.44 CKD is associated with peripheral insulin
resistance,45-47 even at the earliest stages,48 and derangements in parathyroid hormone
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concentrations may impair pancreatic insulin secretion.49 Moen and colleagues recently
described the cumulative effect of these hypo- and hyperglycemic factors, showing that
CKD is a risk factor for hypoglycemia even among patients without diabetes.12 The
protective effect of impaired renal function that we observed may be the result of the
interplay between these hypo- and hyperglycemic features of CKD. Alternatively, there
may be other, immeasurable factors at play. Our study cannot address the effects of these
individual mechanisms, nor can we exclude the effects of unknown or unmeasured
confounders. However, our findings do suggest that renally cleared drugs such as
glyburide play a role in hypoglycemia among patients with moderate CKD that is less
significant than previously thought.

3.4.3

Strengths and Limitations

Our study has a number of strengths. This is the first study to examine drug-specific risks
for hypoglycemia in the context of renal function. We assessed renal function directly
using serum creatinine concentrations. Our results are most applicable to patients over the
age of 65 years, the largest growing segment of the diabetes population.50 We had
adequate power to assess this uncommon but serious adverse drug reaction and our
administrative data were derived from reliable, broadly inclusive datasets.
Our study’s most important limitation is the non-random allocation of diabetes therapies.
Physicians chose to prescribe drugs for specific reasons. It is possible that patients who
were perceived to be at higher risk for hypoglycemia received metformin in lieu of
glyburide or insulin, or were more closely monitored. Similarly, if physicians were more
concerned with the risk of lactic acidosis than hypoglycemia, this “confounding by
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contraindication” may account for the proportionately lower use of metformin we
observed among patients with impaired renal function (table 3-1).
The ascertainment of outcome, exposure and covariate data was limited by our reliance
on health administrative records. By including only cases of hypoglycemia severe
enough to prompt admission or emergency room treatment, we optimized the validity of
our outcome definition but undoubtedly missed mild cases and extremely severe cases
that resulted in pre-hospital death. In ascertaining drug use, the ODB database is known
to be accurate but filling a prescription is not equivalent to taking a medication, nor to
taking it properly. Although we took care to adjust our results for important predictors of
hypoglycemia, the administrative records do not include data on confounding variables
such as diet, exercise, innate insulin resistance, or the individual’s targeted and achieved
level of glucose control.
A selection bias pertinent to the issue of glycemic control could also have affected our
findings. It is likely that diabetes was the etiologic factor for many of our patients’
impaired renal function; therefore, this group may have had relatively poor glycemic
control which could be protective against hypoglycemia.
Our definition of impaired renal function was strong in that it did not rely on
administrative codes, but we recognize that eGFR is not a static value. It is conceivable
that some patients with an eGFR less than 60 ml/min/1.73m2 prior to the index date had
only a transient fall in eGFR, and that factors such as infection could contribute to both a
reduced eGFR and dysglycemia. However, previous studies in Ontario have shown most
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initial single low values of eGFR using outpatient serum creatinine results have proven
persistent with subsequent testing.51
Finally, we had hoped to compare the hypoglycemic risks of other diabetes therapies but
found that only metformin, glyburide and insulin were in common enough use for
meaningful analysis.

3.5 Conclusions
In conclusion, our findings do not justify the use of glyburide in patients with impaired
renal function. Rather, our study supports previous research that has found an increased
risk of hypoglycemia among patients with CKD. Our findings support a multi-factorial
model of hypoglycemia in patients with impaired renal function and deemphasize the role
played by renally cleared diabetes therapies.

78

3.6 Reference List
1.

Intensive blood-glucose control with sulphonylureas or insulin compared with
conventional treatment and risk of complications in patients with type 2 diabetes
(UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:837853, 1998

2.

Sustained effect of intensive treatment of type 1 diabetes mellitus on development
and progression of diabetic nephropathy: the Epidemiology of Diabetes
Interventions and Complications (EDIC) study. JAMA 290:2159-2167, 2003

3. Dahl-Jorgensen K, Bjoro T, Kierulf P, Sandvik L, Bangstad HJ, Hanssen KF: Longterm glycemic control and kidney function in insulin-dependent diabetes mellitus.
Kidney Int 41:920-923, 1992
4. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ,
Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME,
Henderson WG, Huang GD: Glucose control and vascular complications in veterans
with type 2 diabetes. N Engl J Med 360:129-139, 2009
5. Feldt-Rasmussen B, Mathiesen ER, Deckert T: Effect of two years of strict
metabolic control on progression of incipient nephropathy in insulin-dependent
diabetes. Lancet 2:1300-1304, 1986
6. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y,
Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of
diabetic microvascular complications in Japanese patients with non-insulindependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res
Clin Pract 28:103-117, 1995
7. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M,
Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G,
Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan

79

BE, Joshi R, Travert F: Intensive blood glucose control and vascular outcomes in
patients with type 2 diabetes. N Engl J Med 358:2560-2572, 2008
8. Wang PH, Lau J, Chalmers TC: Meta-analysis of effects of intensive blood-glucose
control on late complications of type I diabetes. Lancet 341:1306-1309, 1993
9. Cooper L: USRDS. 2001 Annual Data Report. Nephrol News Issues 15:31, 34-35,
38, 2001
10. Lok CE, Oliver MJ, Rothwell DM, Hux JE: The growing volume of diabetesrelated dialysis: a population based study. Nephrol Dial Transplant 19:3098-3103,
2004
11. Gerstein HC, Riddle MC, Kendall DM, Cohen RM, Goland R, Feinglos MN, Kirk
JK, Hamilton BP, Ismail-Beigi F, Feeney P: Glycemia treatment strategies in the
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol
99:34i-43i, 2007
12. Moen MF, Zhan M, Hsu VD, Walker LD, Einhorn LM, Seliger SL, Fink JC:
Frequency of Hypoglycemia and Its Significance in Chronic Kidney Disease. Clin J
Am Soc Nephrol 2009
13. Gerich JE, Meyer C, Woerle HJ, Stumvoll M: Renal gluconeogenesis: its
importance in human glucose homeostasis. Diabetes Care 24:382-391, 2001
14. Snyder RW, Berns JS: Use of insulin and oral hypoglycemic medications in patients
with diabetes mellitus and advanced kidney disease. Semin Dial 17:365-370, 2004
15. Horst E, Johnson C, Lebowitz H: Carbohydrate metabolism in uremia. Ann Intern
Med 68:63-76, 1968
16. Jackson JE, Bressler R: Clinical pharmacology of sulphonylurea hypoglycaemic
agents: part 2. Drugs 22:295-320, 1981

80

17. Jonsson A, Rydberg T, Ekberg G, Hallengren B, Melander A: Slow elimination of
glyburide in NIDDM subjects. Diabetes Care 17:142-145, 1994
18. Jonsson A, Rydberg T, Sterner G, Melander A: Pharmacokinetics of glibenclamide
and its metabolites in diabetic patients with impaired renal function. Eur J Clin
Pharmacol 53:429-435, 1998
19. Rydberg T, Jonsson A, Roder M, Melander A: Hypoglycemic activity of glyburide
(glibenclamide) metabolites in humans. Diabetes Care 17:1026-1030, 1994
20. Rydberg T, Jonsson A, Melander A: Comparison of the kinetics of glyburide and its
active metabolites in humans. J Clin Pharm Ther 20:283-295, 1995
21.

KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for
Diabetes and Chronic Kidney Disease. Am J Kidney Dis 49:S12-154, 2007

22. Pearson JG, Antal EJ, Raehl CL, Gorsch HK, Craig WA, Albert KS, Welling PG:
Pharmacokinetic disposition of 14C-glyburide in patients with varying renal
function. Clin Pharmacol Ther 39:318-324, 1986
23. Brier ME, Bays H, Sloan R, Stalker DJ, Welshman I, Aronoff GR:
Pharmacokinetics of oral glyburide in subjects with non-insulin-dependent diabetes
mellitus and renal failure. Am J Kidney Dis 29:907-911, 1997
24. Holstein A, Plaschke A, Egberts EH: Lower incidence of severe hypoglycaemia in
patients with type 2 diabetes treated with glimepiride versus glibenclamide.
Diabetes Metab Res Rev 17:467-473, 2001
25. Krepinsky J, Ingram AJ, Clase CM: Prolonged sulfonylurea-induced hypoglycemia
in diabetic patients with end-stage renal disease. Am J Kidney Dis 35:500-505, 2000
26. Holstein A, Plaschke A, Hammer C, Egberts EH: Characteristics and time course of
severe glimepiride- versus glibenclamide-induced hypoglycaemia. Eur J Clin
Pharmacol 59:91-97, 2003

81

27. Coca SG, Krumholz HM, Garg AX, Parikh CR: Underrepresentation of renal
disease in randomized controlled trials of cardiovascular disease. JAMA 296:13771384, 2006
28. von EE, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP: The
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
statement: guidelines for reporting observational studies. J Clin Epidemiol 61:344349, 2008
29. Statistics Canada Census Report 2006. Statistics Canada . 2009. Statistics Canada.
5-4-2009.
30. Ontario Ministry of Finance. Ontario Population Projections (2008 - 2036). page
24. 2009. Toronto, Ontario, ServiceOntario Publications.
31. Levy AR, O'Brien BJ, Sellors C, Grootendorst P, Willison D: Coding accuracy of
administrative drug claims in the Ontario Drug Benefit database. Can J Clin
Pharmacol 10:67-71, 2003
32. Jong P, Gong Y, Liu PP, Austin PC, Lee DS, Tu JV: Care and outcomes of patients
newly hospitalized for heart failure in the community treated by cardiologists
compared with other specialists. Circulation 108:184-191, 2003
33. Juurlink D, Preyra C, Croxford R, Chong A, Austin P, Tu J, and Laupacis A.
Canadian Institute for Health Information Discharge Abstract Database: A
Validation Study. 2006. Toronto, Institute for Clinical Evaluative Sciences. 3-150090.
34. Alter DA, Naylor CD, Austin P, Tu JV: Effects of socioeconomic status on access
to invasive cardiac procedures and on mortality after acute myocardial infarction. N
Engl J Med 341:1359-1367, 1999
35. Levey AS, Greene T, Kusek JW, Beck G, MDRD Study Group: A simplified
equation to predict glomerular filtration rate from serum creatinine [Abstract]. J Am
Soc Nephrol 11:155A, 2000

82

36. Austin PC: Using the Standardized Difference to Comparethe Prevalence of a
Binary Variable BetweenTwo Groups in Observational Research. Communications
in Statistics-Simulation and Computation 38:1228-1234, 2009
37. Mamdani M, Sykora K, Li P, et al: Reader's guide to critical appraisal of cohort
studies: 2. Assessing potential for confounding. BMJ 330:960-962, 2005
38. Altman DG, Bland JM: Interaction revisited: the difference between two estimates.
BMJ 326:219, 2003
39. Shorr RI, Ray WA, Daugherty JR, Griffin MR: Incidence and risk factors for
serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern
Med 157:1681-1686, 1997
40. Stahl M, Berger W: Higher incidence of severe hypoglycaemia leading to hospital
admission in Type 2 diabetic patients treated with long-acting versus short-acting
sulphonylureas. Diabet Med 16:586-590, 1999
41. van ST, Abenhaim L, Monette J: Rates of hypoglycemia in users of sulfonylureas. J
Clin Epidemiol 50:735-741, 1997
42. Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR: Metformin, sulfonylureas,
or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested
case-control analysis. Diabetes Care 31:2086-2091, 2008
43. Phung OJ, Scholle JM, Talwar M, Coleman CI: Effect of noninsulin antidiabetic
drugs added to metformin therapy on glycemic control, weight gain, and
hypoglycemia in type 2 diabetes. JAMA 303:1410-1418, 2010
44. Rabkin R, Simon NM, Steiner S, Colwell JA: Effect of renal disease on renal
uptake and excretion of insulin in man. N Engl J Med 282:182-187, 1970
45. Mak RH, DeFronzo RA: Glucose and insulin metabolism in uremia. Nephron
61:377-382, 1992

83

46. Adrogue HJ: Glucose homeostasis and the kidney. Kidney Int 42:1266-1282, 1992
47. Castellino P, Solini A, Luzi L, Barr JG, Smith DJ, Petrides A, Giordano M, Carroll
C, DeFronzo RA: Glucose and amino acid metabolism in chronic renal failure:
effect of insulin and amino acids. Am J Physiol 262:F168-F176, 1992
48. Fliser D, Pacini G, Engelleiter R, Kautzky-Willer A, Prager R, Franek E, Ritz E:
Insulin resistance and hyperinsulinemia are already present in patients with
incipient renal disease. Kidney Int 53:1343-1347, 1998
49. Perna AF, Fadda GZ, Zhou XJ, Massry SG: Mechanisms of impaired insulin
secretion after chronic excess of parathyroid hormone. Am J Physiol 259:F210F216, 1990
50. Census Snapshot of Canada (Age and Sex). Statistics Canada . 11-21-2008. 5-152009.
51. Garg AX, Mamdani M, Juurlink DN, van WC: Identifying individuals with a
reduced GFR using ambulatory laboratory database surveillance. J Am Soc Nephrol
16:1433-1439, 2005

84

4

Chapter Four: Discussion

4.1 Drug-induced impairment of renal function:
hyperkalemia and trimethoprim-sulfamethoxazole.
The results presented in chapter two highlight the small but significant risk of
hyperkalemia among elderly patients using trimethoprim-sulfamethoxazole (TMP-SMX).
This finding is biologically plausible and was dose-dependent. No interaction with
concomitant beta blocker use was identified, likely due to ß-1-selectivity of modern beta
blockers; however, our study successfully showed the real-world manifestations of
trimethoprim-sulfamethoxazole’s inhibition of the ENaC. Our findings were consistent
with those of Perazella et al and Alappan et al but extend the observations made within
these highly selected cohorts to a general population of ambulatory, elderly residents of
Ontario.1,2 In an additional analysis we observed a low rate of serum potassium testing
among patients using TMP-SMX; changes in this practice may help patients avoid the
potentially serious ramifications and TMP-SMX-induced hyperkalemia.

4.2 Drug accumulation in patients with impaired renal
function: hypoglycemia and glyburide
Although the results of the study presented in chapter three did not support the widely
held belief that impaired kidney function augments glyburide’s hypoglycemic risk, it did
highlight the significant risk of hypoglycemia conferred by both glyburide and insulin
among the elderly residents of Ontario. Our failure to observe the expected interaction
between renal function and glyburide use was likely the result of both study and
biological factors. Although we adjusted for a variety of proven hypoglycemia risk
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factors, some variables that may have influenced this outcome were not recorded in the
databases, such as glucose testing frequency, diet, exercise, and intensity of glycemic
control. Furthermore, the influence of indication bias also may have played a role in the
lack of interaction we found. Biologic factors are also likely to have contributed to our
findings. The potency of glyburide’s active metabolites may have been over-estimated
and the complex and dynamic relationship between renal impairment, insulin metabolism
and peripheral insulin resistance may have rendered the role of glyburide’s active
metabolites relatively minor. Despite observing results contrary to our hypothesis, our
study’s findings are useful in that they support a complex model of drug-induced
hypoglycemia, which should prompt physicians to consider multiple factors when
assessing a patient’s risk for hypoglycemia.

4.3 The role of observational research in shaping clinical
practice
The studies presented in chapters two and three were both observational in design.
Although observational studies have long been employed in epidemiologic research, their
influence on patient management is often viewed with suspicion. 3,4,5 A significant part of
this suspicion probably arises from the discordance between the findings of a number of
prominent randomized control trials and their corresponding observational studies. This
discordance has been seen with vitamin supplementation for the primary or secondary
prevention of cardiovascular disease, 6,7,8 suppression of ventricular premature beats after
myocardial infarction,9 and perhaps most famously, the administration of estrogen for the
prevention of cardiovascular disease in postmenopausal women.10 In some cases, harm
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was done based on the findings of observational work and this has understandably
heightened the suspicion with which some clinicians view observational findings.11,12,13
Observational studies have a number of challenges that can adversely affect the accuracy
of their findings. The most important of these is the nonrandom allocation of exposures.
Non-random exposure allocation introduces a bias in pharmacoepidemiologic studies
commonly referred to as an “indication bias”.14 The assumption underlying this bias is
that outside of a randomized trial, patients are exposed to drugs for particular reasons.
The variables underlying these reasons may predispose patients to the study's outcome of
interest and in addition, these variables may not be readily measurable. For example,
glyburide is a potent antidiabetic medication with a well-known reputation for causing
hypoglycemia. Knowing this, physicians may have prescribed glyburide only to their
more responsible patients: those who were relatively healthy, who checked their blood
sugars regularly and who carefully followed dietary recommendations. If this were the
case, these characteristics may have contributed to the relatively low rates of
hypoglycemia we observed. If these variables are not measurable, the possibility for
mathematical adjustment is lost.
A related challenge encountered with observational research is that of residual
confounding. Despite attempts to balance the effects of variables through study design or
analysis, it is not possible to do so completely. Some important variables may not be
measured accurately, some may not be measured at all, and others may not yet be known.
As with indication bias, randomization is the solution to this problem. Appropriately
conducted randomization will result in treatment and control groups that are balanced
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with respect to both known, and unknown variables; this cannot be achieved in
observation studies.
The immunity of a randomized trial to indication bias and residual confounding make it
the gold standard for establishing causality. However, randomized trials have a number of
important limitations. In studies where the exposure is thought to be harmful,
randomizing patients is unethical. Also, the cost of conducting a trial large enough to
identify rare outcomes such as adverse drug events would likely be prohibitive
(especially considering the pharmaceutical industry’s lack of interest in adverse drug
events research). Finally, results arising from the highly regulated environment of a
clinical trial may not readily generalize to real-world clinical practice. Vulnerable patient
populations such as the elderly and those with CKD are often excluded,15 16,17
medications are administered according to strict protocols, and follow-up is assiduous.
Each of these limitations is pertinent to renal pharmacoepidemiology: exposures are
harmful, outcomes are rare and generalizability is paramount. So despite the limitations
of observational research, studies such as the ones presented in chapters two and three
remain important, although imperfect, tools in the investigation of ADEs.

4.4 Strengths and limitations of the thesis
In addition to the strengths and limitations of observation studies in general, our studies’
use of Ontario’s health administrative databases introduced another layer of strengths and
limitations. Administrative data afforded us the statistical power to detect rare outcomes
such as adverse drug events and it gave us the ability to generalize our findings to broad
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groups of Ontario residents. The use of administrative data also introduced some
limitations additional to those already discussed in the individual chapters.

4.4.1

Ontario’s Health Administrative Databases

Ontario had a population of approximately 13 million in the year 2008, of which 1.8
million were older than 65 years. All residents of Ontario receive universal access to
hospital and physician services, and those over 65 years old receive coverage for
prescription medications. Coverage for medical services and medications from a single
provincial payer provides a comprehensive set of health administrative data, proven to be
effective and reliable in previous pharmacoepidemiologic studies.18,19,20
The data is housed at the Institute for Clinical Evaluative Sciences (ICES) in Toronto,
Ontario. ICES retains a number of primary and derived databases; our studies used the
following resources:
Ontario Drug Benefits (ODB) Database: The ODB formulary includes a wide range of
routine outpatient medications. We use this database to determine exposure to oral beta
blockers and to other drugs that will be used as covariates in our regression models. This
database is highly reliable with a basic error rate under 1% (~0.7%, 95% CI 0.5% to
0.9%).21
Canadian Institute of Health Information (CIHI) Discharge Abstract Database (DAD):
Demographic, diagnostic and procedural variables for each admission to an acute care
hospital in Ontario are collected in the CIHI-DAD. Coding of primary and secondary
diagnoses and inpatient procedures uses the 9th version of the Canadian Modified
International Classification of Disease system (ICD-9 CA) prior to 2002 and the 10th
version (ICD-10 CA) for all diagnoses after 2002.
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Ontario Health Insurance Plan (OHIP) Claims History Database: In all, 95% of
physicians in Ontario submit billing claims using fee and diagnosis codes outlined in the
OHIP Schedule of Benefits. These codes capture information on inpatient, outpatient, and
laboratory services rendered to Ontario residents. In addition, OHIP includes information
on the nature of the service and diagnostic information. In chart re-abstraction studies,
agreement between abstracted OHIP fee codes compared to the actual code recorded on
the chart for the “most responsible” diagnosis was over 90% while percent agreement for
procedural codes was over 88%.21
Registered Persons Database (RPDB): The RPDB captures information regarding
Ontarians’ sex, date of birth, postal code and vital status. Relative to the CIHI-DAD inhospital death flag, the RPDB has a sensitivity of 94% and a positive predictive value of
100%.22

4.4.2
4.4.2.1

Strengths of health administrative data
Strengths of Administrative Data in General

Large sample sizes
Health administrative databases are typically large and provide a high level of statistical
power, allowing researchers to examine important but rare outcomes such as adverse
drug reactions.23
Long follow-up time
The maximum duration of follow-up is usually longer with administrative databases
compared to clinical trails.23 This affords another advantage in detecting adverse drug
events that may not manifest during a short follow-up time.
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High generalizability
Entry into administrative databases typically has few limitations. Drug use and follow-up
are not dictated by study protocols. As such, the results of studies conducted with
administrative data do not incur much selection bias and better reflect “real- world”
clinical practice.24
Objectivity of data acquisition
Because administrative data is not collected with a hypothesis in mind, systematic
misclassification of variables cannot result from the influence of the investigator. In
addition, the recording of variables is not subject to recall bias and patient non-response
cannot limit the completeness of the database.
Practicality of use
Studies conducted with administrative data can be completed relatively quickly and at
relatively low cost. This is particularly important for adverse drug events studies because
it minimizes the time between the first suspicion of an adverse drug event and the
acquisition of data sufficient to take preventative action.

4.4.2.2

Strengths of Ontario’s Administrative Data

Large sample size
Ontario is Canada’s most populous province with more than 13 million people enrolled in
the provincial health insurance plan.25
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High generalizability
Even within the context of administrative databases, Ontario’s includes very little
selection bias because health care coverage is universal. Compared to the Veterans
Administration (VA) database, which predominantly includes older men, Ontario
provides a more realistic representation of age and sex variables. Compared to the
databases of large Health Management Organizations (HMO) such as Kaiser Permanente,
Ontario provides a more representative sample of socio-economic status because
membership does not have to be purchased.
Low churn rate
In administrative data, “churn” refers to the enrolled population’s turnover rate. Ontario’s
population is relatively stable with an annual emigration rate out of OHIP of
approximately 1%.26 This compares favorably with HMO churn rates of 20 – 30% per
year.27
Extensive inter-database linkage
In Ontario, there is excellent linkage of data between multiple sectors of health care
(physician services, hospital records, medications, vital statistics). This allows a wide
range of variables to be ascertained, which is important for building well-adjusted
multivariable models.
Proven validity
The error rate in the Ontario Drug Benefits (ODB) database is less than 1%,21 20 and
demographic information is accurately recorded in the RPDB (see table 4-1). The
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administrative data definitions of many medical conditions and procedures have also
been evaluated and found to be accurate (see table 4-1).

4.4.3
4.4.3.1

Limitations of health administrative data
Limitations of Administrative Data in General

Incomplete coverage of variables
In general, administrative data is limited by its primary purpose. Because it is collected to
guide remuneration and resource allocation, some important variables may not be
available. For example, dietary information would have been useful in both the
hyperkalemia and hypoglycemia studies, but with little administrative utility, this
information was not recorded.
Incomplete validation of diagnostic codes
Although some administrative data definitions have been validated, this is not the case for
the majority. In general, data relating to physician and institutional remuneration is
considered accurate because of the financial incentives involved and the specific
mechanisms in place to submit and encode data. On the other hand, diagnoses that must
be gleaned from the general medical record and converted to ICD-9 or ICD-10 codes are
considered less reliable. This is particularly so for conditions with slow, insidious
onsets.28 For example, table 4-1 shows the low sensitivity and high specificity for the
administrative diagnosis of acute kidney injury. This pattern of operating characteristics
is also seen with diagnoses such as hyponatremia.29,30 Low sensitivity diagnoses can
affect studies by reducing cohort sizes and lowering event rates.
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Table 4-1 Demographic variables and medical conditions for which administrative
definitions have been validated

Variable

Sensitivity, Specificity,
%

%

Positive

Negative

Predictive Predictive
Value, %

Reference

Value, %

Specific Administrative Database Algorithm
Ontario
Sex

98.5

99.5

99.6

97.8

Quinn22

Death

90.2

97.8

94.4

96.1

Quinn22

Outpatient
Dialysis
Renal
Transplantation
Coronary
Artery Disease
Myocardial
Infarction
Heart Failure

100.0

Quinn22

96.0

Quinn22

81.8

100.0

100.0

99.1

83.0

-

92.0

-

Juurlink31

89.0

-

87.0

-

Juurlink31

79.0

-

85.0

-

Juurlink31

57.0

-

80.0

-

Juurlink31

81.0

-

87.0

-

Juurlink31

Diabetes
Mellitus Type
II
Ischemic
Stroke

94

Tu 32

Hypertension

73.0

-

87.0

-

AKI

61.6

95.6

17.3

99.4

Hwang33

20.5

96.9

57.4

85.5

Ronksley 34

63.1

-

84.8

-

James 35

81.9

90.7

41.0

-

Molodecky 36

50.2

-

44.0

-

Nehra 37

-

-

46.0

99.0

Yadav 38

-

-

26.0

-

98.8

69.6

84.9

97.1

77.0

94.0

-

-

McDonald

79.0

-

89.0

-

Jensen 42

Alberta
Chronic kidney
disease
End-stage renal
disease
(dialysis use)
Primary
sclerosising
cholangitis
ICD-9
Cirrhosis
Pancreatitis
Venous
Thrombo-

Spencer 39

embolism
Epilepsy
Ventricular
arrhythmia
Atrial
fibrillation

Jetté40
41

95

Myocardial

80.9

87.7

-

-

Pladevall 43

-

-

50.4

-

Lacasse 44

91.7

98.7

88.0

-

Goldberg 45

-

-

85.2

-

Goldberg 46

-

-

96.0

-

Roumie 47

-

-

98.6

94.0

Jetté40

Pneumonia

89.2

62.0

71.4

84.4

Skull 48

Hyponatremia

30.0

-

99.0

-

Shea 29

Syncope

62.7

99.9

95.0

99.5

infarction
Chronic
obstructive
pulmonary
disease
Hepatocellular
carcinoma
End-stage liver
disease
Ischemic
Stroke
ICD-10
Epilepsy

Ruwald 49

Misclassification of variables
Misclassification of variables in administrative data is often considered to be nondifferential because the acquisition of administrative data is free of recall bias and is
independent of the goals of individual research projects. However, there are three
important features of misclassification to be considered. First, non-differential
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misclassification biases results towards the null hypothesis, which can lead to type II
errors in studies that were otherwise adequately designed and well powered. Second, nondifferential misclassification of covariates can lead to sub-optimal control of confounding
variables. Third, differential misclassification can still occur in administrative data. For
example, if a specific ADE is well known to a treating physician, then patients using that
drug may be more likely to undergo specific testing for that reaction; in this way the
exposure has increased the likelihood of diagnosing the outcome.

4.4.3.2

Limitations of Ontario’s Administrative Data

Information gaps: physical exam variables
The databases of some large Health Management Organizations (HMOs) record physical
exam characteristics such as height, weight and blood pressure during clinical encounters.
This information could be useful in some research studies, but it’s not recorded in
Ontario’s administrative data.
Information gaps: medication use
Despite the accuracy of the ODB database, it has three important shortcomings. First,
with some exceptions, ODB only provides prescription drug coverage for residents over
the age of 65 years. This is the main limitation to the generalizability of
pharmacoepidemiologic studies conducted with Ontario’s administrative data. Second,
although the ODB formulary includes a wide range of medications, its coverage is
certainly not complete. Furthermore, ODB formulary changes can result in gaps in the
data available for drugs that drop off the formulary. Third, there are special settings and
patient populations in which drug coverage is not provided by ODB. Medications
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administered to hospital inpatients are paid for by the hospital’s universal budget and are
not recorded in the ODB database. Patients receiving chronic peritoneal dialysis or
hemodialysis have dialysis-related medications such as vitamins, phosphate binders,
activated vitamin D analogues and erythropoiesis-stimulating agents paid for by the
Ontario Renal Network. Data for drugs administered in these settings, or to these patients
is not available.
Information gaps: physician services
Although 95% of Ontario’s physicians submit claims to the Provincial health insurance
provider (OHIP), the remainder are remunerated through an alternative-funding plan. For
the patients cared for by these physicians, administrative diagnoses that depend on OHIP
claims data cannot be made.

4.5 Future Directions
The critical role played by the kidneys in the development of adverse drug events makes
this area fertile ground for administrative database research. In the upcoming years I will
execute projects in three broad categories of renal adverse drug events: ADEs that result
in acute kidney injury (AKI), ADEs associated with decreased drug clearance in patients
with CKD, and ADEs associated with altered drug clearance in patients on hemodialysis.

ADEs and AKI
There are a number of potential ADEs supported by biologic mechanisms or case-report
data. These ADEs require more thorough investigation to determine their validity, scope
and impact. Examples of subjects in this area include the potential association between
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cholesterol-lowering fibric acid derivatives and acute kidney injury, the weight-loss drug
orlistat and acute kidney injury, and the anti-retroviral tenofovir and acute kidney injury.
ADEs and CKD
The clearance of many drugs and their metabolites relies heavily on renal function. When
renal function is impaired, many drugs need to be prescribed at lower doses to
compensate for the slower rate of clearance. Although information on “renal-adjusted”
drug dosing is readily available, I suspect that many patients with CKD inappropriately
receive full strength doses. I will examine this problem and its ramifications among
patients with CKD by investigating three drugs and their full-dose ADEs. Potential
subject areas include the associations between H2-receptor blockers and delirium,
gabapentin and falls (as measured by traumatic orthopedic injuries), and quinine and
cardiac arrhythmias.
ADEs and Hemodialysis
The efficiency with which hemodialysis removes drugs from a patient’s circulation varies
according to the drug’s degree of protein binding, its volume of distribution and its
lipophilicity. In some cases, these characteristics vary between drugs within the same
therapeutic class. This sets the stage for studies designed to determine the effect of a
drug’s dialyzability on its effectiveness in patients receiving chronic hemodialysis. For
example, beta blockers are a class of medications known to decrease the risk of further
heart damage among patients who have already had a heart attack or experienced heart
failure. However, some beta blockers are readily removed from the circulation by
hemodialysis while others are not. I plan to define a cohort of patients on chronic
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hemodialysis who are receiving a beta blocker for the secondary prevention of
cardiovascular disease. These patients will be divided into an exposed group (those
taking a poorly dialyzed beta blocker) and an unexposed group (those taking a highly
dialyzed beta blocker). The risk of subsequent cardiovascular disease will be compared
between the two groups. Similar studies may also be conducted with angiotensinconverting enzyme inhibitors and HMG-CoA reductase inhibitors.

4.6 Conclusion
Cognizance of kidney-related ADEs is an important part of safe prescribing practice.
Medications may affect the function of normal kidneys, as in the case of trimethoprimsulfamethoxazole, or they may interact in complex ways with impaired renal function, as
is the case with glyburide. Kidney-related ADEs provide a number of research avenues
related to acute kidney injury, drug metabolism and clearance, and the effects of
hemodialysis.
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Short Description of
Research Question

Examine whether exposure to TMP-SMX leads to higher risk of hyperkalemia in a
group of individuals taking other drugs (NSAIDS, Beta-blockers, K sparing diuretics,
K supplements). The drug to be examined first is beta-blockers, and is presented in
detail below. A near identical approach will be used for other drugs. ACE / ARBs
were examined in a previous project.
Trimethoprim inhibits K+ secretion by the principle cells of the late distal tubule and
cortical collecting duct. The mechanism of inhibition is similar to that of amiloride and
triamterene (i.e. inhibition of the sodium channel in the apical membrane of the cell).

Physiologic Rationale Minute-to-minute levels of plasma potassium are controlled by intracellular

to extracellular exchange by the sodium-potassium pump controlled by insulin and beta2
receptors. (Beta receptors are linked to calcium-gated potassium channels, and their
activation allows potassium to enter the cell directly. Beta2 agonists decrease potassium
levels. A beta blocker decreases sodium-potassium adenosine triphosphatase (ATPase)
activity and increases potassium levels. Non-selective beta blockade is known to cause
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elevated potassium levels via this mechanism. Though treatment with beta blockers rarely
causes hyperkalemia by itself, it contributes to the elevation in plasma potassium levels seen
with other conditions or medications (such as TMP-SMX).
Beta-blockers, especially blockade of the beta-1 receptor at the macula densa also inhibits
renin release, thus decreasing the release of aldosterone, causing hyperkalemia.

From Perazella MA. Drug-induced hyperkalemia: old culprits and new offenders. Am J Med.
2000 Sep;109(4):307-14. Review. (about 10 references for statements below provided in this
paper)
Beta blockers. Acute disposal of a potassium load is handled primarily by the cellular uptake of
this cation, which can be impaired by some medications. Nonselective beta blockers have
been associated with the development of hyperkalemia, which may rarely be severe.
Hyperkalemia develops by means of two different mechanisms. First, beta blockers suppress
catecholamine-stimulated renin release, thereby decreasing aldosterone synthesis. Second,
and more importantly, nonselective beta blockers decrease cellular uptake of potassium.
Normally, agonist binding to the beta -adrenergic receptor stimulates the formation of cyclic
2

AMP, which acts through protein kinase A to phosphorylate and activate the Na-K-ATPase
pump, leading to the influx of potassium into cells. Competitive inhibition of the beta receptor
2

by beta blockers decreases Na-K-ATPase function and reduces potassium uptake by cells.
For example, three renal transplant recipients developed hyperkalemia (6.0 to 8.3 mEq/liter).
This occurred within hours of treatment with intravenous labetalol, suggesting that impaired
cellular uptake of potassium, rather than decreased aldosterone synthesis, was responsible.
Nonselective beta blockers have caused or contributed to hyperkalemia in 4% to 17% of
hospitalized patients studied (5 references for this last sentence).

List of Datasets Used

a)

•

ODB

•

NACRS

•

RPDB

•

DAD

•

OHIP

•

Gamma-Dynacare Main List Jan 2002 - Mar 2009 (serum creatinine data
th
from Southwestern Ontario) [Data sharing agreement made October 25 ,
2004. The agreement was reviewed again as part of the development of this
DCP. To confirm, under this agreement we are able to use this dataset to
‘assess the appropriateness of drug use and dosing in patients’]

Design: Case Control design within a Nested Cohort

Considerations: The ‘cohort nest’ in this study is comprised of patients who had a prescription filled for betablockers. We appreciate that within the nested case-control design that we are considering only the risk of
hyperkalemia with TMP-SMX compared to other antibiotics (in patients taking beta-blockers). We are not
considering other risks / adverse events (that may be higher with other antibiotics). We are not considering
the benefits TMP-SMX compared to other antibiotics (i.e. perhaps TMP-SMX reduces the risk of urosepsis,
compared to nitrofurantoin, or the required duration of therapy is shorter with TMP-SMX). With this type of
design, it is possible to obtain indirect estimates of absolute risk / incidence, although the main output is an
odd’s ratio of TMP-SMX compared to other antibiotics (relative terms)). If TMP-SMX is found to be associated
with hyperkalemia, we will be able to perform an additional test interaction between beta-blockers and TMPSMX using 2 nested cohorts – those with and without beta-blocker use (Altman D, Bland JM, Interaction
revisited: the difference between two estimates. BMJ 2003).

b)
Nest cohort

Describe Nest:

Defining the Nest Cohort
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•

Elderly Ontarians continuously taking beta-blockers (patients are allowed to switch
between beta-blockers) and also taking an antibiotic in the 14 days prior to index
date
• in a secondary analysis, 7 and 21 days are used instead of 14 days
• In one of the tertiary analyses, there will be a nest of no evidence of betablocker use, in order to examine for an interaction effect of beta-blockers with
TMP-SMX. In this case the nest will simply be taking an antibiotic in the 14 days
prior to index date.

•

Continuous use defined as:
o Any prescription within 100 day windows starting on date of first
prescription for the drug
o Next 100 day window defined as last prescription date + 100 days
o If no prescription within next 100 day window, end follow-up (follow-up
date defined as 100 days following date of last script)
o Determine if new or chronic use (parameter &dl_lookback):
New use: # days to look back to define new use: ____________
Chronic use (look back = 0)

Codes:
Exclusions
(In order)

•

Drug Claims: – See attached Excel spreadsheet

•

Invalid IKN

•

Missing age or sex

•

Age < 66 at time of cohort entry (parameter &age_restrict)

•

Death on same date as start of beta-blocker

•

In 30 days prior to index date:
o Prescription for another antibiotic (other than study antibiotics)
o Prescribed multiple study antibiotics

•

In 3 years prior to index data:
o Evidence of kidney failure receiving dialysis (see Appendix)

•

In one of the tertiary analyses (described below), use the following exclusion. This
will enable an assessment of the interaction effect of beta-blockers, using the
technique described by Bland and Altman:
o Any prescription for a beta-blocker in 120 days preceding index date

c)

Time Frame Definitions

Observation Window

Accrual Start/End Dates Beginning of Accrual Period for nest (parameter = &start_date): July 1, 1994
End of Accrual Period for nest (parameter = &end_accrual): March 31, 2008
Max Follow-up Date

End of follow-up Period (parameter &end_fup) : March 31, 2008

Cohort entry

Date at which entry into the nest begins (parameter = &reference_date):
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•

th

First ODB Claim for beta-blocker after 66 birthday

When does observation From date of cohort entry to first of:
window terminate?
• Hospital admission for hyperkalemia
[If necessary, two tertiary analyses with other definitions of hyperkalemia
will be considered (as defined in tertiary analysis section)]
•

Death

•

End of follow-up (March 31 2008)

•

Beta-blocker discontinuation (date assigned as 120 days after last
prescription for beta-blocker)

d)
Cases

Variable Definitions

Individuals from the nest cohort who are admitted to hospital for hyperkalemia using the
codes below:
•

Diagnosis and/or procedure codes for outcome condition.
CIHI datasets parameters defined by:
o ICD9 diagnosis codes: 276.7
o ICD10 diagnosis codes: E87.5
o CIHI-DAD Diagnosis Type: admitdx
o CIHI-DAD source:
Inpatient
Same-day-surgery
All

•

Cases have taken a study antibiotic in the 14 days prior to index date (for
secondary analysis, cases have taken an antibiotic of interest in the 7 or 21 days
prior to index date)

•

Cases have not taken multiple study antibiotics in the 30 days prior to index date

•

Cases have not had a prescription for another non-study antibiotic in the 30 days
prior to index date

•

In a tertiary analysis definition of hyperkalemia is expanded to include a hospital
admission for hyperkalemia or first use of K binding resin (see tertiary analysis
section)

Eligible Controls Individuals from the nest cohort who are event free at index date
•

Case to Control Ratio: Match 4 controls to each case

•

Matching criteria:
Age at index date (+/- 1 year)
Sex
Presence of Chronic Kidney Disease in 3 years prior to index date (as
defined in the Appendix)
[in a tertiary analysis restrict sample to those individuals with at least one
serum creatinine value preceding index date who are in GammaDynacare Main List Jan 2002 - Mar 2009, matched on most recent eGFR
2
value proceeding index date +/- 20 mL/min per 1.73 m , instead of
matching based on presence of chronic kidney disease as defined above
using administrative database codes]
Diabetics (use of an oral hypoglycemic OR insulin OR diabetic test
strips in 3 years prior to index date – see attached spreadsheet for list of
diabetic medications)
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•

Controls have taken a study antibiotic in the 14 days prior to index date
[in a secondary analysis, controls have taken an antibiotic of interest in the 7 or 21
days prior to index date]

•

Controls have not taken multiple study antibiotics in the 30 days prior to index
date

•

Cases have not had a prescription for another non-study antibiotic in the 30 days
prior to index dates

•

When full number of matched controls cannot be obtained, the matching process
is maintained, and any available controls are analyzed.

•

Cases without at least 1 matched control are excluded

Index date

Case: Date of the first hospitalization for hyperkalemia occurring after cohort entry [If
necessary, a tertiary analysis will use an expanded definition of hyperkalemia (see tertiary
analysis section)]
Control: The same date as the index date for matched cases

Main Exposure
or Risk Factor

Primary Analysis: Users of antibiotic drug in the 14 days prior to index date:
•

Ciprofloxacin

•

Norfloxacin

•

Nitrofurantoin

•

Amoxicillin (referent group)

•

TMP-SMX

See attached Excel spreadsheet for drug lists for exposure variables
Secondary Analysis:
1. Change lookback to 7 days prior to index date
2. Change lookback to 21 days prior to index date
Tertiary Analysis:
1. Split TMP-SMX into two different types (low dose and high dose) and rerun
analyses (see Excel spreadsheet for labels)
2. Repeat the primary analysis restricting nested cohort to non-cardioselective betablockers (where we expect risk of hyperkalemia to be greater; see attached Excel
spreadsheet, label ‘BBL_NC’).
3. Repeat the primary analysis restricting the nested cohort to cardioselective betablockers (see attached Excel spreadsheet, label ‘BBL_CARD’)
4. Repeat the primary analysis with a nested cohort where do not need to have betablocker use to be in the nest, and there is no evidence of beta-blocker use in 120
days preceding index date (i.e. see sections ‘nest cohort’ and ‘exclusions’ for
description) (sensitivity analysis). Do not expect there to be a major increase in
hyperkalemia with TMP-SMX use across all clinical situations [if see the
magnitude of association is similar to beta-blocker analysis, than have to question
whether it is the beta-blocker TMP-SMX combination per se, or whether the
increase in hyperkalemia is all due to TMP-SMX alone; if see no association with
hyperkalemia when conduct this analysis, then this really will strengthen the
assertion that effect is due to TMP-SMX beta-blocker combination].
5. Repeat the primary analysis, applying the following additional inclusion and
matching criteria: additional inclusion criteria: at least one serum creatinine value
in Gamma-Dynacare dataset preceding index date; AND matching criteria: use

111

the most recent eGFR value prior to index date to match cases and controls [+/2
20 mL/min per 1.73 m ]
If necessary (decide on running these remaining two tertiary analyses only after
reviewing previous analyses):
6. Repeat the primary analysis using a broader definition of hyperkalemia –
‘hyperkalemia hospital admission as defined above, or first claim for a K+binding
resins here [from Brogan’s drug list; subclnam=”POTASSIUM-REMOVING
RESINS” This will increase number of events, increase statistical power
7. Repeat the primary analysis using a broader definition of hyperkalemia –
‘hyperkalemia hospital admission as defined above, or ED visit for hyperkalemia.
As NACRS is only available as of the year 2000, restrict the accrual start date to
st
January 1 , 2000.
NACRS dataset parameters defined by:
o ICD9 diagnosis codes: 276.7
o ICD10 diagnosis codes: E87.5
o CIHI-DAD Diagnosis Type: Main Diagnosis
Methodological Issues: TMP-SMX is frequently used for UTIs, but
can also be used for other infections [ear, skin, sinuses,
gastroenteritis (traveler’s diarrhea, shigellosis), pneumonia
(Pneumocystis carinii)]. The comparator drugs may be used for UTI
and also other types of infections. Although UTI is not associated
with hyperkalemia per se, could someone argue the indication for
the antibiotic used, and not the antibiotic per se, is reason for
any observed association with hyperkalemia.
Nicolle L, et al. Uncomplicated urinary tract infection in women.
Current practice and the effect of antibiotic resistance on
empiric treatment. Can Fam Physician. 2006 May;52:612-8. Review.
Prescribing behaviour suggests that, over the past decade, primary
care physicians have altered their approach to first-line therapy
for uUTI: TMP/SMX prescriptions for uUTI have declined, while
fluoroquinolone prescriptions have increased. Current options for
first-line antimicrobial treatment of uncomplicated urinary tract
infection include TMP/SMX, fluoroquinolone, and nitrofurantoin.
Ampicillin or amoxicillin were once standard therapy for uUTI, but
the resistance of E coli to ampicillin now approaches 50% in most
regions of North America.
At least 8 sets of uUTI treatment guidelines have been available
in Canada for the last 5 years (summarized in Nicole paper above).
Despite a consistent spectrum of causative organisms and treatment
objectives, antimicrobial regimens for uUTI, including drug
selection and duration of therapy, vary widely. Various guidelines
make conflicting recommendations on alternatives to TMP/SMX.
We are only considering 2 fluoroquinolones (ciprofloxacin and
norfloxacin which are used in UTI treatment; we are not
considering ofloxacin or levofloxacin (used for many indications
besides UTI), or gatifloxacin (now off the market)).
Clinically, for UTI in a woman, TMP / SMX effective in a 3 day
course, fluroquinolones effective in a 3 day course, and
nitrofurantoin as a 7 day course
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Besides TMP SMX, amoxicillin and ciprofloxacin were the
antibiotics with the largest number of prescriptions in the
similar ACE / ARB analysis.
Baseline
Characteristics
(see Table 1 for
format for these
variables,
including the renal
function variables)

At index date:
•

Age (as median and in age categories, 65-74, 75-84, 85+, see Table 1a for
format)

•

Sex

•

Year of index date (see Table 1a for format)

•

Socioeconomic status (income quintiles: Income based socio-economic status
(calculated by FSA)) at time of index date (reported as income quintile 1 to 5). If
missing, impute value of ‘3’

•

Number of years using beta-blockers (median) (between cohort entry and index
date)

In 3 years prior to index date
•

Charlson score (based on 3 years of hospitalization data prior to index date,
reported as 0, 1, 2+)

•

Congestive heart failure (see appendix for codes – DXTYPE: ALL)

•

Coronary artery disease including angina (see appendix for codes DXTYPE: ALL)

•

Diabetes mellitus (use of an oral hypoglycemic, insulin or diabetic test strips in 3
years prior to index date – see attached spreadsheet for list of diabetic
medications)

•

At least one hospitalization for hyperkalemia (DXTYPE: ALL)

•

Hyperkalemia:
o At least one hospitalization for hyperkalemia (DXTYPE: ALL) or
o Evidence of use of subclnam=”POTASSIUM-REMOVING RESINS” in
1 year prior to index date

•

Chronic kidney disease (see appendix for algorithm)

•

Evidence of diagnosis related to the genitourinary system:
o OHIP Dx category 10 or
o hospital admission for Dx genitourinary system (DXTYPE: ALL, ICD-9
580 – 625.9, ICD-10 N00-N99) or
o hospital admission for Dx benign or malignant cancer of the prostate
(DXTYPE: ALL, ICD-9 18.5, 222.2, 233.4, 236.5; ICD-10 C61, D075,
D291, D400)

•

Evidence of diagnosis related to cystitis:
o OHIP Dx 595 or
o hospital admission for cystitis (DXTYPE: ALL, ICD-9 595.x, ICD-10
N30)

In 6 weeks prior to index date
•

Evidence of diagnosis related to the genitourinary system in 6 weeks preceding
index date. (Recognize these codes have not been validated):
o OHIP Dx category 10 or
o hospital admission for Dx genitourinary system, (DXTYPE: ALL, ICD-9
580 – 625.9, ICD-10 N00-N99) or

113

hospital admission for Dx benign or malignant cancer of the prostate
(DXTYPE: ALL, ICD-9 18.5, 222.2, 233.4, 236.5; ICD-10 C61, D075,
D291, D400)

o

•

Evidence of at least one OHIP Dx coded related to cystitis in the 6 weeks
preceding index date. (Recognize this code has not been validated):
o OHIP Dx code 595 or
o hospital admission for cystitis (DXTYPE: ALL, ICD-9 595.x, ICD-10 N30)

In 1 year prior to index date
•

Number of distinct drugs used, median (IQR)

•

Number of distinct drugs used, category ≤ 2, 3, 4, 5, ≥ 6 (see Table 1a)

Renal function tests available in Gamma-Dynacare dataset (expect large number
of individuals will have these values missing)
o Most recent serum creatinine prior to index date
o Most recent estimated glomerular filtration rate (eGFR) prior to index date
o Most recent estimated glomerular filtration rate category prior to index
date (see Table)
Use of drugs in the 120 days prior to index date
•

Non-potassium sparing diuretics

•

Potassium sparing diuretics

•

Potassium supplements

•

NSAIDs

•

ACE or ARB

Outpatient Potassium Measurement
•

Report these results in Table 1a, Table 1b and Table 1c

•

Number of days between antibiotic prescription and index date, median (IQR)

•

At least one potassium measurement day after antibiotic prescription to day prior
to index date (hospital admission for cases)

•

•

OHIP fee code L204

•

Do not count measurement done on the date of prescription

•

Do not count measurement done on the date of index date (hospital
admission for cases)

At least one potassium measurement on index date (date of hospital admission for
cases)
•

OHIP fee code L204

Matching results (restricted to cases only)
•

proportion of cases with matching controls, categories: 4 matching controls, 3
matching controls, 2 matching controls, 1 matching control, zero matching
controls

•

reported as N (%) per category

•

we expect no zero matching controls

114

•

Report results in Table 1a only

See attached Drug Lists for dins of drugs listed above
A sample output is presented in table 4. Present results by each type of antibiotic, and
then all cases together.
Variables:

Characteristics
of Hyperkalemic
Events

•

Length of hospital admission, days
o restrict to those who had hospital admission
o reported as median (IQR)

•

Event resulted in death
o Death in hospital or in the emergency department. Use CIHI, NACRS and
enhanced RPDB.
o reported as N (%)

•

Event required admission to Intensive Care Unit
o Defined as any one of the OHIP codes listed in Appendix A.
o reported as N (%)

Nest

Absolute
Incidence
of Events

•

Elderly Ontarians continuously taking beta-blockers (patients are allowed to switch
between beta-blockers)

•

Continuous use defined as:
o Any prescription within 100 day windows starting on date of first
prescription for the drug
o Next 100 day window defined as last prescription date + 100 days
o If no prescription within next 100 day window, end follow-up (follow-up
date defined as 100 days following date of last script)
o Determine if new or chronic use (parameter &dl_lookback):

•

Exclude patients

•

•

Invalid IKN

•

Missing age or sex

•

Age < 66 at time of cohort entry (parameter &age_restrict)

•

Death on same date as start of beta-blocker

Sample output present in Table 5.
•

Number of patients who had at least 1 TMP-SMX prescription during the
time of continuous beta-blocker use

•

Number of patients who died within 21 days after date of first prescription
for TMP-SMX during the time of continuous beta-blocker use

•

Number of patients who had a hospital admission for hyperkalemia (as
defined above) within 21 days after date of first prescription for TMP-SMX
during the time of continuous beta-blocker use

•

Number of patients who had at least 1 Amoxicillin prescription during the
time of continuous beta-blocker use

•

Number of patients who died within 21 days after date of first prescription
for Amoxicillin during the time of continuous beta-blocker use

•

Number of patients who had a hospital admission for hyperkalemia (as
defined above) within 21 days after date of first prescription for Amoxicillin
during the time of continuous beta-blocker use
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Recognize unlike main analysis there may be co-administration of antibiotics in this
analysis.

e)
f)
•
•
•

•
•

Analysis Plan
Descriptive Analysis:

Table 1a of N(%) or median (IQR) for study variables by cases and respective matched-controls (see
Table below for sample output)
Table 1b of N(%) or median (IQR) for study variables by exposure and cases and respective
matched-controls (see Table below for sample output)
Table 1c of N(%) or median (IQR) for study variables by exposure only (see Table below for sample
output)
g)
h)
Conditional Logistic Regression Analysis (Table 2 and 3):
Unadjusted model with only exposure variables included
Adjusted model with all exposure and covariates of interest included.
Model adjusted for:
o Charlson Score (0 referent, 1, 2+)
o Income Quintile (1 - 2 vs. 3 – 5 (referent))
o Congestive heart failure in past 3 years (see appendix for codes) (0 no referent, 1)
o Coronary artery disease in past 3 years (see appendix for codes) (0 no referent, 1)
o Number of distinct drugs used in past 1 year (<=5 (referent), 6 to 10, 11 to 15, 16 to 20, 21
to 25, 26+
o At least one hospitalization for hyperkalemia in past 3 years or claim for potassium binding
resin in past 1 year
o Medication use in preceding 120 days (prior to index date):
o Non-potassium sparing diuretics,
o Potassium sparing diuretics,
o Potassium supplements,
o NSAIDs,
o ACE or ARB
(Do NOT adjust for the factors used in matching, as they are accounted for by the design: index
date, age, sex, presence of chronic kidney disease in 3 years prior to index date, diabetes)
i)
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Tables:
Table 1a: Baseline characteristics for Cases and Matched Controls for Primary
Analysis
Standardized
Variable
Control
Case
Difference
N=
N=
Age (Median (IQR))
Median (IQR) Median (IQR)
65-74
75-84
85+
Female
N (%)
N(%)
Year of Index date *
1994 – 1995
N (%)
N(%)
1996 – 1997
N (%)
N(%)
1998 – 1999
N (%)
N(%)
2000 – 2001
N (%)
N(%)
2002 – 2003
N (%)
N(%)
2004 – 2005
N (%)
N(%)
2006 – 2007
N (%)
N(%)
2008
N (%)
N(%)
Income Quintile
1 to 2
N (%)
N(%)
3 to 5
N (%)
N(%)
Years using beta-blockers
Median(IQR)
Median (IQR)
Charlson Score
0
N (%)
N(%)
1
N (%)
N(%)
2+
N (%)
N(%)
Congestive heart failure in past 3
years
N (%)
N(%)
Coronary artery disease / angina in
past 3 years
N (%)
N(%)
Diabetes in past 3 years
N (%)
N(%)
At least one hospitalization for
hyperkalemia in past 3 years
N (%)
N(%)
At least one hospitalization for
hyperkalemia in past 3 years or
claim for potassium removing resin
in past 1 year
N (%)
N(%)
Chronic kidney disease in past 3
years
N (%)
N(%)
Dx of disorder of genitourinary
system in past 3 years
N (%)
N(%)
Dx of cystitis in the past 3 years
N (%)
N(%)
Dx of disorder of genitourinary
system in past 6 weeks
N (%)
N(%)
Dx of cystitis in the past 6 weeks
N (%)
N(%)
No. of distinct prescription drugs in
previous year
Median (IQR) Median (IQR)
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No. of distinct prescription drugs in
previous year
≤5
6 to 10
11 to 15
16 to 20
21 to 25
26+
Most recent serum creatinine,
umol/L **
2
Most recent eGFR mL/min/1.73 m
**

Most recent eGFR category
= > 60 mL/min/1.73 m2
30 to 50 mL/min/1.73 m2
< 30 mL/min/1.73m2
Missing **
Medication use in preceding 120
days
Non-potassium sparing
diuretics
Potassium sparing diuretics
Potassium supplements
NSAIDs
ACE / ARB
Number of days between antibiotic
prescription and index date
At least one potassium
measurement day after antibiotic
prescription to day prior to index
date (hospital admission for cases)
At least one potassium
measurement on index date
(hospital admission for cases)

Median (IQR)

Median (IQR)

Median (IQR)

Median (IQR)

N (%)
N (%)
N (%)
N

N(%)
N(%)
N(%)
N

N (%)

N(%)

N (%)
N (%)
N (%)
N (%)
N (%)

N(%)
N(%)
N(%)
N(%)
N(%)

Median (IQR)

Median (IQR)

N (%)

N(%)

N (%)

N(%)

Matching results (number of controls matched per case)
4
3
2
1
0

N(%)
N(%)
N(%)
N(%)
***

* may only be looked at for internal purposes to look at distribution, not reported in final manuscript
** expect a large number of individuals will have missing values
*** given exclusion criteria, there should be no matching results of 0
Table 1b: Baseline characteristics for Cases and Matched Controls for Primary Analysis by
Antibiotic type

Cipr
o
N=

Controls
Norfl Nitr Amo
x
o
x
N=
N=
N=

TM
P
SM

Cipr
o
N=

Cases
Norfl Nitr
x
o
N=
N=

Amo
x
N=

TM
P
SM
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X
N=
Age
(Media
n
(IQR))
65-74
75-84
85+

…
… identical variables as that presented in Table 1a.

X
N=
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Table 1c: Baseline characteristics for Primary Analysis by Antibiotic Type
(Cases and Controls together)

Cipro
N=

Norflx
N=

Nitro
N=

Age (Median
(IQR))
65-74
75-84
85+

…
… identical variables as that presented in Table 1a.

Amox
N=

TMP
SMX
N=
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Table 2: Conditional Logistic Regression Results for Primary Outcome (OR and 95% CI)
Exposure
Unadjusted
Adjusted
OR SE
LCL
UCL OR SE
LCL
UCL
Primary Analysis: Previous 14 days (Beta-blocker nest)
Ciprofloxacin (reference)
1
---Norfloxacin
Nitrofurantoin
Amoxicillin
TMP-SMX
Secondary Analysis: Previous 7 days
Ciprofloxacin (reference)
1
-Norfloxacin
Nitrofurantoin
Amoxicillin
TMP-SMX
Secondary Analysis: Previous 21 days
Ciprofloxacin (reference)
1
-Norfloxacin
Nitrofurantoin
Amoxicillin
TMP-SMX
Tertiary Analysis: Previous 14 days
Ciprofloxacin (reference)
1
-Norfloxacin
Nitrofurantoin
Amoxicillin
TMP-SMX type 1
(800/160)
TMP-SMX Type 2
(400/80)

--

--

--

--

1

--

--

--

--

--

1

--

--

--

--

--

1

--

--

--

1

--

--

--

1

--

--

--

1

--

--

--

Tertiary Analysis, Nest: Cardioselective beta-blockers *
Ciprofloxacin (reference)
1
---Norfloxacin
Nitrofurantoin
Amoxicillin
TMP-SMX
1

--

--

Tertiary Analysis, Nest: Non-cardioselective beta-blockers *
Ciprofloxacin (reference)
1
---Norfloxacin
Nitrofurantoin
Amoxicillin
TMP-SMX

Tertiary Analysis, No Nest *
Ciprofloxacin (reference)

1

--

--
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Norfloxacin
Nitrofurantoin
Amoxicillin
TMP-SMX
Tertiary Analysis, Gamma-Dynacare Inclusion and Matching *
Ciprofloxacin (reference)
1
---1
Norfloxacin
Nitrofurantoin
Amoxicillin
TMP-SMX
Tertiary Analysis, Broader Definition of Hyperkalemia *
Ciprofloxacin (reference)
1
---Norfloxacin
Nitrofurantoin
Amoxicillin
TMP-SMX

1

--

--

--

--

--

--

--

--

Tertiary Analysis, Definition of Hyperkalemia which includes ED visits*
Ciprofloxacin (reference)
1
---1
-Norfloxacin
Nitrofurantoin
Amoxicillin
TMP-SMX

* otherwise identical to primary analysis
* in addition to reporting OR, LCL, UCL for unadjusted and adjusted, also report the standard
error for unadjusted and adjusted estimates (each in a separate column) [update table above
accordingly]. Report all values to at least 4 decimal points. Will be using the method described by
Altman and Bland to compare the odd’s ratio for no nest (no beta-blocker) to primary analysis
with beta-blocker nest.

Interaction revisited: The difference between two estimates
Douglas G Altman; J Martin Bland British Medical Journal; Jan 25, 2003; 326, 7382;
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Table 3: Conditional Logistic Regression Results for Primary Outcome (OR and 95% CI)
Primary Analysis (Previous 14 days, beta-blocker nest)
Results of full model
Exposure
Unadjusted
Adjusted
OR
SE
LCL
UCL
OR
SE
LCL
UCL
Antibiotic used
Ciprofloxacin (reference)
1
---1
---Norfloxacin
Nitrofurantoin
Amoxicillin
TMP-SMX
Charlson Score
0 (reference)
1
---1
---1
2+
Income Quintile
1 (reference)
1
---1
---2
3
4
5
Congestive Heart Failure
no (reference)
1
---1
---Yes
Coronary artery disease / angina
no (reference)
1
---1
---Yes
Number of distinct drugs in past year
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≤ 2 (reference)
1
---1
---3
4
5
≥6
At least one hospitalization for hyperkalemia in past 3 years or claim for potassium binding resin
in past year
no (reference)
1
---1
---yes
Non-potassium sparring diuretic use in preceding 120 days
no (reference)
1
---1
---yes
Potassium sparring diuretic use in preceding 120 days
no (reference)
1
---1
---yes
Potassium supplement use in preceding 120 days
no (reference)
1
---1
---yes
NSAID use in preceding 120 days
no (reference)
1
---1
---yes
ACE or ARB use in preceding 120 days
no (reference)
1
---1
---yes
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Table A5: Outcomes and Severity of Cases (CASES ONLY)

Variable

Ciprofl
oxacin

Norfloxa
cin

Nitrofura
ntoin

Amoxicill
in

TMP-SMX

N=

N=

N=

N=

N=

Duration of hospital visit (median,
IQR)
Death during hospital admission, n
Intubation / ICU visit during hospital,
stay, n

Table 4 Characteristics of Hyperkalemic Events

Table 5 Absolute Incidence of Events
Number
TMP-SMX
Number of patients who had at least 1 TMP-SMX prescription during the
time of continuous beta-blocker use
Number of patients who died within 21 days after date of first
prescription for TMP-SMX during the time of continuous beta-blocker
use
Number of patients who had a hospital admission for hyperkalemia
within 21 days after date of first prescription for TMP-SMX during the
time of continuous beta-blocker use
Amoxicillin
Number of patients who had at least 1 Amoxicillin prescription during the
time of continuous beta-blocker use
Number of patients who died within 21 days after date of first
prescription for Amoxicillin during the time of continuous beta-blocker
use
Number of patients who had a hospital admission for hyperkalemia
within 21 days after date of first prescription for Amoxicillin during the
time of continuous beta-blocker use

Total
N=
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j)

Checklist of Parameters

Date Variables
*Start Date of Accrual
*End Date of Accrual
*End Date of Follow-up
*Reference Date (date at which entry into nest begins)
Define Population
*Age restriction (minimum age included in cohort)
*Sex restriction (Male, Female, or both)
Any other inclusion/exclusion criteria
Define Nest (project specific – more information than below may be required)
ICD9/ICD10 diagnosis or procedure codes for nest
Diagnosis Type
Source from DAD (inpatient, same day surgery or both)
OHIP diagnosis or fee codes for subgrouping condition
OHIP source (lab, nonlab or all)
ODB DIN list for any drugs used to define nest
*Lookback period from start of accrual to identify subgrouping condition
Matching Cases to Controls
*Case:Control ratio defined
*Matching variables described (include calipers)
Definition of Exposure Drugs
*Drug List includes all DINs for drugs to be investigated
*Exposure Drug Names (DCLASS names to ID exposure drugs in DIN list)
Outcome Definition (project specific – more information than below may be required)
ICD9/ICD10 diagnosis or procedure codes for outcome condition
Diagnosis type (CIHI datasets)
Source from DAD (inpatient, same day surgery, or both)
OHIP diagnosis or fee codes for outcome condition
OHIP source (lab, nonlab or all)
Definition of Variables for Statistical Adjustment
*All variables required for statistical adjustment defined
*Lookback periods for variables defined (e.g. history of AMI in past 5 years)
Analyses
*List of all continuous covariates of interest (included in Table 1 and adjusted model)
*List of all dichotomous covariates of interest (included in Table 1 and adjusted model)
*List of all categorical covariates of interest (included in Table 1 and adjusted model)
*List of referent categories to be used in regression analysis for categorical variables
* Denotes required field
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Drugs in Excel spreadsheet below:
1. TMP-SMX (with additional specification of low dose and high dose for tertiary analysis)
2. Beta-adrenergic receptor antagonists (with additional specification of cardioselective and
non-selective for tertiary analysis)
3. Other variables for adjustment:
a. Non-potassium sparing diuretics
b. Potassium sparing diuretics
c. Potassium supplements
d. NSAIDs
e. ACE & ARB lists
4. Lists for additional analyses
a. Beta- Non cardioselective beta-adrenergic receptor antagonists
b. Cardioselective beta-adrenergic receptor antagonists
c. Calcium Channel Blockers
d. Statins
5. Other oral antibiotics

Drug List June 5

Drug list for SMBG test strips:

SMBG Drug List

Diabetes Drugs

Drug list for Potassium-removing resins:

Druglist for
K-removing Resins
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Appendix A:
Variable/Conditio
n

ICD9 Dxcode

ICD10 Dxcode

OHIP

CONGESTIVE
HEART FAILURE

ALL DIAGNOSIS
TYPES
425
428x
518.4
514
997.1;

ALL DIAGNOSIS TYPES
I255, I42, I43, I50, J81;

OHIP dxcode
428

CCI prcodes 1HP53, 1HP55,
1HZ53GRFR, 1HZ53LAFR,
1HZ53SYFR;

CCP: 49.6, 49.61,
49.62, 49.63, 49.64;
Hyperkalemia

For outcome, use
admitdx, for history
of hyperkalemia, use
all diagnosis types:
276.7:
HYPERPOTASSEMIA

For outcome, use admitdx, for
history of hyperkalemia, use all
diagnosis types:
E87.5: Hyperkalaemia

None

CORONARY
ARTERY DISEASE
(including angina)

ALL DIAGNOSIS
TYPES
ICD9- 410 to 414,
429.2, 429.5, 429.6,
429.7;

ALL DIAGNOSIS TYPES

• OHIP
feecodes
R741, R742,
R743, Z434,
G298, E646,
E651, E652,
E654, G262;

CCP prcodes 48.1,
48.11 to 48.19
[inclusive], 48.0, 48.01
to 48.09 [inclusive],
48.2, 48.3

CIHI ICD10 dxcodes I20 to I25;
CCI prcodes 1IJ76, 1IJ50, 1IJ26,
1IJ27, 1IJ54, 1IJ57;

• ODB
subclnam=‘C
ORONARY
VASODILATO
RS’

Kidney Failure
receiving dialysis

CCP: 5195
(hemodialysis), 6698
(peritoneal dialysis),

Chronic kidney
disease

1 physician or 1 hospital-based claim in three years (see list below, all
diagnosis types)
Which in the work by Ruth Hall had a SN of 22.9%, SP of 87.5% and PPV of
2
44.4% against a reference standard of a eGFR < 60 mL/min per 1.73 m removed fluid and electrolyte and transplant components of these codes.

Intensive Care Unit
Admission

CCI: 1PZ21 (dialysis, urinary
system)

All the Renal
Diagnosis
Feecodes
(OHIP) listed
below.

OHIP feecodes
G400, G401,
G405, G406,
G557, G558,
G559
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Renal Disease Feecodes (OHIP):
Hemodialysis
R849
Dialysis - Heamodialysis - Initial & acute
R850
Dialysis - Haemodialysis - insert of Scribner shunt
G323
Dialysis - Haemodialysis - Acute, repeat (max 3)
G325
Dialysis - Haemodialysis - Medical component(incl in unit fee)
G326
Dialysis - Chronic, contin. haemodialysis or haemofiltration each
G860
Chronic hemodialysis hospital location
G862
Hospital self care Chronic hemodialysis
G863
Chronic hemodialysis IHF location
G865
Chronic Home hemodialysis
G866
Intermittent hemodailysis treatment centre
Peritoneal dialysis
G330
Peritoneal dialysis - Acute (up to 48 hrs)
G331
Peritoneal dialysis - Repeat acute (up to 48 hrs) max. 3
G332
Peritoneal dialysis - Chronic (up to 48 hrs)
G861
Chronic peritoneal dialysis hospital location
G864
Chronic Home peritoneal dialysis
CRRT
G082
Continuous venovenous haemodialfiltration
G083
Continuous venovenous haemodialysis
G085
Continuous venovenous haemofiltration
G090
Veneovenous slow continuous ultrafiltration
G091
Continuous arteriovenous haemodialysis
G092
Continuous arteriovenous haemodiafiltration
G093
Haemodiafiltration - Contin. Init & Acute (repeatx3)
G094
Haemodiafiltration - Contin. Chronic
G095
Slow Continuous Ultra Filtration - Initial & Acute (repeat)
G096
Slow Continuous Ultra Filtration – Chronic
G294
Arteriovenous slow continuous ultrafiltration init and acute
G295
Continuous aterivenous haemofiltration initial and acute
OTHER
G333
Home/self-care dialysis
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Chronic Kidney Disease Codes

Description
Renal related
Hypertension

Nephritis

Acute Renal Disease

icd9 codes
403, 404.0,404.1,
404.9,
405.0, 405.1, 405.9

icd10ca
I12.x, I13.x, I15.00 I15.01,
I15.10, I15.11

582.0, 582.1, 582.2,
582.8, 582.9, 583.0,
583.1, 583.2, 583.4,
583.8, 583.9,

N01.x, N03.x, N05.x, N07.x,
N14.x, N15.0

580.0, 580.1, 580.4,
580.8, 580.9
581.0, 581.1, 581.2,
581.3, 581.8
581.9, 584.6, 584.7,
584.8, 584.9

OHIP
code
403

N00.x, N04.x, N08.x

584

N17.x

580, 581

585, 586.0

N18.x N19.x

585

587

N26.x

NA

Disorders Resulting in
Impaired Renal
Function

588.0, 588.1, 588.8,
588.9

N25.x

NA

Other Disorders of Kidney,
Ureter

593.1, 593.2, 593.3,
593.5, 593.6, 593.7,
593.8, 593.9

N13.4, N13.5, N13.7, N28.0,
N28.1,
N28.80, N28.88

593

788

N06.x, N23, N39.2, R30.x, R33,
R34, R35.x, R36, R39.x

Renal Failure
Renal Sclerosis

Renal Colic & Urinary
Symptoms

788
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Appendix B Data Creation Plan: Glyburide and hypoglycemia in CKD
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Hypoglycemia in Impaired Kidney Function
Risk of hypoglycemia requiring ER visit or hospitalization in patients with low kidney
Name and Number of function.
Study
This DCP is examining the relationship between various diabetic agents, low kidney
function and risk of hypoglycemia.
Amit Garg
Tara Gomes
Dan Hackam
Arsh Jain
PI and P&B Contacts David Juurlink
Jeff Mahon, Endocrinologist, UWO
Muhammad Mamdani
Mike Paterson
Matthew Weir
PIA Approved?

Yes (July 23, 2009)

DCP update history

Version 8: July 27, 2009 (MW)
Version 7: July 22, 2009 (MW) – after teleconference with Tara (with comments from
Dan, Mike, Jeff and Muhammad)
Version 6: July 18, 2009 (AG)
Version 5: July 17, 2009 (MW)
Version 4: July 16, 2009 (AG)
Version 3: July 16, 2009 (MW)
Version 2: July 12, 2009 (AG)
Version 1: July 10, 2009 (MW) – after conference call with Tara and Muhammad
Version 0: June – July 2009 (broad comments from all, Lawson grant application)

Short Description of
Research Question

To determine the risk of severe hypoglycemic events associated with specific oral
hypoglycemic agents in people with low and normal kidney function.
Diabetes mellitus is the cause low kidney function in 25% of cases; therefore, oral
hypoglycemic agents are commonly used in these patients. Some of these drugs are
cleared by the kidneys, making the risk of severe hypoglycemic events higher in
those with reduced kidney function. Despite the known risks, further information is
needed in this area for a two main reasons:

First, pharmacokinetic data regarding the mechanism of hypoglycemia in patients
Physiologic Rationale with low kidney function does not explain the different risks reported with some
closely related agents (eg: glyburide and glimepiride). Real-world data will clarify the
actual risks associated with these agents and provide a better context for existing
mechanistic theories.
Second, despite the known risks associated with some agents, patients with low
kidney function continue to use them. This may result from an under-appreciation of
the risks or the state of a patient’s kidney function. Either way, awareness must be
drawn to this issue to improve the safety of patients with low kidney function.
1. ODB
List of Datasets Used
2. NACRS
3. RPDB
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4. DAD
5. OHIP
6. Gamma-Dynacare Main List Jan 2002 - Mar 2009 (serum creatinine data
th
from Southwestern Ontario) [Data sharing agreement made October 25 ,
2004. The agreement was reviewed again as part of the development of this
DCP. To confirm, under this agreement we are able to use this dataset to
‘assess the appropriateness of drug use and dosing in patients’]
Study Design

Methodology
Considerations

Nested case-control. See Appendix C, Figure 1.
Considerations: We appreciate that within the nested case-control design that we are
considering only the risk of hypoglycemia with glyburide (one type of OHA) compared
to other OHA or insulin. We are then looking for an interaction by CKD status, using
the formula of Altman D, Bland JM, Interaction revisited: the difference between two
estimates. BMJ 2003, enclosed near end of DCP). We are not considering the
benefits of one type of OHA compared to another (i.e. is metformin the only oral
hypoglycemia associated with improved survival despite varying hypoglycemic risk
with various OHA?). With this type of design, it may be possible to obtain indirect
estimates of absolute risk / incidence, although the main output is an odd’s ratio of
one OHA compared to another OHA or insulin (i.e. results expressed in relative
terms).

1.

Nest cohort

Defining characteristics:
2. Ontario resident registered in the RPDB
3. At least one serum creatinine level recorded in the Gamma-Dynacare database,
entering the cohort at the time of first serum creatinine measurement.
4. Evidence of at least one prescription for either an oral hypoglycemic agent or
insulin after time of first serum creatinine measurement (see Appendix D, “oral
hypoglycemic agents” and “insulins”)
•

Exclusion
Criteria

Defining the Nest Cohort

This definition has been included in attempts to limit the number of
subjects included in the nest, for ease of programming.

The following features will result in exclusion from the nest cohort:
1. Invalid IKN
2. Missing date of birth
3. Missing sex
st
st
4. Age < 66 years on March 31 , 2008 (Date of birth after March 31 , 1942 as March
st
31 , 2008 is last possible day of cohort entry, this would make the patient less than
66 years of age at time of last possible day of cohort entry).
•

This definition has been included in attempts to limit the number of
subjects included in the nest, for ease of programming.

5.

Time Frame Definitions

Beginning of Accrual Period for nest: January 1, 2002 (this is the earliest data
Accrual Start/End Dates point in the Gamma-Dynacare database)
End of Accrual Period for nest: March 31, 2008
Max Follow-up Date
Nest Cohort Entry

End of follow-up Period: March 31, 2008
Date of first Gamma-Dynacare serum creatinine level
st

Look Back Window

Conditions: 5 years prior to Index Date; earliest potential date is Jan 1 , 1997
st
Medications: 1 year prior to Index Date; earliest potential date is Jan 1 , 2001

When does observation Termination occurs with any of the following events
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window terminate?

1. Hypoglycemic event (admission or emergency department visit)
2. Death
3. End of follow-up (March 31 2008)

6.

Variable Definitions

ANALYSIS A (Low Kidney Function) - see Appendix C, figure 1
Looking forward from the time of entry into the nest, cases will be individuals from the nest
cohort who experience a hypoglycemic event (first event looking forward) as defined by
the codes below:
•

Cases
Patients with a
hypoglycemic
event using either
a single oral
hypoglycemic
agent or insulin

Diagnosis codes for outcome condition. CIHI and NACRS datasets parameters
defined by:
o ICD9 dxcodes:
o 250.8, 251.0, 251.1, 251.2, 962.3
o ICD10 dxcodes:
o E10.63, E11.63, E13.63, E14.63, E15, E16.0, E16.1, E16.2

•

CIHI-DAD Diagnosis Type: admitdx

•

CIHI-DAD source:
Inpatient
Same-day-surgery
All

•

NACRS Diagnosis Type: main diagnosis

•

Exclusion criteria for cases:
o
Age < 66 years of age at the time of hypoglycemic event [index date] (to allow
for a one year medication look-back in ODB)
o
Medication characteristics prompting exclusion (see Table 1 below)
•

NO prescription for any type OHA or insulin in the 120 days prior to the
date of the hypoglycemic event. (using 120 vs. 100 days to provide a 20
day grace period to the routine 100 day requirement for script renewal; we
are excluding non-diabetics who present with hypoglycemia)

•

A prescription for more than one type of oral hypoglycemic agent (OHA) in
the 120 days prior to the date of the hypoglycemic event. (individuals with
multiple prescriptions for the same type of oral hypoglycemic are eligible
for study participation)

A prescription for both insulin and any type of OHA in the 120 days prior
to the hypoglycemic event.
(See Appendix D, “oral hypoglycemic agents” and “insulins”)
•

Table 1. Medication related inclusion and exclusion criteria.
Prescription (within 120 days
before index date)

Status
Included

Single OHA

√

Single insulin product

√

Multiple insulin products

√

Excluded

OHA and Insulin

√

≥ 2 different OHAs

√

No OHA or Insulin

√
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o

Other characteristics prompting exclusion
•

No available matching control.

•

Evidence of one or more dialysis codes in 5 years prior to the index date
(see Appendix B)

•

Most recent eGFR prior to index date ≥ 60 mL/min per 1.73 m

2

ANALYSIS B (Normal Kidney Function) – see Appendix C, figure 1
Definitions are identical to those of Analysis A except that subjects whose most
2
recent eGFR prior to the index date is < 60 ml/min per 1.73m are excluded and
2
those whose most recent eGFR prior to the index date is ≥ 60 ml/min/1.73m are
included.

•

ANALYSIS A (Low Kidney Function) - see Appendix C, figure 1
Individuals from the nest cohort who are event-free at index date.
•

Case to Control Ratio: Match 4 controls to each case

•

Matching criteria:
Age at index date (± 1 year)
Gender
2
Most recent eGFR prior to index date (± 20 mL/min per 1.73 m ) [may need to
augment range (e.g. 25 mL/min) if matching on this characteristic is difficult, or
alternatively to 15 mL/min if eGFR characteristic between cases and controls is
not similar].

•

Exclusion criteria for controls:
o
Age < 66 years of age at index date (to allow for a one year medication lookback in ODB)
o
Medication characteristics prompting exclusion (see Table 1 above)

Eligible Controls

•

NO prescription for any type OHA or insulin in the 120 days prior to the
date of the hypoglycemic event. (using 120 vs. 100 days to provide a 20
day grace period; we are excluding non-diabetics who present with
hypoglycemia)

•

A prescription for more than one type of oral hypoglycemic agent (OHA)
in the 120 days prior to the date of the hypoglycemic event. (individuals
with multiple prescriptions for the same type of oral hypoglycemic are
eligible for study participation)

A prescription for both insulin and any type of OHA in the 120 days prior
to the hypoglycemic event.
(see Appendix D, “oral hypoglycemic agents” and “insulins”)
•

o

•

Other characteristics prompting exclusion
•

Evidence of one or more dialysis codes in 5 years prior to the index date
(see Appendix B)

•

Most recent eGFR prior to index date ≥ 60 mL/min per 1.73 m

2

When full number of matched controls cannot be obtained (i.e. 4 controls per
case), the matching process is maintained, and any available controls are
analyzed.

ANALYSIS B (Normal Kidney Function) – see Appendix C, figure 1
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•

Index date

Definitions are identical to those of Analysis A except that subjects (cases and
controls) whose most recent eGFR prior to the index date is < 60 ml/min per
2
1.73m are excluded and those whose most recent eGFR prior to the index date
2
is ≥ 60 ml/min/1.73m are included.

Case: Date of the first hypoglycemic event after cohort entry
Control: The same date as the index date for matched cases
Exposure status for both Analysis A and Analysis B is determined by the specific
medication the subject was using in the 120 days prior to the index date.

Main Exposure
or Risk Factor

•

Acarbose (referent group)

•

Gliclazide

•

Glyburide

•

Glimepiride

•

Chlorpropamide

•

Tolbutamide

•

Metformin

•

Pioglitazone

•

Rosiglitazone

•

Nateglinide

•

Repaglinide

• Insulin
(see Appendix D, “oral hypoglycemic agents” and “insulins”)
•

Age at index date
o as median (IQR) and in age categories (see Appendix A, Table A1)

•

Gender
o reported as N (%) women

•

Income
o reported as income quintiles: Income based socio-economic status
(calculated by FSA)) at cohort entry date (reported as two groups: income
quintiles ≤ 2 and quintiles ≥ 3; for multivariable analysis any missing data
should be coded as 3)

•

Year of index date
o reported as categories 2002-2003, 2004-2005, 2006-2007, and 2008 (see
Appendix A, table A1).

•

Number of distinct drugs used in the year prior to the index date
o reported as median (IQR) and as categories ≤ 5, 6-10, 11-15, 16-20, 2126, or ≥26 (referent = ≤5)

•

Charlson score based on 5 years of hospitalization data
o reported as ≤ 1, 2, or ≥ 3; if there are no hospitalizations, code as ≤ 1 and
not as ‘missing’

•

Hospital discharge (CIHI-DAD) within 30 days prior to index date
o reported as N (%)

•

Recent infection
o defined by an anti-infective outpatient prescription within 21 days prior to
index date. (see Appendix D, “Anti-Infective Agents”). Reported as N

Baseline
Characteristics
(see Appendix A,
Table A1 for
formatting of
these variables,
including the renal
function variables)

137

(%).
•

Liver disease in 5 year prior to index date
o defined in Appendix B, reported as N (%).

•

Alcoholism in 5 year prior to index date
o defined in Appendix B, reported as N (%).

•

Coronary artery disease within 5 years prior to index
o defined in Appendix B, reported as N (%).

•

Congestive heart failure within 5 years prior to index
o defined in Appendix B, reported as N (%).

•

Cerebrovascular disease within 5 years prior to index
o defined in Appendix B, reported as N (%).

•

Number of primary care visits in 5 years prior to index date
o defined in Appendix B, reported as median (IQR) and a N (%) per
categories ≤ 15, 16-29, or ≥ 30 (referent = ≤ 6) .
o if more than one code appears on a single day count as one encounter.

•

Number of internist visits in 5 years prior to index date
o defined in Appendix B, reported as median (IQR) and as N (%) per
categories ≤ 5, 6-14, or ≥ 15 (referent = ≤ 4).
o if more than one code appears on a single day count as one encounter.

•

Previous hypoglycemic event in 5 years prior to index date
o defined as in definition of cases, reported as N (%)

•

Matching results (restricted to cases only)
o proportion of cases with matching controls, categories: 4 matching
controls, 3 matching controls, 2 matching controls, 1 matching control,
zero matching controls
o reported as N (%) per category
o we expect no zero matching controls

•

Number of serum creatinine measurements in Gamma-Dynacare database prior
to index date
o reported as median (IQR)

•

Time between index date and most recent serum creatinine prior to index date
o measured in days and reported as median (IQR).

•

Most recent serum creatinine prior to index date
o reported as median (IQR)

•

Most recent estimated glomerular filtration rate (eGFR) prior to index date
2
o measured in ml/min/1.73m and reported as median (IQR)

•

Most recent estimated glomerular filtration rate category prior to index date
o defined by most recent eGFR prior to index date

o

2

!

Normal: ≥ 90 ml/min/1.73m

!

Borderline: 60 – 89 ml/min/1.73m

!

CKD III: 30 – 59 ml/min/1.73m

!

CKD IV: 15 – 29 ml/min/1.73m

!

CKD V: < 15 ml/min/1.73m

reported as N (%) per category

2

2
2

2
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Potential Confounding Medications
Medications with hypoglycemic effects (within 120 days prior to index date):
•

β-blockers

•

ACE Inhibitors

• MAOI drugs
Other Variables
(see Appendix D, “Hypoglycemic Medications”)
for statistical
Medications
with hyperglycemic effects (within 120 days prior to index date):
adjustment
• Corticosteroids
•

Thiazide diuretics

•

Niacin

• Atypical anti-psychotics
(see Appendix D, “Hyperglycemic Medications”)
Case Outcomes and Severity Analysis
Purpose
Nest

This will be a descriptive analysis of the outcomes and severity of the hypoglycemic events
that we collect.
As above, except this analysis will be restricted to cases only.
A sample output is presented in Appendix A, table A5.
Variables: (reported as N and median (IQR) as specified in table A5)

Characterizing
the Nature of
Hypoglycemic
Events

•

Event did not require hospital admission
o Hypoglycemic event defined as it is in the ‘Cases’ section but restricted to
NACRS database. Diagnosis type: Main diagnosis.
o reported as N (%)

•

Event required hospital admission
o Hypoglycemic event defined as it is in the ‘Cases’ section but restricted to
CIHI-DAD. Diagnosis Type: admitdx. Source: Inpatient
o reported as N (%)

•

Length of hospital admission, days
o restrict to those who had hospital admission
o reported as median (IQR)

•

Event resulted in death
o Death during hospital admission or in the emergency department. Use
CIHI, NACRS and enhanced RPDB.
o reported as N (%)

•

Event required admission to Intensive Care Unit during the hospital admission
o restrict to those who had hospital admission
o Defined as any one of the OHIP codes listed in Appendix B.
o reported as N (%)
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7.
8.
•
•
•

Analysis Plan

Descriptive Analysis: (see Appendix A for sample output tables)

Table A1. Table of N(%) or median (IQR) for study variables by cases and respective matchedcontrols (see Appendix A, table A1).
Sample Table A2. Table of N(%) or median (IQR) for study variables by hypoglycemic agent
used, inclusive of both cases and controls (see Appendix A, table A2)
Sample Table A3 and Table A4. Tables of N (%) or median (IQR) for study variables by
hypoglycemic agent used, separated by cases (table A3) and controls (table A4).

Absolute Event Rate:
•

Sample Table A4.1. Estimated absolute risk of hypoglycemia for each hypoglycemic agent.
Within the nest cohort determine the number of patients with at least one prescription for each of
the three diabetes therapies (metformin, glyburide and insulin).

Outcome Severity Analysis:
•

Sample Table A5. Table of N or median (IQR) for severity of outcome parameters by
hypoglycemic agent use, restricted to cases only (see Appendix A, table A5).

Covariate Analysis (Bivariate):
•

Bivariate conditional logistic regression assessing risk of hypoglycemia conferred by each nonmatched covariate (see Table 2 below). Results will be used to guide final model construction.
For sample output format, see Appendix A, table A6.
Table 2. Covariate Analysis
Variable
Hypoglycemic event

Outcome
Exposure

Modeling
Yes/No

Model 1

Income

Quintiles (referent = lowest)
If missing impute 3

Model 2

Year of index date

4 categories, 2002-2003 (referent),
2004-2005, 2006-2007, and 2008

Model 3
Model 4
Model 5
Model 6
Model 7
Model 8
Model 9
Model 10
Model 11
Model 12
Model 13
Model 14
Model 15
Model 16
Model 17
Model 18
Model 19

Number of distinct drugs in year prior to index *
Charlson score
Hospital discharge, ≤ 30 days prior to index
Recent infection
Liver disease ≤ 5 yr prior to index
Alcoholism ≤ 5 yr prior to index
Coronary artery disease ≤5 yr prior to index
Congestive heart failure ≤ 5 yr prior to index
Cerebrovascular disease ≤ 5 yr prior to index
Number of primary care visits ≤ 5 yr prior to
index *
Number of internist visits ≤ 5 years prior to
index *
Hypoglycemic events ≤ 5 yr prior to index
β-blocker prescription ≤ 120 days prior to index
ACE-inhibitor prescription ≤ 120 days prior to
index

Continuous
≤ 5, 6-10, 11-15, 16-20, 21-26, or
≥ 26 (referent = ≤ 5)
1, 2, or ≥ 3 (referent = 1)
Yes/No
Yes/No
Yes/No
Yes/No
Yes/No
Yes/No
Continuous
≤ 15, 16-29, or ≥ 30 (referent =
≤15)
Continuous
≤ 5, 6-14, or ≥ 15 (referent = ≤ 5)
0, 1, or ≥ 2 (referent = 0)
Yes/No
Yes/No
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Model 20
Model 21
Model 22
Model 23

MAOI prescription ≤ 120 days prior to index
Corticosteroid prescription ≤ 120 days prior to
index
Thiazide diuretic prescription ≤ 120 days prior
to index
Niacin prescription ≤ 120 days prior to index

Yes/No
Yes/No
Yes/No
Yes/No

Table 3. Unadjusted conditional logistic models for Analysis A
Variable
Modeling
Unadjusted Model

Exposure

Outcome

Hypoglycemic agent

Hypoglycemic event
Atypical anti-psychotic prescription ≤ 120 days
Model 24
prior to index
* Two modeling options exist for each of these variables.

Acarbose (referent)
Gliclazide
Glyburide
Glimepiride
Chlorpropamide
Tolbutamide
Metformin
Pioglitazone
Rosiglitazone
Nateglinide
Repaglinide
Insulin
Yes/No
Yes/No

Analysis A:
2
• Risk of hypoglycemia among subjects with LOW kidney function (eGFR < 60 ml/min/1.73m )
comparing each of gliclazide, glyburide, glimepiride, metformin, pioglitazone and insulin to the
referent drug, acarbose.
• Unadjusted models (see Table 3 below). Sample output format for these unadjusted models is
presented in Appendix A, table A7.
•

•

Adjusted models (see Table 4 below). Conditional logistic regression models for each
hypoglycemic agent. Output formatting for adjusted models is presented in Appendix A, table
A7.
Variables for adjustment in each model:
o Forced into the models..
1. Charlson score (≤1, 2, or ≥ 3)
2. Hospital discharge within 30 days prior to index date (no, yes)
3. Recent infection (no, yes)
4. Liver disease (no, yes)
5. Alcoholism (no, yes)
o Added to models if found to be predictive of outcome. This will be determined
through the covariate analysis described in Table 2 (above). Any covariate with a p value
< 0.2 will be included in the adjusted models.
1. Income (1, 2, 3, 4, 5)
2. Year of index date (2002-2003, 2004-2005, 2006-2007, or 2008)
3. Number of distinct drugs used in year prior to index (see Table for input)
4. Coronary artery disease within 5 years prior to index (yes, no)
5. Congestive heart failure within 5 years prior to index (yes, no)
6. Cerebrovascular disease within 5 years prior to index (yes, no)
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o

7. Number of primary care visits within 5 years prior to index (see Table for input)
8. Number of internist visits within 5 years prior to index (see Table for input)
9. Hypoglycemic events within 5 years prior to index (0, 1, or ≥ 2)
10. β-blocker use in 120 days prior to index (yes, no)
11. ACE-inhibitor use in 120 days prior to index (yes, no)
12. MAOI use in 120 days prior to index (yes, no)
13. Corticosteroid use in 120 days prior to index (yes, no)
14. Thiazide use in 120 days prior to index (yes, no)
15. Niacin use in 120 days prior to index (yes, no)
16. Atypical anti-psychotic use in 120 days prior to index (yes, no)
NOT to be included in the model (these variables are accounted for through matching):
1. Age
2. Gender
3. Index date
4. GFR

Table 4. Adjusted conditional logistic regression models for Analysis A
Adjusted Model
Variable
Modeling
Outcome
Hypoglycemic event
Yes/No

Exposure of interest

Hypoglycemic agent

Forced covariates
(included in the model regardless
of performance in covariate
analysis)

Charlson score
Hospitalization within 30 days
prior to index
Recent infection
Liver disease within 5 years prior
to index
Alcoholism within 5 years prior to
index
Income
Year of index date

Potential covariates
(included based on performance
in covariate analysis, Table 2
above)

Acarbose (referent)
Gliclazide
Glyburide
Glimepiride
Chlorpropamide
Tolbutamide
Metformin
Pioglitazone
Rosiglitazone
Nateglinide
Repaglinide
Insulin
1, 2, ≥3 (referent = 1)
Yes, No (referent = no)
Yes, No (referent = no)
Yes, No (referent = no)
Yes, No (referent = no)
Quintiles (referent = lowest
group)
4 categories,
2002-2003 (referent), 2004-2005,
2006-2007, or 2008

Number of distinct drugs used in
year prior to index
Coronary artery disease within 5
years prior to index

Yes, No (referent = no)

Congestive heart failure within 5
years prior to index

Yes, No (referent = no)

To be determined *
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Cerebrovascular disease within 5
years prior to index
Number of primary care visits in 5
years prior to index
Number of internist visits in 5
years prior to index
Hypoglycemic events within 5
years prior to index
β-blocker use in 120 days prior
to index

Yes, No (referent = no)
To be determined *
To be determined *
0, 1, or ≥ 2 (referent = 0)
Yes, No (referent = no)

Ace inhibitor use in 120 days prior
to index

Yes, No (referent = no)

MAOI use in 120 days prior to
index

Yes, No (referent = no)

Corticosteroid use in 120 days
prior to index

Yes, No (referent = no)

Thiazide diuretic use in 120 days
prior to index

Yes, No (referent = no)

Niacin use in 120 days prior to
index

Yes, No (referent = no)

Atypical anti-psychotic use in 120
days prior to index

Yes, No (referent = no)

* determined by performance of modeling options in “Covariate Analysis” (table 2)
• If neither ordinal nor continuous modeling is significantly associated with hypoglycemic events (p
≥ 0.2), the covariate is NOT included in the adjusted models.
• If both ordinal and continuous modeling is significantly associated with hypoglycemic events (p <
0.2), the covariate will be included in the adjusted models as an ordinal variable.
• If only the continuous modeling is significantly associated with hypoglycemic events (p < 0.2),
the covariate will be included in the adjusted models as a continuous variable.
• If only the ordinal modeling is significantly associated with hypoglycemic events (p < 0.2), the
covariate will be included in the adjusted models as an ordinal variable.
Table 4.1: Absolute incidence of hypoglycemia
Total Cohort
Total size of nest cohort
Metformin
No. of patients with at least on prescription for metformin
No. of hypoglycemic events among patients using metformin
Events per 10,000 patients
Glyburide
No. of patients with at least on prescription for glyburide
No. of hypoglycemic events among patients using glyburide
Events per 10,000 patients

N = 19,620
N=
N = 56

N=
N = 162
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Insulin
No. of patients with at least on prescription for insulin
No. of hypoglycemic events among patients using insulin
Events per 10,000 patients
Normal Kidney Function
Total number of patients with normal kidney function
Metformin
No. of patients with at least on prescription for metformin
No. of hypoglycemic events among patients using metformin
Events per 10,000 patients
Glyburide
No. of patients with at least on prescription for glyburide
No. of hypoglycemic events among patients using glyburide
Events per 10,000 patients
Insulin
No. of patients with at least on prescription for insulin
No. of hypoglycemic events among patients using insulin
Events per 10,000 patients
Low Kidney Function
Total number of patients with low kidney function
Metformin
No. of patients with at least on prescription for metformin
No. of hypoglycemic events among patients using metformin
Events per 10,000 patients
Glyburide
No. of patients with at least on prescription for glyburide
No. of hypoglycemic events among patients using glyburide
Events per 10,000 patients
Insulin
No. of patients with at least on prescription for insulin
No. of hypoglycemic events among patients using insulin
Events per 10,000 patients

N=
N = 240

N=
N=
N = 27

N=
N = 53

N=
N = 124

N=
N=
N = 29

N=
N = 109

N=
N = 216

* the sum of these numbers will not likely equal 19,620 because some patients will, at different times, have
had prescriptions for more than one diabetic therapy. Therefore, I would expect their sum to exceed
19,620.
† these numbers are the total number of cases
Analysis B:
• Risk of hypoglycemia among subjects with NORMAL kidney function (eGFR ≥ 60) comparing
each of gliclazide, glyburide, glimepiride, metformin, pioglitazone and insulin to the referent drug,
acarbose.
•

Unadjusted models (see Table 5 below). Sample output format for these unadjusted models is
presented in Appendix A, table A7.

•

Adjusted models (see Table 6 below). Conditional logistic regression models for each of the
hypoglycemic agents. Sample output format for these adjusted models is presented in Appendix
A, table A7. In this Table also present associations with other variables in final adjusted model.
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Table 6. Adjusted conditional logistic regression models for Analysis B
Variable
Modeling
Adjusted Model
Table cells identical to those of Table 4
Additional Analyses:
•

Using the same adjusted conditional logistic regression model from Analysis A, please re-run
the analysis with the following changes:
o Additional Analysis 1: Cases and controls restricted to subjects with eGFR ≤ 45
2
ml/min/1.73m . Sample output table is presented in Appendix A, table A8.
o

Additional Analysis 2: Cases and controls restricted to subjects with eGFR ≤ 30
2
ml/min/1.73m . Sample output table is presented in Appendix A, table A9.

Table 5. Unadjusted conditional logistic models for Analysis B
Variable
Modeling
Unadjusted
Table cells identical to those of Table 3
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Appendix A
Table A1. Baseline characteristics for Cases and Matched Controls
Control

Case

N=

N=

Median
(IQR)
Median
(IQR)
Median
(IQR)

Median
(IQR)
Median
(IQR)
Median
(IQR)

N (%)

N(%)

≤2

N (%)

N(%)

≥3

N (%)

N(%)

Missing

N (%)

N(%)

2002 – 2003

N (%)

N(%)

2004 – 2005

N (%)

N(%)

2006 – 2007

N (%)

N(%)

2008

N (%)

N(%)

Variable

Demographics
Age at Index Date
66-74
75-84
85+
Female
Income Quintile

Year of Index date *

No. of distinct drugs in year prior to index

Co-morbidity
Median
(IQR)

Median
(IQR)

No. of distinct drugs in year prior, categories
≤5

N (%)

N (%)

6 - 10

N (%)

N (%)

11 - 15

N (%)

N (%)

16 - 20

N (%)

N (%)

21 – 25

N (%)

N (%)

≥ 26

N (%)

N (%)

≤1

N (%)

N(%)

2

N (%)

N(%)

≥3

N (%)

N(%)

Missing

N (%)

N(%)

Hospital discharge within 30 days prior to index date

N (%)

N(%)

Recent infection

N (%)

N(%)

Liver disease within 5 years before index

N (%)

N(%)

Alcoholism within 5 years before index

N (%)

N(%)

Coronary artery disease within 5 years before index

N (%)

N(%)

Congestive heart failure within 5 years before index

N (%)

N (%)

Cerebrovascular disease within 5 years before index
Number of primary care visits within 5 years of index,
median

N (%)
Median
(IQR)

N (%)
Median
(IQR)

Charlson Score

Number of primary care visits within 5 years of index, by category
≤ 15 (referent)

N (%)

N(%)

Standardized
Difference
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16 – 29

N (%)

N(%)

≥ 30

N (%)
Median
(IQR)

N(%)
Median
(IQR)

Number of internist visits within 5 years before index

Number of internist visits within 5 years before index, by category
≤5

N (%)

N(%)

6 – 14

N (%)

N(%)

≥ 15

N (%)

N(%)

Number of hypoglycemic events within 5 years before index
0

N (%)

N(%)

1

N (%)

N(%)

≥2

N (%)

N(%)

Matching results (number of controls matched per case)
4

N(%)

3

N(%)

2

N(%)

1

N(%)

0

**

Kidney Function
Number of serum creatinine measurements in
Median
database
(IQR)
Time between index date and most recent serum
Median
creatinine, days
(IQR)
Median
Most recent serum creatinine, µmol/L
(IQR)
Median
2
Most recent eGFR mL/min/1.73 m
(IQR)

Median
(IQR)
Median
(IQR)
Median
(IQR)
Median
(IQR)

Most recent eGFR category
Normal: ≥ 90 mL/min/1.73m

2

Normal: 60 to 89 mL/min/1.73m
CKD III: 30 to 59 mL/min/1.73m
CKD V: < 15 mL/min/1.73m

N (%)

N(%)

N (%)

N(%)

2

N (%)

N(%)

2

N (%)

N(%)

CKD IV: 15 to 29 mL/min/1.73m
2

2

N (%)
Hypoglycemic Medications

N(%)

β – Blockers

N (%)

N(%)

ACE Inhibitors

N (%)

N(%)

MAOI

N (%)
Hyperglycemic Medications

N(%)

Corticosteroids

N (%)

N(%)

Thiazide diuretics

N (%)

N(%)

Niacin

N (%)

N(%)

N (%)

N(%)

Atypical antipsychotics

Oral Hypoglycemic Agent Use
Acarbose (referent)

N (%)

N(%)

Gliclazide

N (%)

N(%)

Glyburide

N (%)

N(%)

Glimepiride

N (%)

N(%)

Chlorpropamide

N (%)

N(%)

Tolbutamide

N (%)

N(%)
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Metformin

N (%)

N(%)

Pioglitazone

N (%)

N(%)

Rosiglitazone

N (%)

N(%)

Nateglinide

N (%)

N(%)

Repaglinide
Insulin

N (%)

N(%)

N (%)

N(%)

* may only be looked at for internal purposes to look at distribution, not reported in final
manuscript
** given exclusion criteria, we do not expect to have any subjects in this category

Gliclazide

Glyburide

Glimepiride

Chlorpropamide

Tolbutamide

Metformin

Pioglitazone

Rosiglitazone

Nateglinide

Repaglinide

Insulin

Variable

Acarbose

Table A2: Baseline characteristics for users of single oral hypoglycemic agents
CASES & CONTROLS

N=

N=

N=

N=

N=

N=

N=

N=

N=

N=

N=

N=

Demographics
Age [Median (IQR)]
66-74
75-84
85+
Female [N (%)]
Income Quintile [N (%)]
≤2
≥3
Missing
Year of Index date [N (%)] *
2002 – 2003
2004 – 2005
2006 – 2007
2008
Co-morbidity
No. of distinct drugs in previous
year [Median (IQR)]
No. of distinct drugs in previous year, by category [N (%)]
≤5
6 - 10
11 - 15
16 - 20
21 – 25
≥ 26
Charlson Score [N (%)]
≤1
2
≥3
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Missing
Coronary artery disease within 5
years before index [N (%)]
Congestive heart failure within 5
years before index [N (%)]
Cerebrovascular disease within 5
years before index [N (%)]
Number of primary care visits within
5 years of index [Median (IQR)]
Number of primary care visits within 5 years of index, by category [N (%)]
≤ 6 (referent)
7 - 13
≥ 14
Number of internist visits within 5
years before index [Median (IQR)]
Number of internist visits within 5 years before index, by category [N (%)]
≤4
5–9
≥ 10
Number of hypoglycemic events with 5 years before index
0
1
≥2
Kidney Function
Number of serum creatinine
measurements in database [Median
(IQR)]
Time between index date and most
recent serum creatinine, days
[Median (IQR)]
Most recent serum creatinine,
µmol/L [Median (IQR)]
2
Most recent eGFR mL/min/1.73 m
[Median (IQR)]
Most recent eGFR category [N (%)]
Normal ≥ 90 mL/min/1.73m

2

Normal ≥ 60 mL/min/1.73m

2

CKD III 30-59 mL/min/1.73m

2

CKD IV 15-29 mL/min/1.73m
CKD V < 15 mL/min/1.73m

2

2

Hypoglycemic Medications
β – Blockers [N (%)]
ACE Inhibitors [N (%)]
MAOI [N (%)]
Hyperglycemic Medications
Corticosteroids
Thiazide diuretics
Niacin
Atypical antipsychotics

* may only be looked at for internal purposes to look at distribution, not reported in final
manuscript
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Gliclazide

Glyburide

Glimepiride

Chlorpropamide

Tolbutamide

Metformin

Pioglitazone

Rosiglitazone

Nateglinide

Repaglinide

Insulin

Variable

Acarbose

Table A3: Baseline characteristics for users of single oral hypoglycemic agents
CASES ONLY

N=

N=

N=

N=

N=

N=

N=

N=

N=

N=

N=

N=

Demographics
Age [Median (IQR)]
…
Replicate variables in Table A2.

Gliclazide

Glyburide

Glimepiride

Chlorpropamide

Tolbutamide

Metformin

Pioglitazone

Rosiglitazone

Nateglinide

Repaglinide

Insulin

Variable

Acarbose

Table A4: Baseline characteristics for users of single oral hypoglycemic agents
CONTROLS ONLY

N=

N=

N=

N=

N=

N=

N=

N=

N=

N=

N=

N=

Demographics
Age [Median (IQR)]
…
Replicate variables in Table A2.

Table A5: Outcomes and Severity of Cases (CASES ONLY)

Gliclazide

Glyburide

Glimepiride

Chlorpropamide

Tolbutamide

Metformin

Pioglitazone

Rosiglitazone

Nateglinide

Repaglinide

Insulin

Variable

Acarbose

150

N=

N=

N=

N=

N=

N=

N=

N=

N=

N=

N=

N=

Event did not require admission, n
Event was hospital admission, n
Duration of hospital visit (median,
IQR)*
Death in ER or during hospital
admission, n
ICU visit during hospital stay, n *
* Restrict these analyses to only those patients who were admitted to hospital (no ER visits).
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Table A6: Covariate analysis outcomes
Model

Model 1

Model 2
Model 3
Model 4

Exposure Variable
Income (quintiles)
* for missing income
data input 3
(mid-point)
Year of index date
(4 categories)
Number of distinct
drugs in year prior to
index

Model 5

Charlson score

Model 6

Hospital discharge in
30 days prior to index

Model 7

Recent infection

Model 8
Model 9
Model 10
Model 11
Model 12
Model 13
Model 14
Model 15
Model 16

Model 17
Model 18

Liver disease in 5
years prior to index
Alcoholism in 5 years
prior to index
Coronary artery
disease in 5 years
prior to index
Congestive heart
failure in 5 years prior
to index
Cerebrovascular
disease in 5 years
prior to index
Number of primary
care visits in 5 years
prior to index

Number of internist
visits in 5 years prior
to index
Hypoglycemic events
in 5 years prior to
index
β-blocker prescription
in 120 days prior to
index

Modeling
1 lowest (referent)
2
3
4
5 highest
2002-2003 (referent)
2004-2005
2006-2007
2008

OR

LCL

UCL

1.000

--

--

1.000

--

--

1.000

--

--

1.000

--

--

1.000

--

--

1.000

--

--

1.000

--

--

1.000

--

--

1.000

--

--

1.000

--

--

1.000

--

--

1.000

--

--

1.000

--

--

1.000

--

--

1.000

--

--

Continuous (per drug)
≤ 3 (referent)
4–7
>7
0
1
≥2
No (referent)
Yes
No (referent)
Yes
No (referent)
Yes
No (referent)
Yes
No (referent)
Yes
No (referent)
Yes
No (referent)
Yes
Continuous (per visit)
≤ 15 (referent)
16-29
≥ 30
Continuous (per visit)
≤ 5 (referent)
6-14
≥ 15
0 (referent)
1
≥2
No (referent)
Yes
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Model 19
Model 20
Model 21
Model 22
Model 23

Model 24

ACE-inhibitor
prescription in 120
days prior to index
MAOI prescription in
120 days prior to
index
Corticosteroid
prescription in 120
days prior to index
Thiazide diuretic
prescription in 120
days prior to index
Niacin prescription in
120 days prior to
index
Atypical antipsychotic prescription
in 120 days prior to
index

No (referent)

1.000

--

--

1.000

--

--

1.000

--

--

1.000

--

--

1.000

--

--

1.000

--

--

Yes
No (referent)
Yes
No (referent)
Yes
No (referent)
Yes
No (referent)
Yes
No (referent)
Yes
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Table A7: Conditional Logistic Regression Results for Primary Outcome (OR and 95% CI) *
Exposure
Unadjusted
Adjusted
OR
SE
LCL
UCL
OR
SE
LCL
2
Analysis A (eGFR < 60 mL/min per 1.73 m )
1.0000
---1.0000
--Acarbose (referent)

UCL
--

Gliclazide
Glyburide
Glimepiride
Chlorpropamide
Tolbutamide
Metformin
Pioglitazone
Rosiglitazone
Nateglinide
Repaglinide
Insulin

1.0000
Charlson score: 1 (referent)
---1.0000
2
≥3
1.0000
Hospital discharge 30 days: no (referent)
---1.0000
yes
1.0000
Recent infection: no (referent)
---1.0000
yes
1.0000
Liver disease: no (referent)
---1.0000
yes
1.0000
Alcholism: no (referent)
---1.0000
yes
Describe other variables in adjusted model
2
Secondary Analysis (eGFR ≥ 60 mL/min per 1.73 m )
1.0000
---1.0000
Acarbose (referent)

--

--

--

--

--

--

--

--

--

--

--

--

--

--

--

--

--

--

Gliclazide
Glyburide
Glimepiride
Chlorpropamide
Tolbutamide
Metformin
Pioglitazone
Rosiglitazone
Nateglinide
Repaglinide
Insulin

Charlson score: 1 (referent)
2
≥3
Hospital discharge 30 days: no (referent)
yes
Recent infection: no (referent)
yes

1.0000

--

--

--

1.0000

--

--

--

1.0000

--

--

--

1.0000

--

--

--

1.0000

--

--

--

1.0000

--

--

--
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Liver disease: no (referent)
yes
Alcholism: no (referent)
yes
Describe other variables in adjusted model

1.0000

--

--

--

1.0000

--

--

--

1.0000

--

--

--

1.0000

--

--

--

* report results to 4 decimal points
Table A8: Conditional Logistic Regression Results for Additional Analysis 1 (OR and 95% CI) *
Exposure
Unadjusted
Adjusted
OR
SE
LCL
UCL
OR
SE
LCL
UCL
2
Primary Analysis (eGFR < 45 mL/min per 1.73 m )
1.0000
---1.0000
---Acarbose (referent)
Gliclazide
Glyburide
Glimepiride
Chlorpropamide
Tolbutamide
Metformin
Pioglitazone
Rosiglitazone
Nateglinide
Repaglinide
Insulin

Table A9: Conditional Logistic Regression Results for Additional Analysis 2 (OR and 95% CI) *
Exposure
Unadjusted
Adjusted
OR
SE
LCL
UCL
OR
SE
LCL
UCL
2
Primary Analysis (eGFR < 30 mL/min per 1.73 m )
1.0000
---1.0000
---Acarbose (referent)
Gliclazide
Glyburide
Glimepiride
Chlorpropamide
Tolbutamide
Metformin
Pioglitazone
Rosiglitazone
Nateglinide
Repaglinide
Insulin
*Regression model for both Additional Analyses 1 and 2 should be the same as that for the Analysis A and B
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Table A8: Interaction
Drug:
Adjusted OR from model
CI for adjusted OR

Impaired Kidney Function
0.67
0.46
0.98

Normal Kidney Function
0.88
0.71
1.08

log Transformation of OR to normalize the distribution
log OR
CI for log OR

-0.4005
-0.7765

-0.1278
-0.0202

-0.3425

0.0770

Obtain the standard error for log OR
Width of CI for log OR
SE of log OR

0.7563
0.1929

0.4195
0.1070

Comparison of the log ORs
Difference in log ORs
SE of the difference
CI for the difference

-0.2726
0.2206
-0.7051

0.1598

Describing the interaction
Test of interaction (z test)
Ratio of ORs (ROR)
CI for ROR

-1.2358
0.7614
0.4941

1.1733

Double click on table to edit highlighted fields. Table and sample values derived from Interaction
revisited: The difference between two estimates. Douglas G Altman; J Martin Bland British
Medical Journal; Jan 25, 2003; 326, 7382. OR, odds ratio; CI, confidence interval; SE standard
error; ROR, ratio of odds ratios.
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Appendix B:
Variable/Condition
(Defined by the
presence of any of the
listed codes)

ICD9 Dxcode

ICD10 Dxcode

Other
CCP prcodes 48.1,
48.11 to 48.19
[inclusive], 48.0, 48.01 to
48.09 [inclusive], 48.2,
48.3

Coronary Artery
Disease
(including angina)

Congestive Heart
Failure

410 to 414, 429.2,
429.5, 429.6, 429.7

I20 to I25

CCI prcodes 1IJ76,
1IJ50, 1IJ26, 1IJ27,
1IJ54, 1IJ57;
OHIP feecodes R741,
R742, R743, Z434,
G298, E646, E651,
E652, E654, G262
ODB
subclnam=‘CORONARY
VASODILATORS’

425, 428, 518.4, 514,
997.1

I255, I42, I43, I50, J81

CCP prcodes: 49.6,
49.61, 49.62, 49.63,
49.64
CCI prcodes 1HP53,
1HP55, 1HZ53GRFR,
1HZ53LAFR,
1HZ53SYFR
OHIP dxcode 428
OHIP feecodes R701,
R702, Z429
CCP prcodes 50.11,
50.12, 51.28;

Cerebral Vascular
Disease

430 to 438, 362.3

I60 to I69, G45 to G46,
H34

CCI prcodes 1JE50,
1JE57, 1JE87, 1JW50,
1JX57, 1JW57, 1JW76;
OHIP dxcodes 432,
435, 436, 437;
OHIP fee codes R792,
N220, N223, J050,
N104, N157, N120

Liver Disease

Alcohol Abuse

456.0, 456.1, 456.2,
070.2, 070.3, 070.4,
070.5, 070.6, 070.9,
571, 572.2, 572.3,
572.4, 572.8, 573,
782.4, V02.60 to V02.69,
275.0, 789.5, 789.1

B16 to B19, I85, R17,
R18, R160, R162, B942,
Z2250, Z2251, Z2258,
E8310, K70, K713,
K714, K715, K717,
K721, K729, K73 to K74,
K753, K754, K758,
K759, K76, K77

303, 303.00, 303.01,
303.02, 303.90, 303.91,
303.92, 305.0

E24.4, E51.2, F10,
G31.2. G62.1, G72.1,
I42.6, K29.2, K70,
K86.0, T51.0, X45, X65,
Y15, Y57.3 Z50.2 Z71.4,
Z72.1

571, 573, 070
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Kidney Failure
receiving dialysis

Intensive Care Unit
Admission
Primary Care Visit
Internist Visit

CCP prcodes: 5195
(hemodialysis), 6698
(peritoneal dialysis),
CCI prcodes: 1PZ21
(dialysis, urinary system)
OHIP Feecodes: listed
below. *
OHIP feecodes G400,
G401, G405, G406,
G557, G558, G559
OHIP feecodes A003,
A004, A005, A006,
A905, A901
OHIP feecodes A131,
A133, A134, A135,
A136, A435,

* Renal Disease OHIP feecodes:
R849
R850
G323
G325
G326
G860
G862
G863
G865
G866
G330
G331
G332
G861
G864
G082
G083
G085
G090
G091
G092
G093
G094
G095
G096
G294
G295
G333

Hemodialysis
Dialysis - Heamodialysis - Initial & acute
Dialysis - Haemodialysis - insert of Scribner shunt
Dialysis - Haemodialysis - Acute, repeat (max 3)
Dialysis - Haemodialysis - Medical component(incl in unit fee)
Dialysis - Chronic, contin. haemodialysis or haemofiltration each
Chronic hemodialysis hospital location
Hospital self care Chronic hemodialysis
Chronic hemodialysis IHF location
Chronic Home hemodialysis
Intermittent hemodailysis treatment centre
Peritoneal dialysis
Peritoneal dialysis - Acute (up to 48 hrs)
Peritoneal dialysis - Repeat acute (up to 48 hrs) max. 3
Peritoneal dialysis - Chronic (up to 48 hrs)
Chronic peritoneal dialysis hospital location
Chronic Home peritoneal dialysis
CRRT
Continuous venovenous haemodialfiltration
Continuous venovenous haemodialysis
Continuous venovenous haemofiltration
Veneovenous slow continuous ultrafiltration
Continuous arteriovenous haemodialysis
Continuous arteriovenous haemodiafiltration
Haemodiafiltration - Contin. Init & Acute (repeatx3)
Haemodiafiltration - Contin. Chronic
Slow Continuous Ultra Filtration - Initial & Acute (repeat)
Slow Continuous Ultra Filtration – Chronic
Arteriovenous slow continuous ultrafiltration init and acute
Continuous aterivenous haemofiltration initial and acute
OTHER
Home/self-care dialysis
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Appendix C: Figure 1

Ontario
1.

Registered in RPDB

2.

≥ 1 serum
creatinine level in
GDC database

3.

Evidence of at least
1 Rx for an OHA or
insulin

4.

Birth date earlier
than March 31st,
1942

Nest
Low Kidney Function

1.
2.
3.
4.
5.

Case: hypoglycemic
event, Control: no
hypoglycemic event.
≥ 1 serum creatinine
value prior to index
date.
Single OHA type or
insulin Rx prior to
index date.
At least one matching
control per case
No evidence of
dialysis.

Controls

Controls
Cases

Analysis A

Cases

Normal Kidney Function

Controls
Cases

Analysis B

159

Appendix D. Drug Lists
1. Oral hypoglycemic agents – exposure of interest

Oral Hypoglycemic
Agents

2. Insulins – exposure of interest

Insulins

3. Ant- infective agents - used to define recent infection. Three worksheets covering antiviral, anti-fungal and anti-bacterial agents.

Anti-Infective
Agents

4. HYPOglycemic medications – potential confounders. Three worksheets covering βblockers, ACE inhibitors and MAOIs

Hypoglycemic
Medications

5. HYPERglycemic medications – potential confounders. Four worksheets covering
corticosteroids, thiazide diuretics, niacin and atypical anti-psychotics.

Hyperglycemic
Medications

6. Coronary vasodilators – used to help define coronary artery disease

Vasodilators
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Checklist of Parameters
Date Variables
*Start Date of Accrual
*End Date of Accrual
*End Date of Follow-up
*Reference Date (date at which entry into nest begins)
Define Population
*Age restriction (minimum age included in cohort)
*Sex restriction (Male, Female, or both)
Any other inclusion/exclusion criteria
Define Nest (project specific – more information than below may be required)
ICD9/ICD10 diagnosis or procedure codes for nest
Diagnosis Type
Source from DAD (inpatient, same day surgery or both)
OHIP diagnosis or fee codes for subgrouping condition
OHIP source (lab, nonlab or all)
ODB DIN list for any drugs used to define nest
*Lookback period from start of accrual to identify subgrouping condition
Matching Cases to Controls
*Case:Control ratio defined
*Matching variables described (include calipers)
Definition of Exposure Drugs
*Drug List includes all DINs for drugs to be investigated
*Exposure Drug Names (DCLASS names to ID exposure drugs in DIN list)
Outcome Definition (project specific – more information than below may be required)
ICD9/ICD10 diagnosis or procedure codes for outcome condition
Diagnosis type (CIHI datasets)
Source from DAD (inpatient, same day surgery, or both)
OHIP diagnosis or fee codes for outcome condition
OHIP source (lab, nonlab or all)
Definition of Variables for Statistical Adjustment
*All variables required for statistical adjustment defined
*Lookback periods for variables defined (e.g. history of AMI in past 5 years)
Analyses
*List of all continuous covariates of interest (included in Table 1 and adjusted model)
*List of all dichotomous covariates of interest (included in Table 1 and adjusted model)
*List of all categorical covariates of interest (included in Table 1 and adjusted model)
*List of referent categories to be used in regression analysis for categorical variables
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Appendix C Chapter 2 License Agreement with the Clinical Journal of the
American Society of Nephrology for use of “Beta-blockers, trimethoprimsulfamethoxazole and the risk of hyperkalemia requiring hospitalization in the
elderly: a nested case-control study”
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Appendix D Chapter 3 License Agreement with the Nephrology, Dialysis,
Transplantation for use of “Impaired renal function modifies the risk of severe
hypoglycaemia among users of insulin but not glyburide: a population-based nested
case-control study”
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